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Chapter 1 
General Introduction 
Partialy based on: Genome organization and genetic 
variation of feline immunodeficiency virus 
Mamix L. Bosch, Kees H.J. Siebelink, and Albert D.M.E. Osterhaus 
In: W.C. Koff, F. Wong-Staal, and R.C. Kennedy (eds.), 
AIDS research reviews 3, p. 21-39, New York, 
Marcel Dekker inc. (1993). 

Feline immunodeficiency virus (FIV) is classified as a member of the genus 
Lentivirus (subfamily Lentivirinae) of the Retroviridae family on basis of its 
morphology, biochemical characteristics, genomic organization, Mg'+ dependent 
reverse transcriptase, and nucleotide sequence homology with other members of this 
genus. Lentiviruses cause chronic, lifelong infections in their respective host 
species, which may be followed by a slowly progressive and degenerative disease 
(2,16,53,104,108,115,199,236,248,289). FIV was first isolated from a domestic cat 
suffering from an immunodeficiency syndrome reminiscent of AIDS in humans 
(199). Subsequently it was shown that upon FIV infection, domestic cats may 
develop an immunodeficiency syndrome, hallmarked by secondary and opportunistic 
infections. The clinical stages preceding the final stage of feline AIDS, are similar 
to those observed in humans with HIV infection: the acute stage is followed by the 
asymptomatic carrier (AC) stage, after which a persistent generalized 
lymphadenopathy (PGL) gradually leads to the stage of AIDS related complex 
(ARC) (116). Then the animal develops filII blown AIDS. The different stages of 
F1V infection of cats may often not be quite distinct and rapid transitions between 
the respective stages may be observed (see below). 
FIV infections occur virtually worldwide in domestic cats and to date three viral 
clades (A, B, and C) with partially overlapping geographical distributions have been 
identified on basis of env sequences (245). This indicates that FIV infection of 
domestic cats has occurred for a long period of time. Recent serological and 
molecular phylogenetic studies have shown the occurrence of infections with FlV or 
. closely related lentiviruses in zoo collections and in fi'ee ranging populations of 
non-domestic felid species (190). Molecular phylogenetic analyses of the gag and 
pol genes showed that FlV is more related to the ungulate lentiviruses (Fig. 1). 
However, the pathogenesis of FlV infection shows more resemblance to that of 
primate lentivirus infections. 
The virus 
Structure 
Mature lentivirus particles are spherical to ellipsoid particles of approximately 
100 - 125 nm in diameter with a bar- or cone shaped core (Fig. 2; 199,288). The 
core is composed of viral capsid (CA) proteins of 24 kD (P24). Inside this core two 
identical positive RNA strands are found, with which the enzyme reverse 
transcriptase (RT) and nucleocapsid (NC) protein of 7 kD (P7) is closely associated. 
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Figure 1. Phylogenetic tree based on nucleotide sequences of lentiviruses pol and gag genes. Data were 
extracted from GenBank databases: FlV Petaluma (M2538 I), FIV PPR (M36968), FlV TM2 (M59418), 
FIV Puma (U03982), FIV Utrecht 113 (x68019), HIV-I BH5 (K02012) HIV-2 SBLISY (G04498), 
SlVmac32H (DO 1065), Visna Iceland 1514 (MI0608), CAEV Clement (M33677), EIA V clone 
1369/409-2 (MI6575), and BIV HXB3 (U32690). Sequences coding for the Pol- and Gag polyproteins 
were aligned using the PileUp programm of the GCG software package (79) (version 8.0) with a gap 
creation penalty value of 3.0 and gap extension limits of 0.1, respectively. Distances were calculated 
according the Kimura.2·parameter equation and the tree constructed utilizing the neighbour~joining 
method (124). Branches are drawn proportionally to the relative genetic distances as indicated by the 
bar. For phylogenetic analysis the software package MEGA release l.01 (134) was employed. 
The viral surface, the envelope, is a lipid bilayer membrane which is derived from 
the infected cell through a budding proces. The inner side of the membrane is 
covered by the matrix protein (MA) that helps providing the shape of the virus 
patiicle (49). The CA-, the MA-, and the NC proteins are derived from one Gag 
precursor protein of 55 kD (57,62,253). The envelope glycoproteins cover the viral 
membrane. They consist of a transmembrane (TM) protein of 41 kD (gp41) and a 
surface (SU) protein of 95 kD (gp95) in the case of FlY. They are derived fi'om a 
envelope precursor protein of 160 kD, which is first processed by trimming and 
cleavage of the leader protein resulting in a 135 kD protein (254,276). The TM 
glycoprotein is anchored in the membrane. This results in the presentation of the 
central and N-tenninal part outside the virion. The SU glycoprotein is attached to 
the TM glycoprotein by non-covalent bounds (100). 
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Genome organization 
The proviral genome of FlY is approximately 9500 bp in length and is bordered 
by two long terminal repeats (LTR). (Fig. 3) Three large open reading frames 
(ORP), gag, pol and env encode stmctural and enzymatic proteins. Several shott 
ORPs (sORPs) or short exons of multiple spliced mRNAs encode for virus 
regulatory and accessory proteins which have a direct or indirect influence on virus 
replication (for a review, see reference 61,174). 
LTR. The LTRs direct and control viral DNA and RNA synthesis and the 
integration of proviral DNA into the genome of the host cell. The length of the 
LTRs of FlY, approx. 350 bp, is comparable with those of CAEY, Visna vims and 
EIA V, and is significantly shorter than the L TRs of the primate lentivimses 
(101,173,189,237,238,252,259). Within the FIV LTR a number of regulatOlY 
sequences like TAT A box, polyadenylation signal and polyadenylation site and 
enhancer sequences can be found, although not all of these features are conserved 
(249). 
A 
C 
Gag protoins 
MA (pI5) 
CA (p24) 
NC (ptO) 
B 
Envelope 
Envelope Pol proteins 
proteins 
TM(gp4l) AT (p55) SU p9S) :~~~~~~~~(T--~ PR 14
IN (p3I) 
Figure 2. Electron micrograph of FrY budding from infected cells (A, magnification 38,000), virus 
particles (B, magnification 62,000), and schemalic representation of FlY (C). 
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Gag. The gag gene is approximately 1350 bp in length and encodes a Gag 
precursor protein of 55 kD (P55), which is cleaved into the MA- (pI5), CA- (p24) 
and NC- (p7) proteins (57,62,253). Alignments of the FlV gag gene sequences with 
those of the gag genes of other lentivimses have revealed significant homologies in 
the respective Gag proteins, ranging from about 49% amino acid identity with the 
EIA V gag gene products, to about 40% amino acid identity with those of the HIV-I 
Gag protein (57,61,189). Antibodies directed against the Gag proteins of FIV and 
EIA V proved to be reciprocally cross reactive in ELISA and Western blot assays 
(57). The gag gene is rather well conserved within FlV strains: The highest degree 
of conservation is observed for the CA protein and most of the variation is observed 
for the NC protein (157). 
Gag-Pol jrameshif/. The gag and pol gene reading frames of FlV partially 
overlap (Fig. 3) with the pol being in the -I reading frame of the gag gene (178). 
Two consensus sequences for frameshifting have been observed in the overlapping 
region (GGGAAAC and GAGAAAC resp.) and similar sites are also found in the 
homologous regions of type D retrovimses and Visna viIlls (205,247). Mutational 
analyses have demonstrated that frameshifting occurs in the GGGAAAC sequence, 
possibly at the asparagine codon (AAC) within this sequence (178). In this study 
the need for RNA pseudo knot formation downstream of this signal sequence was 
also demonstrated. 
Pol. The pol gene is approximately 3360 bp and encodes a precursor polyprotein. 
Comparative analysis of the pol sequence with known amino-termini of HIV-I pol 
products (146) identifies the predicted cleavage sites of the FlV Pol precursor (62). 
The resulting cleavage products are the (predicted) protease (PR: 123 amino acids), 
RT (559 amino acids), endonuclease or integrase (IN: 278 amino acids) and a 
protease-like protein of 131 to 132 amino acids is located between RT and IN 
(165). Computer searches have identified this latter protein as a putative dUTPase 
(167). The dUTPase of FIV is required for efficient growth in primary PBMC 
(279). Such a dUTPase-like sequence is present in EIA V and Visna vims but not in 
the primate lentivimses HIV-I, HIV-2 and SIV (28,60). 
Ellv. In the primate lentiviruses the env gene products control many functions 
which are important for viral pathogenesis and also for vaccine development (for a 
review, see reference 143). They contain the binding site for the cellular receptor 
CD4 (142,191), the fusion domain involved in entry of the vims into target cells 
and in syncytium formation (27,74,88,133), and as yet unidentified regions 
controlling the viral host range and cytopathicity (10,38). Furthermore they contain 
neutralizing determinants, most notably in the V3 region (76,118) through which 
antibodies can interfere with viral infection of target cells. 
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The FlV ellv gene codes for a precursor protein of approx. 843 amino acids 
containing multiple potential glycosylation sites (254). A highly hydrophobic 
putative leader sequence is found at amino acid position 156 through 186 which 
would put the start of the SU protein around position 190 and would identify the 
preceding region as a potential homologue of the L gene of Visna virus 
(49,130,254,276). Around amino acid position 618 (depending on the isolate) a 
consensus sequence for susceptibility of a trypsin-like enzyme is found, similar in 
position and sequence to those found for the primate lentiviruses, in which cleavage 
of the Env precursor is indeed demonstrated at this position (275). The cleavage 
products most likely correspond to the gp95 and gp40 glycoproteins observed on 
protein gels of FIV or FIV-infected cells (253,254). The env gene is clearly more 
variable than the gag and pol genes (86). It has been noted previously that variation 
in the ellv is not randomly distributed (173,179,198,204) and this has led to the 
definition of five hypervariable regions: HVI to HV-5. Like HIV-I, FlV can be 
divided in different subtypes. Based on the genetic diversity pattern of the region 
encompassing the variable regions HV3, HV4, and HV5, three distinct envelope 
sequence subtypes are presently recognized (245). 
Other ORFs. In the original papers on the molecular cloning of FlV it was noted 
that the sequence of FIV, like those of the primate lentivimses, contains a number 
of open reading frames (ORFs) which might be attributed to regulatory genes 
(179,188,189,204,259). Extensive homology searches have not revealed similarities 
between these ORFs and the regulatOlY gene sequences of HIV and SIV. 
Furthermore not all of the initially noted ORFs could be found in full length FIV 
clones fi'om later dates. Four of the additional ORFs are presented here: the 
presumed vi/, rev, A ORF and H ORF (also designated B ORF). 
Vif. The location, size and nmction of the presumed vif gene is similar to 
that of the primate lentivimses (266) The vif gene encodes a hydrophobic and basic 
protein and it is highly conserved in different FIV isolates (157,204,259). Its degree 
of conservation between the different FlV isolates is similar to that observed for 
gag. Vif deletion mutants of FlV produced virion associated reverse transcriptase 
activity in CrFK cells upon transfection, but cell free virus did not infect feline 
CD4+ cells indicating that, as was shown for various primate lentiviruses, vif 
activity of FIV is essential for cell free infection (266). 
Rev. The Rev protein is encoded by a multiple spliced mRNA of which the 
first coding exon is located in the L domain of the ellv ORF and the second exon is 
probably identical to the H ORF at the 3' end of env extending into the 3' L TR 
(125,203,267). Rev is a regulatory protein that is translocated into the nuclei of 
infected cells where it binds to specific cis-acting target sequences in the viral 
17 
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Figure 3. Comparative genome organization of representative lentiviruses 
mRNA before splicing, termed the Rev responsive elements (RRE), and it facilitates 
the translocation of full length or single spliced viral mRNAs from the nucleus to 
the cytoplasm (159). The RRE of FIV is mapped to a 243 bp region at the 3' end 
of ellV (160,203). In other lentivinlses the RRE is found in the env gene at the SU-
TM junction (37,158,224). At low concentrations of Rev in the cytoplasm of 
infected cells the viral mRNAs are predominantly small and multiple spliced 
(63,68). Multiple spliced mRNAs encode regulatory proteins. At high concentrations 
of Rev in the cytoplasm, the viral mRNAs are predominantly Ibll length or single 
spliced. Full length or single spliced viral mRNAs encode stnlctural proteins 
resulting in the production of vims particles. Thus the concentration of Rev plays a 
pivotal role in determining whether a lentivims infection is latent or productive. 
A ORF. The A ORF is located between the pol- and ellV gene in a region, 
where in the primate lentivimses the first exon of lal (transactivator) and rev are 
found. It is conserved in most FIV clones, although it is interrupted in the 34TFIO 
clone (204). The 34TFIO clone is replication competent which indicates that the A 
ORF product is dispensible for virus replication. Using A ORF frameshift mutants 
of FIV it was shown that replication and propagation of these mutant viruses was 
reduced in established T cell lines and that thc productivc infection of primary 
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PBMC with these mutant viruses was severely reduced when compared to wild type 
virus (265). This suggests that the ORF A gene enhances viral replication in 
primary PBMC. 
H ORF. The H (or B) ORF is found in all FIV clones directly 3' of env, 
where the lief gene is located in the primate lentiviruses (204). This ORF is longer 
in the molecular clone pFTMI9 due to an extension at the 5' end. In all clones the 
H ORF contains a stretch of basic amino acids reminiscent of a nuclear or nucleolar 
localization signal which is also found in HIV-I and HIV-2 Rev (52,103). This 
finding is therefore compatible with the involvement of the H ORF in FIV rev gene 
activity (see above). 
Pathogenesis and epidemiology 
Like in the clinical course of HIV infection in humans, five different' stages can 
be recognized in the clinical course of FlV infection in cats (116). Specified 
pathogen free (SPF) cats experimentally infected with FlV develop a transient low 
grade fever, neutropenia and generalized lymphadenopathy (20 I ,289). The fever and 
neutropenia may persist for some days up to several weeks while the generalized 
lymphadenopathy can persist for several months. Most cats recover from these acute 
symptoms (16,\8,33,80,269,285). During this period the cats seroconvert and serum 
antibodies to the structural proteins can be demonstrated, which may be used for 
diagnostic purposes (50,109,150,277). The acute phase is followed by the AC stage 
in which no apperent clinical symptoms are observed. This phase can last for 
years. In lIlV infected humans this stage is followed by a phase characterized by 
PGL. Only few infected cats have shown to develop PGL (1\6), which indicates 
that in FlV infection this phase may exist, but that the duration is relatively shOlt 
and that the illness proceeds fast to the next stage of ARC in those cats that develop 
disease. This is characterized by weight loss, chronic dian-hea, stomatitis, gingivitis, 
upper respiratory tract infections and skin infections. Within several months to a 
year this stage leads to AIDS. Cats with AIDS suffer from severe 
immunodeficiency symptoms like those of the previous stage aggravated by 
OpporhllllstlC infections, emaciation, anemia, lymphopenia, neutropenia, 
thrombocytopenia, tumours, and neurological disorders (1\6). 
Before the onset of clinical signs, during the acute stage of infection, high 
numbers of infected cells are present in lymphoid organs, including the thymus, 
bone marrow, lymph nodes, spleen, tonsil, and lymphoid tissues of the intestinal 
tract (\8). Like HIV and SIV, FIV appears to selectively infect T cells and cells of 
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the monocyte/macrophage lineage (19,29,30,65,201). It has been shown that FIV 
can infect other cells than CD3+ cells, like B cells, astrocytes and megakariocytes ill 
vivo and feline kidney cells (CrFK cell line) in vitro (41,53,65,289). However, the 
cat CD4 molecule does not seem to function as the primary receptor for FIV (III). 
Another cell surface molecule, the feline homologue of CD9, has recently been 
identified as the most likely candidate for an FlY receptor (283). Human CD9 has 
been implicated as a signal transduction molecule and is expressed on the surface of 
a wide range of haematopoietic cells. This may explain why FIV can infect a wide 
variety of cell types, both in vivo and in vitro. 
In line with HIY infection in humans a selective loss of CD4+ lymphocytes is 
observed in cats infected with FIV (2,16,80,104,184,269). Witliin six months after 
infection a decrease in percentages and numbers of circulating CD4+ lymphocytes 
and in the CD4+/CD8+ T cell ratio is observed in SPF cats, experimentally infected 
with the Petaluma strain of FlY (269). CD4+/CD8+ ratio inversions have been 
repOlied to occur early «3 months) (268) or later in the infection (18 - 24 months) 
(2,16). A rapid expansion of the CD8+ lymphocyte subpopulation, which can occur 
within 4 weeks post infection, contributes to the CD4+/CD8+ inversion (282). The 
depletion of CD4+ lymphocytes may be the result of a direct clearance of the 
infected CD4+ cells or of un infected CD4+ cells loaded with circulating gp120, by 
cytotoxic T cells (CTL). Also the direct cytotoxic effect of FIV as a result of 
intense virus budding causing changes in membrane integrity, syncytium formation, 
apoptosis (22,186), and accumulation of unintegrated viral DNA may cause 
depletion of CD4+ cells. Early precursors of CD4+ cells could also be infected, 
which may lead to a reduced quantity of fresh mature lymphocytes (71). 
Epidemiological studies have revealed a worldwide distribution of FIV. 
Serological surveys of domestic cats with symptoms reminiscent of an 
immunodeficient syndrome, showed a varying incidence from 3% - 14% in Europe 
and the United States through 44% in Japan (l5,117,152,201,248,285). The 
prevalence of FIV infection in the overall domestic cat population worldwide ranges 
between I % and 30%. The large variations of prevalence in the different countries 
may reflect differences in life styles of cats. In general the older free roaming male 
cats have the highest incidence of FLY infection. Cross reactive antibodies to FIV 
were common in several free ranging populations of large cats, including the East 
african lion (Panthera leo), the cheetah (Acinonyx jubatus), the puma (Felis 
concolor) and the bobcat (Lynx rufus) and in several zoo populations including 
lions, cheetahs and pumas (190). No apparent clinical symptoms are observed in 
these large cats. Molecular phylogenetic comparison of the pol genes of the puma 
lentivirus (PLY) and FlY, and the antigenic relationship showed that the PL V 
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isolates are more related to FlY than to other lentiviruses (l40,190). 
FlY can be isolated from blood, plasma, cerebrospinal fluid and saliva of 
infected cats (53,163,289). Although the modes of transmission are not fully 
understood, the presence of infectious FlY in the saliva suggests bite wounds may 
account for a major proportion in the transmission (248,285). This can explain the 
higher incidence in free roaming male cats, which are known to express more 
territorial aggression. The vertical transmission of lentiviruses may occor in utero 
during the intrapartum period, or in the early post natal period (3,40,59,145,164, 
226,260). Although in utero infection can not fully be excluded, it seems to be 
uncommon in FIV infection (32,273). FIV can be transmitted via milk during acute 
mate,:nal infection and much less efficiently or not during chronic maternal 
infection (233). 
Humoral immune response 
Within eight weeks after infection almost all FlY infected cats seroconvert 
(13,58,72,109,185). Serum antibodies directed to the Env glycoprotein can be 
demonstrated first, followed by antibodies to the Gag protein. Antibodies to non 
structural proteins can also be demonstrated. At present no data are available on the 
presence and kinetics of different (sub)classes of immunoglobulins directed to FlY 
proteins upon FlY infection. 
Since the Gag proteins are well conserved among the different FIV strains, 
antibodies to the Gag proteins are valuable for routine diagnostic screening of F1V 
infection in cats using ELISA systems. Like in HIY infection in humans, 
confirmation of the ELISA data can be performed by more expensive and time 
consuming assays like western blot analysis, PCR and virus isolation. Like in 
humans and monkeys exposed to HIV and SIV respectively, it was shown that in 
persistently seronegative cats, which were housed together with FlY infected cats, 
FlY DNA could be detected in their PBMC and bone marrow cells by PCR (46). 
Within the envelope glycoprotein, several antigenic sites reactive with sera from 
FlY infected cats can be found (13,50,56,72,148,197). Three linear 
immunodominant epitopes have been mapped: The first within the l-IV3 region of 
SU, the second at the COOH terminus of SU and the third on the TM2 region of 
the transmembrane protein. These immunodominant sites are reminiscent of HIV - I 
in which at similar positions immunodominant sites have been described (for a 
review, see reference 143). There are indications that antibodies directed to the 
envelope protein not only neutralize but may also enhance FlY infection ill vivo and 
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in vitro (110,221-223). 
Virus neutralizing antibodies 
Virus neutralizing serum antibodies arise soon after infection and are generally 
believed to play a role in the protective immune response against lentiviruses. The 
major target of lentiviruses to which neutralizing antibodies are directed is the SU 
protein. The SU protein of HlV contains several regions that arc involved in 
neutralization, including the principle neutralization determinant (PND) in the V3 
loop, the CD4 binding site and sites in the second conserved (C2) and V2 regions 
(10,103,208,264, for a review, see reference 143). Mutations within or outside these 
regions may render the virus resistant to virus neutralizing antibodies (169,214,284, 
for a review, see reference 187). Continuous variation of the envelope glycoprotein 
sequences and of the subsequent antibody response are observed (4,11,31,119,176, 
182). On the SU protein of FlV a linear immunodominant neutralizing determinant 
has also been mapped to the HV3 region (50,56,148). 
Detection of virus neutralizing antibodies in vitro is largely dependent on the 
vitus and cell substrate used (14). Using CrFK cells and CrFK adapted vitus strains 
high titers of broadly neutralizing antibodies have been detected in the sera of 
naturally and experimentally infected cats. In contrast, in VN assays using primary 
virus isolates and Con A stimulated T cells or T lymphoid cell lines, no or only low 
titers of highly type specific neutralizing serum antibodies were demonstrated 
(14,243). Similar results have been obtained with HIV virus neutralization assays 
when different cell substrates and cell line adapted vs non adapted viruses were 
used (230). Since T cells are natural host cells for FlY (18), their use in VN assays 
seems more likely to reflect the ill vivo situation than the use of CrFK cells and 
CrFK adapted viruses in these assays. The mechanisms underlying these differences 
are still unclear. Immunization of cats with the inllllunodominant epitope of the V3 
region of the SU protein was shown to elicit senlln antibodies that proved to be 
broadly neutralizing in the CrFK assay. However, these antibodies did not confer 
protection against FlY infection (149). 
Virus enhancing antibodies 
Antibody dependent enhancement (ADE) of viral infection is a phenomenon by 
which antibodies directed against the virus facilitate and enhance the process of 
infection (for a review, see reference 161,173). It was described that immunization 
with inactivated whole FlY may elicit enhancing antibodies (110). At least two 
different mechanisms of ADE have been described for lentiviruses (107,121,175, 
221-223,258). One described mechanism operates through Fe receptors on 
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macrophages which act as a receptor for immunoglobnlin complexed with virus. 
Once internalized via this mechanism, the virions are not effectively iuaetivated and 
can replicate within the macrophage. Another mechanism of ADE operates via the 
activation of complement by the virus-antibody complex: complement-mediated 
ADE (C'-ADE). The complement-antibody-virus complex binds to complement 
receptors On cells, and the complex is subsequently internalized. Both types of ADE 
has been reported for a number of viruses (for a review, see reference 161,257). 
Recently a third mechanism of ADE has been described for HIV-I, in which the 
same antibodies either neutralized or enhanced HIV -I, dependent on the phenotype 
of the virus involved. Polyclonal and monoclonal antibodies directed to different 
domains of the envelope glycoprotein may neutralize one HIV -I strain but cnhance 
another (94,128,232). Titers of enhancing antibodies in sera from HIV-l infected 
humans may be extremely high (up to I :65,000), which may cause a dramatic 
reduction or abolishing of the neutralizing activity measured against HIV-l. 
Cellular immune response 
Despite the induction and persistence of virus neutralizing serum antibodies (271, 
272), lentiviruses cause a persistent infection in their respective hosts. Cell-mediated 
immune mechanisms, especially natural killer (NK) cells and cytotoxic T cells 
(CTL) but also the T-helper cell responses have been shown to be important in the 
clearance of virus and in the control of persistent virus infections. NK cells 
recognize and kill infected cells in a non MHC restricted manner and may play an 
impotiant role in the clearance of HIV infected cells in humans. Before the onset of 
clinical symptoms mitogen- and antigen induced proliferative T cell responses are 
decreased (2,16,94,269). During the acute FIV infection the primary and secondary 
T cell responses are impaired (23,24). To date no data of NK activity or FlV 
specific T helper cell responses are available in FlV infected cats. 
FIV specific CTL have been detected in peripheral blood of experimentally 
infected cats, 7 to 9 weeks post infection. These cells proved to be predominantly 
CD8+, which indicates that the lysis of FIV infected cells is, at least in part, MHC 
class I restricted (246). CD8+ CTL's have been detected in the peripheral blood of 
3 out of 4 cats immunized with 17-mer peptides (70). These CTL's lysed 
autologous and not allogeneic skin fibroblasts pulsed with a homologous lO-mer 
peptide. An antibody response and proliferative response to the 17-mer peptide were 
also measured in vitro in these cats, which indicates a class II MHC restricted T cell 
response. For HIV it has been shown that CD8+ cells can suppress the replication of 
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HIV in CD4+ cells ill vitro without killing these cells. This antiviral activity of 
CD8+ cells has not been identified in FIV infected cats. 
Vaccine development 
Although it is not known at present what correlates with protective immunity in 
lentivirus infections, the ideal vaccine probably should induce both a humoral and 
cellular immune response. The induced antibodies should preferably neutralize a 
wide variety of vims strains and therefore be preferably directed to conserved 
neutralizing sites. FUlihennore the induction of infectivity enhancing antibodies 
should be avoided (for a review, see reference 161,257). Since the most common 
natural mode of infection in cats is probably not via mucosal surfaces (285), the 
induction of mucosal immunity, which is supposed to be of major importance in the 
prevention of HIV-l infection, may be less relevant in the prevention of FlV 
infection of the cat. The induction of a potent T helper cell response may be a 
prerequisite for the generation of protective and long lasting antibody and CTL 
responses. To date, virtually all the classical and modern approaches for the 
development of viral vaccines have been or are being explored for the development 
of lentivirus vaccines, with varying degrees of success (for a review, see reference 
35,217). Probably, the most successful vaccination studies in a lentivirus system 
have been carried out in the FIV-cat system: cats vaccinated with paraformaldehyde 
fixed T cells (FL-4 cells) persistently infected with FIV, and cats vaccinated with 
paraformaldehyde inactivated FIV derived from the same cells, proved to be 
protected from homologous and to a lesser extent from heterologous FlV challenge 
infection (286,287). The protective immunity could be transferred to naive cats with 
the plasma of thus vaccinated animals, indicating that FIV specific antibodies were 
at the basis of the induced protection (105). Although these experiments could be 
confirmed by others with the same vaccine preparations, a similar approach with 
vaccine candidates produced in other cells was unsuccesfull in several experiments 
(110,278). In one of these experiments, the induced response even seemed to 
predispose for enhancement of infection rather than for protection. Experiments 
with non-replicating subunit vaccines, predominantly containing the envelope 
glycoproteins of FIV or selected domains, all failed to show the induction of 
protective immunity (110,149). Similar approaches have yielded a certain degree of 
success in the SIV/macaque- and HIV-lIchimpanzee system (20,34,75,82,120,192, 
193,211,251). When this approach was combined with the use of live recombinant 
viruses expressing thc envelope glycoproteins, the induction of protective immunity 
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proved to be more efficient in the SlY-macaque systems (I13). So far this approach 
has not been studied in the FlY -cat system. The use of attenuated lentivil1lses 
(47,209), like the nel gene deleted or mutated viruses, which proved to be 
successfhl in the SlY-macaque system, has also not been documented in the FlY cat 
system. 
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Outline of this thesis 
Aftcr the dcscription of the present knowledge of FlY and FlY infection of cats 
in this chapter, chapter 2 describes the establishment of the FlY model system uscd 
in this thesis for studying aspects of the pathogcnesis of FlY infection and for the 
evaluation of different vaccination strategies. In this chapter it is shown that 
infected cats develop a mild immune suppression, serological assays are described, 
and a series of molecular clones are generated directly from the bone marrow DNA 
of a naturally infected cat in The Netherlands. These clones are used in chapter 3 to 
identifY determinants involved in the tropism of FlV to replicate in CrFK cells, 
which are continuously growing non-lymphoid cells, originating from feline 
kidneys. These molecular clones of FlY are also used to identifY mechanisms of 
escape from VN activity of serum antibodies from experimentally infected cats at 
the molecular level. In chapter 4, the generation and evaluation of a candidate 
subunit vaccine for the induction of FlV specific immunity is described. To this end 
FIV envelope glycoproteins are produced in a recombinant vaccinia expression 
system and subsequently formulated in an iscom presentation form. After the 
demonstration of the induction of FlY specific antibodies in cats with this and other 
FIV envelope protein preparations, the results of a parenteral challenge with 
homologous FlY strain in thus vaccinated cats are described. In the last chapter, the 
results of the experimcnts carried out in the framework of this thesis are 
summarizcd and discussed. 
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FIV-Induced Impairment 
of Immune Function 
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Kees Weijer, Rob van Herwijnen, Peter Knell, 
Herman F. Egberink, Marnix L. Bosch 
and Albert n.M.E. Osterhaus 
AIDS Res. and Hum. Retrovir. 6:1373-1378 (1990) 

Abstract 
To assess the value of feline immunodeficiency virus (FlY) infection as a model 
for human immunodeficiency vims (HIY) infection in man, we studied the 
impairment of certain immunological fimctions following natural or experimental 
FlY infection. Proliferative responses of peripheral blood mononuclear cells 
(PBMe) from symptomatic and asymptomatic cats after naturally or experimentally 
acquired FlY infection, induced by activation with the mitogens concanavalin A, 
pokeweed mitogen or lipopolysaccharide or by stimulation with human interleukin-2 
(IL-2), were significantly lower than the proliferative responses found with PBMe 
from non infected control cats. Also IL-2 production levels of mitogen-activated 
PBMe from naturally infected symptomatic cats were significantly reduced. These 
data confirm that the pathogenesis of FlY infection in the cat, like HIY infection in 
man, is characterized by a serious malfunction of the immune system. 
Introduction 
Since the discovery (>f human immunodeficiency virus type I (HIY-l) as the 
cause of acquired immunodeficiency syndrome (AIDS) in 1983 (17,77), it was 
realized that there is an urgent need for animal models to study the pathogenesis of 
HIY-l infection and possibilities for interventional strategies. Apart from 
chimpanzees and gibbons no animal species can be infected with HIY-l, and these 
apes do not develop clinical symptoms similar to AIDS upon experimental infection 
(9,151). However, it has been shown that certain monkey species can be infected 
with HIY-2 and with a number of simian immunodeficiency viruses (SlY), and that 
they may subsequently develop an AIDS-like syndrome (for a review, see reference 
250). Recently, a lentivims of the cat, feline immunodeficiency virus (FlY), has 
been identified in cats with an AIDS-like syndrome (199). Since cats are less 
expensive and easier to handle than monkeys, the FlY infection model may be of 
special interest for testing the potential of antiviral drugs and vaccination strategies 
in relation to HIY infection in man. 
The knowledge about the pathogenesis of FlY infections is limited at present (for 
review see references 200,248). Although infection under natural circumstances 
seems to be associated with the development of chronic disease symptoms 
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eventually leading to AIDS-like disease, it is difficult to reproduce the disease by 
experimental infection of cats (289) .. Therefore, we have now undertaken studies 
regarding the functioning of the immune system of cats following natural or 
experimental infection with FIV. The progression to AIDS in man following HIV-I 
infection is characterized by the gradual impairment of in vivo and in vitro immune 
fimctions (112,225,262). Specifically, loss of mitogen-induced lymphocyte 
proliferation is seen shortly after infection in asymptomatic individuals (172,263). 
In this report, we present studies on mitogen and interleukin-2- (IL-2) induced 
proliferative responses and IL-2 production of peripheral blood mononuclear cells 
(PBMC) of cats after infection with FIV. 
Materials and Methods 
FIV-infected and control animals 
Four different groups of cats were used in these studies. Fifteen private 
household cats were identified as seropositive for FIV in an enzyme-linked 
inutlunosorbent assay (ELISA) (239). Five of these cats (3-9 years old), designated 
Group S, showed clinical signs of chronic disease suggestive for feline AIDS (289). 
The other ten (2-6 years old), designated Group A, were healthy at the time of 
sampling. Twelve specific pathogen-free (SPF) cats (1.5-3 years old), designated 
Group E, had previously been experimentally infected subcutaneously with a Dutch 
field isolate of FIV (n~IO) or the Petaluma strain (n~2) (199), 12 to 30 months 
before sampling. These animals were negative for antibodies against a number of 
viruses which commonly infect cats, including feline leukemia virus (FeLV), feline 
panleukopenia virus (FPV), feline calici virus (FCa V), feline herpes virus-I 
(FHV-I), feline syncytium-forming virus (FeSFV) and feline corona virus (FCV) as 
demonstrated in regular serological screening procedures. The last group consisting 
of 25 private household cats (1.5-10 years old) seronegative for FlV, was 
designated Group C and served as a noninfected control group. Comparison of the 
data obtained in Group C for proliferative responses and IL-2 production upon 
mitogen stimulation to data obtained previously in our lab for a group of SPF cats 
(n~4) demonstrated no significant differences between these two groups (data not 
shown). Therefore, only non-SPF cats were used as controls in these assay systems. 
Sampling 
Blood samples were collected once from cats of Group S and Group A. From 12 
experimentally infected cats (Group E) blood samples were collected monthly for 
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determination of lymphocyte counts and once, 0.5 to 2 years after infection, to 
assess the mitogen and IL-2-induced proliferation and IL-2 production of PBMC. 
Peripheral blood mononuclear cells (PBMC) were isolated from preservative-free 
heparinized blood by density gradient centrifugation on Ficoll-Isopaque. The cells 
were washed three times with RPMI 1640 (Gibco, Grand Island, NY), 
supplemented with penicillin (100 IU/ml), streptomycin (100 f!g/ml), L-glutamin 
(2mM) and B-mercaptoethanol (2.10" M), hereafter designated as culture medium 
(CM). The lymphocyte counts from the experimentally infected cats were 
determined monthly. The lymphocyte counts from the three other groups of cats 
were determined once. 
Mitogen-induced proliferation 
PBMC (10' cells/well) were cultured at 37"C, 5% CO" in a humid environment 
in CM, supplemented with 10% heat-inactivated calf bovine serum (FCS) with 
concanavalin A (ConA (5 f!g/ml) (Flow Laboratories) or pokeweed mitogen (PWM) 
(I f!g/ml) (Flow Laboratories) for 72 h or lipopolysaccharide (LPS) (50 f!g/ml) 
(Escherichia coli 0.27:B8, Difco Laboratories) for 96 h in round-bottomed tissue 
culture plates using unstimulated cells as a control. The optimum concentration of 
mitogens and time of culture were first defined by dose-response curve. 
Proliferative responses were measured by ['Hj-thymidine incorporation (1 
f!Ci/culture). Results presented are the mean of triplicate wells. Differences were 
found significant for p < 0.01 as calculated according to the Student's t-test. 
Proliferative response to exogeneous IL-2 
The response of PBMC to exogeneous IL-2 was tested using a method similar to 
the one described by Goitsuka et al. (83) PBMC (106 cells/ml) were incubated with 
ConA (2 f!g/ml) for I hat 37"C in CM, supplemented with 10% FCS in 12 x 75 
mm culture tubes (Falcon, catnr. 2085, Becton and Dickinson, E. Rutherford, NJ). 
The cells were washed three times with CM and cultured for 96 h with 100 IU 
recombinant human IL-2/ml (rIL-2) (Boehringer Mannheim, Germany) in 96 wells 
flat-bottomed tissue culture plates. Sixteen hours before harvesting, the cells were 
pulsed with ['Hj-thymidine to measure their rate of proliferation, using unstimulated 
cells as control. The stimulation index was calculated by dividing the cpm of the 
IL-2 stimulated culture by the cpm of the unstimulated culture. Differences were 
found significant for p <0.0 I as calculated according to Student's I-test. 
IL-2 production 
Production of IL-2 was measured using the method described by R. Goitsuka et 
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al.(83) PBMC (lOs/well) were cultured with or without ConA (10 llglml) in CM 
supplemented with 10% FCS in 96-well round-bottomed culture plates. After 24 h, 
the culture supernatants were tested for the presence of IL-2, using an IL-2-
dependent cloned murine cytotoxic T cell line (CTLL): CTLL cells (5.10'), in the 
logarithmic phase, were seeded into 96 wells of round-bottomed micro titer plates. 
Twofold serial dilutions of the culture supernatants were added. After three days the 
cells were pulsed with ['H)-thymidine and after 16 h harvested and counted in a 
scintillation counter (LKB). The units of IL-2 were determined by probit analysis at 
50% of the rIL-2-standard (Boehringer). In preliminary experiments optimal 
conditions for cell concentration, dosage of mitogens, and culture time were 
determined. Differences were found signilicant for p <0.0 I as calculated according 
to Students t-test. 
Results 
Mitogen-induced proliferative responses of PEMe 
To assess the effect of FIV infection on the immune system, we studied the 
proliferative responses to various mitogens of PBMC from symptomatic and 
asymptomatic cats infected with FlV. The data are presented in Figure I. ConA-
induced proliferative responses of PBMC from live naturally infected cats with 
clinical symptoms (Group S) were signilicantly lower than the responses of PBMC 
from 25 control cats (Group C). Also for 10 naturally and 12 experimentally 
infected FlV seropositive cats without apparent clinical symptoms (Groups A and 
E), signilicantly lower proliferative responses were found. The geometric means of 
the values found for the control group, the symptomatic and the two asymptomatic 
seropositive groups were 75,769, 5,151, 35,834 and 33,908 cpm, respectively (Fig. 
IA). Similar results were found for PWM- and LPS-induced proliferative responses: 
PBMC from the 5 naturally infected cats with clinical symptoms and from the 10 
naturally and the 12 experimentally infected asymptomatic cats showed signilicantly 
lower PWM- and LPS-induced proliferative responses than the PBMC from the 25 
control cats. The geometric means of the values found upon stimulation with PWM 
for the control group, the symptomatic, and the two asymptomatic seropositive 
groups were 31,918, 1,159, 14,348 and 10,829 cpm, respectively (Fig. IB). 
Following stimulation with LPS the geometric means of the values found for the 
control group, the symptomatic, and the asymptomatic seroJlositive groups were 
8,399, 1,286, 4,802 and 2,382 cpm, respectively (Fig. I C). 
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Figure 1. Mitogen·induced proliferative responses of PBMC from the control (C), naturally infected 
symptomatic (S), and naturally infected asymptomatic (A) and experimentally infected asymptomatic (E) 
cats. Proliferative responses induced by ConA (A), PWM (8) and LPS (C) arc expressed as counts per 
minute of tritiated thymidine incorperation. 
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IL-2 production and proliferative responses to exogeneous IL-2 
The impaired responses to mitogens in FlY-infected cats could be due either to 
reduced IL-2 production or to a reduced response to the IL-2 produced. Therefore 
IL-2 production and proliferative responses to exogeneous IL-2 by PBMC from cats 
were measured. 
ConA-induced production of IL-2 by PBMC from the 5 naturally infected cats 
with clinical symptoms and from the 12 experimentally infected cats was 
significantly lower than the production of IL-2 by PBMC from the 25 control cats. 
No significant differences were found when the ConA-induced production of IL-2 
by PBMC from the 10 naturally infected cats without apparent clinical symptoms 
were compared with the IL-2 production by PBMC from the 25 control cats. The 
geometric means of the IL-2 production found for the control group, the 
symptomatic seropositive group, and the two asymptomatic groups were 13, I, 16 
and 9 IU IL-2/ml, respectively (Fig. 2). No IL-2 production « 0.2 U/ml) could be 
measured in the unstimulated cultures. 
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Figure 2. IL-2 production, after 
stimulation with ConA, of PBMC 
from control (C), naturally infected 
symptomatic (S), naturally infected 
asymptomatic (A) and experimentally 
infected (E) cats. Results are 
expressed as international units (lU) 
of IL·2 per ml. 
The proliferative responses of COIlA-activated PBMC from the 5 naturally 
infected cats with clinical symptoms to a saturating amount of human recombinant 
IL-2 (100 IU IL-2/ml) were significantly lower than the responses of the PBMC 
from the 25 control cats. Also, for PBMC from the 10 naturally and the 12 
experimentally infected asymptomatic cats, significantly lower proliferative 
responses to IL-2 were found. The geometric means of the control group increased 
from 5,917 cpm to 25,088 cpm upon cultivation in the presence ofIL-2 (Fig. 3A). 
For the naturally and experimentally infected seropositive nonsymptomatic cats, 
these values increased from 1,153 to 12,958 cpm and from 3,466 to 18,522 cpm, 
respectively. 
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The geometric mean cpm of the PBMC from naturally infected symptomatic cats 
was 139 cpm and did not increase significantly when the cells were cultured in the 
presence of IL-2. The stimulation indices of these cultures were 4.2, 11.3, 5.4 and 
1.4 respectively. Similar results were obtained when PBMC were not activated with 
ConA prior to the addition of IL-2, although the differences in proliferative 
responses found between the respective groups were less pronounced but the 
stimulation indices remained the same (Fig. 3B). 
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Figure 3. Proliferative responsiveness of PBMC from the fouf groups of cats, in cultures with and 
without recombinant human IL-2 (100 IU/ml). Proliferative responses after stimulation with ConA (JA) 
or without ConA (38) are expressed as counts per minute of tritiated thymidine incorporation. Control 
Group (C); naturally infected symptomatic (S) and naturally infected asymptomatic (A) cats, 
experimentally infected cats (E). 
37 
Establishment of FIV infection model 
Development of lymphopenia 
All 5 of the naturally infccted cats with clinical symptoms (Group S), showed 
lymphopenia «1.5 X 1012 lymphocytes!L blood) at the time of sampling. No 
lymphopenia was found in thc naturally flY-infected cats without clinical 
symptoms (Group A). Of the experimentally infected cats, only the two animals that 
were infected with the Petaluma strain showed lymphopenia, developing within four 
months after infection (154), and which persisted throughout the two years of 
observation. Similar lymphopenia was never observed in the cats experimentally 
infected with the Dutch flY strain during a followup period of 2 years. All the 
mitogen- and IL-2-induced proliferative repsonses and the ConA-induced IL-2 
production of the PBMC of these two cats were significantly lower than those of 
the nonlymphopenic animals in Group E. 
Discussion 
We have studied ill vitro parameters of the felinc immune system following 
natural or experimental infection with FlY. Proliferation responses of PBMC from 
symptomatic and asymptomatic cats after natural or experimental infection with 
FlY, induced by activation with mitogens or human IL-2, were significantly lower 
than those of noninfected cats. Similarly, IL-2 production levels of PBMC from 
symptomatic and experimentally infected asymptomatic cats were significantly 
lower, whereas the production of IL-2 by PBMC from asymptomatic naturally 
infected cats was unchanged. It may be concluded that the immune function of the 
symptomatic, and also of the asymptomatic FlY seropositive cats studied, was 
seriously impaircd. All of these parameters are generally also reduced in HIY 
seropositive individuals soon after infection (5,25,42,97,181,207). The data of our 
. studies are in line with earlier findings, showing that alterations in the immune 
system in flY seropositive cats parallel those in HIY seropositive individuals as 
exemplified by changes CD4!CD8 ratios (2,200) and lymph node morphology (W. 
Jarrett, personal communication). 
Since most of the FlY seropositive cats in these studies were privately owned 
spontaneously infected animals, in which the moment of FlY infection was not 
known, we could not conclude whether the differcnces in the responses found 
between individual animals were related to the duration of infection. The data 
obtained from the 12 experimentally infected cats that were still asymptomatic 
(followup time: two years) showed that loss of immune function occurs within, at 
most, 6 months after infection, before the onset of clinical symptoms. Apparently, 
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an early sign of immunological dysfhnction was a reduced responsiveness to lL-2, 
since no longitudinal data were available from these animals this could not further 
be substantiated. The fact that ConA-activated cells of infected cats show a reduced 
response to exogeneous lL-2 while the stimulation indices of these cells for Groups 
C, A and E stay the same suggests a reduction of the number of cells responding 
rather than a reduced response per cell. Further studies are needed to clarifY this 
issue. The development of lymphopenia in two of the experimentally infected cats 
without apparent clinical symptoms, within four months after experimental infection 
plus the observation that the proliferative responses and the lL-2 production of the 
PBMC of these two cats was significantly lower than those of the other cats in this 
group, indicate that either there are individual differences in susceptibility for the 
development of malnmction of the immune system upon infection, or that strain 
differences of FlV playa role in the pathogenicity of the virus. 
Since secondary infections play a major role in the pathogenesis of human 
AIDS, it was decided to study whether differences could be found between the 
respective groups, with regard to virus infections that are commonly found in cats. 
The experimentally infected cats (Group E) all remained free from these virus 
infections during the course of these experiments, as shown by serological 
screening. Serological studies in the symptomatic (Group S) and asymptomatic 
(Group A) cats, that had naturally acquired FlV infection, revealed no significant 
differences between these two groups: as expected, serum antibodies to FPV, FCaV, 
FHV, FeSFV and FCV were present in the majority of the cats of both groups. 
None of the cats in this study tested positive for FeLV, an impOitant cofactor in the 
development of feline AIDS following FlV infection (200). 
Although more longitudinal studies are needed to define the factors that 
determine the clinical course of experimental FlV infection of the cat, it may be 
concluded on the basis of the data presented, the clinical manifestations, and 
immunological alterations found in symptomatic cats, that the course of FlV 
infection in the cat resembles that of HIV infection in man. This underlines the 
value of the FlV model for the development of intervention strategies for AIDS. 
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Abstract 
In order to monitor the antibody response to feline immunodeficiency virus 
(FlV) in cats, following experimental and natural infection, enzyme-linked 
immunosorbent assays (ELISAs) were developed using recombinant ellY and gag 
proteins and p24-specific monoclonal antibodies. It was shown that in 
experimentally infected cats an eny protein-specific antibody response was directly 
followed by a gag protein-specific response. FlIlihennore, an ELISA for the 
detection of ellY protein-specific serum antibodies proved more sensitive in 
identifying experimentally and naturally infected cats than ELISAs demonstrating 
gag protein-specific antibodies. It was concluded that, like in HIV infection of 
humans, the detection of eny protein-specific serum antibodies in addition to gag 
protein-specific antibodies is not only an impotiant tool in the diagnosis of the 
infection but also in studies concerning the pathogenesis of the disease. 
Introduction 
Feline immunodeficiency virus (FIV) is a T-Iymphotropic lentivirus that was 
first isolated from domestic cats suffering from clinical signs indicative of an 
immunodeficiency syndrome (I99). The disease in cats is characterized by 
lymphadenopathy and severe impairment of immune function (2,241,269) 
accompanied by a decrease of the number of CD4 T lymphocytes (104). FIV has 
been shown to infect cat macrophages (30), astrocytes (53) and the CD4+ subset of 
T lymphocytes: a cell tropism similar to that of human immunodeficiency virus 
(HIV). Thus in many respects FIV infection in cats resembles mv infection in man 
and therefore FIV infection should be considered a useful animal model for AIDS 
in man. The model has been shown suitable to study the potential of celiain 
antiviral compounds (55,215), approaches for experimental vaccination (287) and 
the pathogenesis of lentivirus induced immunodeficiency (289). For these studies 
the development of assays to monitor the FIV-specific immune response after FIV 
infection and immunization with candidate vaccines is of critical importance. 
Several serological assays which demonstrate antibodies specific for the structural 
proteins of FIV have been described. These include enzyme-linked immunosorbant 
assays (ELISAs) based on whole virus preparations and immunofluorescence assays 
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(IF A), both of which do not discriminate between antibodies directed against the 
individual FlY proteins (185,239). Also Western blot and radio 
immunoprecipitation assays have been described (58,109,153), which are, however, 
too laborious for routine serological procedures. Recently, virus neutralization 
assays have been developed, which demonstrate antibodies that may directly be 
involved in protection from infection or development of disease (271). 
With the advent of hybridoma, recombinant DNA and peptide synthesis 
technologies it has become possible to develop assay systems which can 
demonstrate antibodies directed to individual proteins or even individual epitopes. 
In the present paper we describe the comparison of four newly developed ELISAs 
based on the use of FIY-env and 1'24 recombinant proteins and p24-specific 
monoclonal antibodies to monitor FlY -specific antibody development in the sera of 
naturally and experimentally infected cats. 
Materials and Methods 
Vims preparations 
An FlY isolate (Adam 4) from a Dutch cat seronegative to FeLY and FeSFY, 
was obtained by cocultivating peripheral blood mononuclear cells (PBMC) with 
Concanavalin-A and Interleukin-2 stimulated PBMC from a specified pathogen-free 
(SPF) cat as previously described (240). The FlY Petaluma strain was kindly 
provided by Dr. N.C. Pedersen (Davis, CA, USA). Crandell feline kidney (CrFK) 
cells (41) were infected with FlY by cocultivation of CrFK cells with the infected 
PBMC as described (239) and cultured in Dulbecco's minimal essential medium 
containing 100 IU/ml penicillin, 100 f!g/ml streptomycin, 0.002 M glutamin and 5% 
fetal calf serum (FCS). Culture supernatants of the infected (and non-infected) 
CrFK cells were collected seven to ten days after passage of the cells in fresh 
medium. The culture supernatants were used as antigens in the CTB-ELISA (see 
below) after clarification by low speed centrifugation (10 min, 2000 rpm). 
For immunization purposes FlY was purified from culture supernatant by density 
gradient centrifugation. The virns was first pelleted by centrifhgation for one hour 
at 100,000 g at 4°C. The pellet was resuspended in phosphate buffered saline (PBS) 
and then layered over a discontinuous metrizamide (Nyegaard and Co, Oslo, 
Nonvay) gradient. After centrifugation for one hour at 100,000 g at 4°C, vims 
containing fractions identified by a previously described ELISA (239) were 
collected. 
Concentration and partial purification of FlY antigen from culture supernatant 
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was also performed by precipitation in polymer based aqueous two phase systems as 
described for other retroviruses (90-92). Polyethylene glycol 6000 (Merck, 
Schuckardt, Germany) and Dextran T 500 (Phannacia, Uppsala, Sweden) were 
added to the culture supernatants at final concentrations of 7% and 0.2% 
respectively. The mixture was allowed to equilibrate by gently rocking for 16 hours 
at 4°C. Two phases were allowed to settle for another 16 hours at 4°C. Bottom and 
interphase (containing FIV) and top phase were collected separately. In this way a 
concentration of FIV of about 100-fold was achieved. This antigen was used for 
Western blot assays (see below). 
Generation and selection of mOl/oclonal antibodies (//lAbs) 
A panel of hybridoma's producing mAbs in ELISA reactive with FIV, was 
generated essentially as previously described for the generation of mAbs against 
poliovirus (195). Briefly, spleen cells from BALBlc mice, which were 
subcutaneously immunized with 5 ~lg gradient purified FIV in Freund's complete 
adjuvant on day 0 and in Freund's incomplete adjuvant on day 14, were fused with 
a mouse myeloma cell line after intraperitoneal booster injections on days 28, 29 
and 30 with 5 pg of pelleted F1V. Hybridomas producing FIV-specific mAbs were 
selected by screening culture media in an ELISA. For this ELISA microtiter plates 
(Costar, High binding RIAIEIA plates) were treated by incubating 50 ~ll volumes of 
a PBS solution containing 0.125 mg poly-L-Iysine and 10 mg l-ethyl-3(3-
dimethylaminopropyl)-carbodiimidehydrochloride (EDC) (Sigma, St. Louis, USA) 
per ml, for one hour at room temperature. After each incubation the plates were 
washed with demineralized water containing 0.05% Tween-80 (Merck, Schuckardt, 
Germany) (DWT). Fifty pi volumes containing 300 ng of pelleted F1V or control 
antigen were coated in 0.1 M carbonate buffer, pH 9.6 for 16 hours at 20°C. The 
plates were blocked with 50 ~ll volumes of PBS containing 0.05% Tween-80 and 
1% bovine serum albumin (BSA) (PBS-TB) for one hour at 37°C. Fifty pi of 
undiluted culture supernatants were transfered to the wells and incubated for one 
hour at 3rC. After washing, 50 pi volumes of a horse raddish peroxidase (HRP) 
conjugated goat anti-mouse IgG (Fc) antibody preparation (Cappel, Cooper 
Biomedical, Malvern, USA) were added to the wells and incubated for one hour. 
The plates were washed and 100 pi volumes of substrate solution (0.1 mgiml 
tetramethyl benzidin (TMB) and 0.003% H,O, in 0.1 M NaAc buffer, pH 5.5) were 
added to each well. After incubation for 10 min. at 20°C 100 pi volumes of 2 M 
H,S04 were added to stop the color reaction. The absorbance at 450 nm (A450) was 
read in a Titertek Multiscan (Titellek, Flow Laboratories). Hybridomas were 
selected and single cell cloned twice by micromanipulation. Mouse ascitic fluids 
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were produced in BALB/c mice. Immunoglobulins (Ig) were isolated from mouse 
ascitic fluids by precipitation with ammonium sulphate and affinity chromatography 
using protein A sepharose (Pharmacia Fine Chemicals, Uppsala, Sweden) (234). Ig 
classes and isotypes were determined in an indirect ELISA with specific anti-Ig 
conjugates (Zymed Laboratories, CA, USA) and indicated in brackets. 
Monoclonal antibodies were conjugated to biotin by incubating the antibody 
solution, which was dialyzed against 0.1 M NaCO], pH 8.3 (I mg protein per ml) 
with N-hydroxysuccinimido biotin (Sigma, St. Louis, USA) solubilized in dimethyl 
sulphoxide (Img/ml) at a 1:8 (w/w) ratio (biotin:protein) for four hours at room 
temperature. The conjugates were dialyzed against PBS and stored at -20°C. 
SDS-PAGE alld Westem blot analysis 
FIV (Adam 4) preparations were denatured in the presence of sodium 
dodecylsulphate and 2-mercnptoethanol and the individual viral proteins were 
separated on polyacrylamidc gel (12%) by using the discontinuous buffer system 
(136). Polypeptides were then electrically transfered to nitrocellulose sheets (270). 
For immunostaining the nitrocellulose was blocked with PBS-TB for one hour at 
20°C and after each incubation washed three times for 10 min. 
After incubation with monoclonal antibodies or cat sera for one hour at 20°C, 
the nitrocellulose was incubated with horse radish peroxidase (HRP) conjugated 
goat anti-mouse IgG (Fc) or goat anti-cat IgG (Cappel, Cooper Biomedical, 
Malvern, USA) respectively. Subsequently the nitrocellulose strips were developed 
with 24 mg tetramethyl benzidin and 80 mg dioctyl sodium sulfosuccinate diluted in 
10 ml ethanol supplemented with 30 ml 0.1 M citrate/phosphate buffer pH 5.5 and 
25 JlI 30% 1-1,02' 
Recolllbinant FIV proteins 
Recombinant FIV ellv protein, derived by PCR amplification of DNA from bone 
marrow cells of a naturally FIV-infected cat (cat Adam 19), was obtained by 
expression through recombinant vaccinia virus (rVV) vGR657 as described (219). 
In brief, HeLa spinner cells or BHK spinner cells were infected at a m.o.L of five 
with rVV vGR657. After 48 hours, the cells were washed with PBS and lysed in 
PBS containing 0.5% NP-40 and 0.5% SDS. After centrifugation for 20 min. at 
10,000 x g, the supernatant was used as FIV-env antigen in the respective assays. 
Recombinant FIV p24 and p 17 protein were obtained by expression in E.coli as 
fusion proteins using the pGEX-2T expression plasmid as previously described 
(213). 
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Cats and serum samples 
Six female SPF cats of about 12 weeks old from a breeding colony (Harlan 
CPB, Zeist, The Netherlands), which is regularly screened for the absence of viral 
pathogens, were infected via the intravenous route with about 100 TCIDso of one of 
three different FIV strains. Two (#5 and #6) with the Petaluma strain (kindly 
provided by Dr. N.C. Pedersen, Davis, CA, USA), two (#11 and #12) with a Dutch 
isolate (Adam 19) and two (#13 and 1114) with the progeny vims of the infectious 
molecular clone 19K I that was obtained directly from bone marrow DNA of a 
naturally infected cat, from which also FIV isolate Adam 19 was obtained (240). 
Serum samples were collected at regular intervals after infection, while the animals 
were kept in strict isolation. 
Serum samples were also collected from II privately owned Dutch cats which 
were suspected of FIV infection on clinical grounds and positive serology in a 
commercial test (Petcheck, IDEXX Corporation) and from 26 privately owned 
Dutch cats without clinical signs. 
ELISAs for the detection of FIV-specific antibodies 
For the detection of FIV-specific antibodies, four indirect ELISAs were used. 
These ELISAs differed only in the antigen preparations used for the coating of the 
ELISA plates (Costar RIAJEIA, High binding). Optimal concentrations of the 
reagents used were determined by checkerboard titration. The coating procedures of 
the four ELISAs were as follows: 
1. Total virus ELISA (IV-ELISA). For the TV-ELISA, FlV antigen for coating 
was concentrated by ultracentrifugation from supernatants of infected CrFK cell 
cultures. After solubilization with 1% w/v Triton X-100 (Merck, Schuckardt, 
Germany), the antigen was diluted in 0.1 M NaAc buffer, pH 5.5, 50 III volumes 
were added pel' well and the plates were incubated at room temperature for 16 
hours. The wells were then emptied and fixed with 4% (w/v) paraformaldehyde for 
10 min. at room temperature. After washing the plates were blocked with PBS 
containing 0.05% Tween-80 and 10% FCS. 
2. ELISA based on FIV-specific mAbs (MTV-ELISA). For the MTV-ELISA 
microtiter plates were coated with purified mAb 8-21 (see below) in 0.1 M 
carbonate buffer, pH 9.6. The plates were washed with DWT containing 0.05% 
Tween-80 after each incubation. After blocking with PBS-TB for one hour at 37°C, 
50 III volumes of culture supernatants of FlV infected (or non-infected) CrFK cells, 
to which I % Triton X-100 and 5% NaCI was added, were incubated for one hour at 
3TC. 
3. ELISA based on recombinant FIV-ellv protein (rec.env-ELISA). For the 
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rec.env-ELISA cell lysates of rYY vGR657 (or wild type vaccinia virus) infected 
RK13, BHK or HeLa cells were coated in 0.1 M NaAc buffer, pH 5.5 in 50 III 
volumes for 16 hours at room temperature. The wells were then emptied and fixed 
with 4% (w/v) para formaldehyde for 10 min. at room temperature. After washing 
the plates were blocked with PBS containing 0.05% Tween-80 anp iO% FCS. 
4. ELISA based on recombinant FIV p24/p17 proteins (rec.gag-ELISA). The 
rec.gag-ELISA, based on recombinant gag proteins, was purchased from the 
European Veterinary Laboratory B.Y., Amsterdam, The Netherlands (FIY-p24/pI7 
antibody test kit, cat no. FI002-ABOI) and performed essentially as described 
previously (213). 
After coating and blocking of the microtiter plates, 50 fll of twofold serial 
dilutions of serum samples in PBS-TB supplemented with 5% NaCI were added at a 
starting dilution of I :40 or I :20. Then the plates were incubated for one hour at 
3TC. Subsequently 50 III volumes of a biotin conjugated mouse mAb directed to 
cat IgG (Sigma, St. Louis, USA) or an HRP conjugated goat anti-cat IgG antibody 
preparation (Cappel, Cooper Biomedicals, Malvern, USA) were added and the 
plates were incubated for one hour at 37°C. HRP bound streptavidin (Amersham, 
Amersham, UK) was allowed to bind to biotin for 30 min. at 37°C. After each of 
these incubations the plates were washed with OWT and subsequently developed 
with TMB as described above. 00"0 values were determined in a Titertek 
multiscan. Titres were given as the reciprocals of the dilutions still giving more 
than three times background values obtained with control antigen coated plates. 
Complex trapping blocking ELISA (CTE-ELISA) for the detection of FIV p24-
specific antibodies 
For the CTB-ELISA microtiter plates were coated with FlY p24-specific mAb 8-
21 and blocked with PBS-TB as described for the MTY-ELISA. The plates were 
washed twice after each incubation with OWT. Twenty-five III volumes of twofold 
serial dilutions of cat serum samples, starting at a dilution of 1:5 were added 
simultaneously with 25 III of a dilution of culture supernatant of flY infected CrFK 
cells giving 75% of maximum binding. All dilutions were prepared in PBS-TB 
supplemented with 1% Triton X-100 and 5% NaCI. After incubation for two hours 
at 3TC, remaining binding of flY antigen was detected using biotin conjugated 
mAb 2-13 (see below). The combination ofmAb 8-21 as capture antibody and mAb 
2-13 as conjugated antibody was chosen as it proved to be the most sensitive among 
those tested with the mAbs generated in these studies. After incubation with biotin 
conjugated mAb 2-13 for one hour at 37°C, HRP bound streptavidin was allowed to 
bind to biotin for 30 min. at 37°C. The plates were developed as described above. 
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Test samples were considered positive if a reduction of 50% or more of the signal 
was observed. 
Results 
Selection and characterization of FIV-specijic IIlAbs 
Five hybridomas, producing antibodies reactive with FIV antigen as determined 
in the hybridoma screening ELISA, were obtained from two fusion events. These 
mAbs were designated 2-11 (IgGl,k), 2-13 (IgG2b,k), 3-20 (IgG2a,k), 4-22 
(IgGI,k) and 8-21 (IgGI,k). When tested for their reactivities in Western blot 
analysis, these five mAbs all reacted with the denatmed p24 core protein of FlV 
(Fig. I). No reactivity was found with control antigen concentrated and purified in 
the same way. The specificity of these five mAbs for the FlV gag protein was 
confirmed by demonstrating their reactivities in the rcc.gag-ELISA (00450 >800 per 
50 ng Ig) in which their respective isotype control mAbs did not react (data not 
shown). 
23456789 
I 
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Figure 1. Western blot analysis of FIV-specific 
MAbs. Viral proteins of two phase system purified 
FIV (lanes 1-7) or control antigen (lanes 8 and 9) 
were separated by SOS-PAGE and electrically 
transferred to nitrocellulose. For imlllunostaining 
individual lanes were incubated with serum of a FIV 
seropositive cat (diluted 1:100, lanes I and 8), serum 
of a seronegative cat (diluted 1:100, lane 2), culture 
slipernatants of MAbs 2-11 (lane 3), 2-13 (lane 4), 3-
20 (lane 5), 4-22 (lane 6) alld 8-21 (iane 7). 
FIV-specijic antibody responses in experimentally infected SPF cats 
The development of FIV.specific serum antibodies in experimentally infected 
cats was monitored in the respective ELiSAs (Fig. 2). In two SPF cats (#11 and 
#12) infected intravenously with the Dutch FIV isolate Adam 19 and two other SPF 
cats (#13 and #14) infected with the progeny of infectious molecular clone (Adam 
19K!), the development of serum antibodies to whole vims, FlV env and FlV gag 
proteins followed similar kinetics (Fig. 2a). Immediately after the onset of env-
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Figure 2. Development of FIV-specific antibodies in experimentally infected cats. Antibody responses 
were monitored in the TV-ELISA (II-II), MTV-ELISA (0-0), rec.ellv-ELISA (0-0), rec.gag-ELISA 
(0-0) and CTB-ELISA (0-0) of: cats infected with the Dutch isolate Adam 19 of FIV (eats# II and 
#12), cats infected with the progeny of infectious molecular clone Adam 19K1 (cats #13 and #14) and 
cats infected with the Petaluma strain of FIV (cats #5 and #6). 
specific response detected in the rec.el/v-ELISA which was found within three 
weeks post infection and led to titres >5120 within five weeks, FlV gag protein-
specific antibodies, measured in the rec.gag-ELISA and in the CTB-ELISA were 
detected. These increased rapidly during the subsequent weeks_ In cat # 13 the 
antibody response to FlV gag protein seemed to develop slightly later. Antibodies 
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measured in the TV- and MTV-ELISAs developed concomittently with the env-
specific antibodies in these four cats. A relatively late development of FIV gag 
protein-specific serum antibodies was more pronounced in the two SPF cats (#5 and 
#6) infected intravenously with the CrFK-cell adapted Petaluma strain of FIV (Fig. 
2b). In cat #5 no FIV gag protein-specific antibodies could be detected within eight 
weeks post infection, whereas in cat #6 FIV gag protein-specific antibody titres 
slowly increased from five weeks post infection onward. These data coincided with 
the development of FIV gag protein-specific antibodies detectable in Western blot 
analysis in these two cats (data not shown). The development of env-specific serum 
antibodies did exhibit kinetics similar to those observed in the other four cats. 
Serum antibodies measured in the TV- and MTV-ELISAs in cat #6 were also 
similar to those of the other four cats, whereas the development of these antibodies 
in cat #5 again proved to be slower. 
FIV-specific antibodies in clinically healthy alld clinically suspected cats 
Privately owned Dutch cats (n~37) with (n~ll; positive in the TV-ELISA; 
Petcheck, IDEXX Corporation) and without (n~26; negative in the TV-ELISA) 
clinical signs indicative for FIV infection, were tested for the presence of FIV-
specific serum antibodies in the four newly developed ELISAs: MTV-, reC.eIlV-, 
rec.gag- and CTB-ELISAs (Fig. 3). 
None of the serum samples from cats without clinical signs scored positive in 
any of the newly developed ELISAs. The II cats with clinical signs indicative for 
feline AIDS, all scored positive in the rec.env-ELISA, with titres ranging from 320 
to 25120. Of the II positive samples three (samples A, B and C) scored 
consistently negative in the rec.gag- and the CTB-ELISA, and negative or low 
titred (titre~20) in the MTV-ELISA. There proved to be an overall relation between 
the values found with the individual serum samples in the MTV-, rec.gag- and 
CTB-ELISAs which was not the case when the results of these assays were 
compared with those obtained in the more sensitive rec.env-ELISA. 
Discussion 
In this paper we have described four newly developed ELISAs based on different 
principles using recombinant FIV proteins or gag protein-specific monoclonal 
antibodies. New generations of diagnostic ELISAs are needed since the presently 
used classical assays, based on whole virus preparations have been shown to score 
too many false positives (213,239). Furthermore, ELISAs based on this principle do 
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Figure 3. Comparison of FlY-specific antibody levels in sera from naturally infected cats (n-l I) 
obtained in the rec.en\'- and MTY-ELISAs, the rec.ellv- and rec.gag-ELISAs, the rec.env- and eTB-
ELISAs, the rec.gag- and the CTB-ELISAs, the CTB- and the MTY-ELISAs and Ihe rec.gag- and 
MTV-ELISAs. (For A, B, C: see Results) 
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not allow the identification of antibodies directed against individual viral proteins, 
which as in the case of HIV infection of humans may be of major imp011ance for 
studies concerning the pathogenesis of the disease (7,8,137,281). All except the 
CTB-ELISA were based on the use of antigen coated plates to quantitate FlV gag-
or env-specific antibodies in feline sera. With sera from experimentally infected cats 
it was shown that, as in H1V-I infections in man (212,228), env-specific antibodies 
were detected before the appearance of gag-specific antibodies. This difference was 
most pronounced in cats infected intravenously with the CrFK adapted Petaluma 
strain of FlV. The overall slower development of FlV-specific antibodies in these 
two cats as compared to those infected with the Dutch isolate Adam 19 or the 
molecular clone 19K I indicates that either strain differences or adaptation of the 
vhus to CrFK cells may directly influence the initial replication rate of the virus. 
The relatively slow development of gag-specific antibodies in the cats infected with 
the Petaluma strain was confirmed by showing that these findings coincided well 
with the development of antibodies reactive with p24 in the Western blot assay (not 
shown). After having monitored the development of se11lm antibodies, detectable 
with these assays in the experimentally infected cats during the first months after 
infection, their value for the detection of naturally infected domestic cats was 
studied by testing the serum samples of II cats suspected of suffering from FlV 
infection on basis of clinical signs and subsequent positive serology in the Petcheck 
ELISA. All the 26 clinically healthy cats scored negative when tested in all the 
newly developed serological tests. Among the 11 TV-ELISA positive cats, all 
scored positive in the rec.ellv-ELISA. Of these, three (samples A, B and C) were 
negative or borderline positive in the ELISAs detecting antibodies directed to the 
FlV gag protein. From cats A and C PBMC could be obtained, from which FIV 
was isolated (data not shown). This indicates that results found in the rec.env-
ELISA are indeed confinnative for FIV infection and that the other three ELISAs 
may fail to identify some FIV infected cats. 
Although the envelope glycoprotein is subject to antigenic variation which may 
result in lack of reactivity with se11lm antibodies of cats infected with heterologous 
virus, no evidence was provided with the serum samples tested that this was the 
case. However, the combination of serological assays detecting both FlV ell v- and 
gag-specific antibodies, circumvents this possible problem and should be considered 
confirmative for FlV infection. 
For the detection of gag-specific antibodies, the use of the MTV-ELISA based 
on FlV gag-specific monoclonal antibodies may be less suitable since agglomerates 
of different virus proteins may be bound to the plates. The results obtained with 
sera from experimentally infected (#5 and #6) cats suggest that this is indeed the 
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case (Fig. 2). 
A discrepancy in the presence of e/lv- vs. gag-specific antibodies, as was shown 
in the early stages of infection in the experimentally infected cats #5 and #6, may 
cause false negative serological results when a system is used that does not detect 
e/lv-specific antibodies. Such discrepant results may perhaps also be expected when 
cats progress towards AIDS, as has been documented in HIY symptomatic 
infections in man, in which gag-specific antibodies, either due to immune complex 
formation or loss of functional B lymphocytes, decline while e/lv-specific antibodies 
persist (137-139,168,261,281). The discrepancies found in FlY gag- vs. e/IV-specific 
antibodies in cats A, Band C may be a reflection of this phenomenon since they all 
exhibited serious signs of immunodeficiency at the time of sampling. Since a small 
number of animals has been tested, these ELISA systems should be used to test 
more cats in different stages of disease to assess that these phenomenons indeed 
play a role in FlY pathogenesis. The documented failure of serological assays to 
identifY "silently" FlY infected cats (108), may perhaps be attributed to their 
inability to detect FlY e/lv protein-specific antibodies. A similar observation has 
been described for certain HIY infections which initially were believed not to 
induce serum antibodies (212,228). 
In conclusion the data presented indicate that ELISAs based on the simultaneous 
detection of FlY e/lv and gag protein-specific serum antibodies are highly specific 
and sensitive tools for the serology of FlY infection in cats. They also allow 
detailed studies of mechanisms underlying certain kinetics of the FlY-specific 
antibody response that have been documented also in HIY infections of humans. 
Acknowledgements 
The authors wish to thank Jan Groen for preparation of the graphics and Ms. 
Conny Kmyssen and Ms. Miek Eskens for preparing the manuscript. 
54 
Chapter 2.3 
Isolation and Partial Characterization of Infectious 
Molecular Clones of Feline Immunodeficiency 
Virus Obtained Directly from Bone Marrrow 
DNA of a Naturally Infected Cat 
Kees H.J. Siebelink, I-Hai ehu, Guus F. Rimmelzwaan, 
Kees Weijer, Albert D.M.E. Osterhaus, 
and Mamix L. Bosch 
J. Virol. 66:1091-1097 (1992) 

Abstract 
Replication-competent molecular clones of feline immunodeficiency virus (FIV) 
were isolated directly from the DNA of bone man-ow cells of a naturally FlV-
infected cat. After transfection in a feline kidney cell line (CrFK) and subsequent 
cocultivation with peripheral blood mononuclear cells (PBMC), the viral progeny 
of the clones was infectious for PBMC but not for CrFK cells. PBMC infected with 
these clones showed syncytium formation, a decrease in cell viability, and gradual 
loss of CD4+ cells. The restriction maps of these clones differed from those 
obtained for previously described molecular clones of FIV derived from cats in the 
United States. The predicted amino acid sequence similarity of the envelope genes 
of the two clones was 99.3%, whereas the similarities of the sequences of the clones 
to those of two molecular clones from the United States, Petaluma and PPR, were 
86 and 88%, respectively. Most of the differences between the amino acid 
sequences of the two clones and those of the clones from the United States were 
found in five different hypervariable (HV) regions, HV-l through HV-5. The viral 
progeny of one of these clones was inoculated into two specific-pathogen-free cats. 
The animals seroconverted, and the virus could be reisolated from their PBMC. 
Introduction 
Feline immunodeficiency virus (FIV) is a T-lymphotropic lentivirus, initially 
isolated from an immunodeficient cat (199). FlV infection in cats can lead to 
immunological abnormalities similar to those seen in human immunodeficiency 
virus type I (HIV-l) infected humans, like a depletion of CD4+ cells in circulation 
(2,16,269). Similarly, the peripheral blood mononuclear cells (PBMC) from FlV 
infected cats show reduced proliferative responses to mitogens and to exogenous 
interleukin 2 (IL-2) in vitro (16,94,241). These similarities in biological behavior 
between HIV-I and FIV may make FIV infection of cats a suitable small-animal 
system to study lentivirus pathogenesis as a model for human AIDS and may 
likewise identify the FIV system as a model for HIV vaccine development. 
Lentiviruses display a large degree of molecular and biological variation. This 
variation is generally ascribed to the low fidelity of the viral enzyme reverse 
transcriptase (RT) in copying the viral genomic RNA to DNA (206,220). The use 
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of complete molecular clones allows one to obtain genomically homogeneous viral 
populations. Relating the biological properties of such populations to the genomic 
structure of the molecular clone from which they were derived may reveal the 
molecular basis of biological variation and may identify determinants of viral 
virulence. To date, molecular clones of three FlV strains have been described, two 
from the United States (the 34TF I 0 clone of the Petaluma strain [(188,259)] and 
the PPR clone of the San Diego strain [(204)] and one from Japan (JMI [(173)]), 
which were all obtained from the DNA of in vitro-propagated cells. Culturing in 
vitro may select for celiain virus subpopulations and can induce new features in the 
propagated virus. Culturing of simian immunodeficiency virus (SIV) in human cells, 
e.g., can lead to the introduction of a premature termination codon in the viral 
transmembrane glycoprotein (102,132). These problems make the availibility of 
complete molecular clones obtained directly from the DNA of ill vivo-infected cells 
highly desirable. Here we report two replication-competent molecular clones derived 
directly from the DNA of bone marrow cells from an FIV-infected cat. The 
genomic structure of these clones and their presumed envelope gene sequences are 
presented. 
HIV-I, HIV-2 and SIV infect cells via the CD4 molecule which acts as the 
cellular receptor for these viruses (45,127,156,166). These viruses are also 
cytopathic for CD4+ cells ill vitro, and this cytopathic effect may at least in part 
underlie the virally induced immunodeficieucy characterized by CD4+ cell depletion 
ill vivo. The CD4 analog in cats has been identified recently (I), but its role in FIV 
binding aud entry is not yet clear. FIV infection also results in a reduction of CD4+ 
cells in circulation iu infected cats. We have therefore investigated whether the 
molecular clones of FIV described here are cytopathic for CD4+ cells ill vitro. 
Materials and Methods 
Cells and virus 
Bone marrow cells were obtained from the femur of a 4-year-old naturally FIV-
infected free-roaming cat (Amsterdam-19) suffering from a generally debilitating 
disease and intermittent disease symptoms, including respiratory infections and 
chronic diarrhea, all suggestive of an immunodeficiency syndrome (199,289). The 
cells were washed twice and used for isolation of genomic DNA (see below). 
PBMC were isolated from heparinized blood from the cat by Ficoll density 
gradient centrifugation. The PBMC were washed three times with RPM! 1640 
(GIBCO), supplemented with penicillin (100 IU/ml), streptomycin (100 ug/ml), L-
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glutamin (2 mM), and ll-mercaptoethanol (2 x 10-5 M), designated culture medium 
(CM). A total of 10' PBMC were stimulated with 5 ug concanavalin A (ConA) 
(Flow Laboratories, Inc) per ml in CM supplemented with 10 % heat-inactivated 
fetal calf serum (FCS). After 3 days, the cells were washed once and further 
cultured with CM supplemented with 10% FCS and IL-2 (100 10/011) (Cetus). The 
culture supernatant was monitored weekly for the presence of FIV antigen in an 
F1V antigen capture enzyme linked immunosorbent assay (ELISA) as described 
previously (239). A virus stock of FIV from cat Amsterdam-19 (designated FIV 
Amsterdam-19) was made from the supernatant of this culture 21 days after 
stimulation and stored in aliquots at -135 DC. The RT activity was assayed and was 
7.0 x 10' cpmlml. 
PBMC were derived from heparinized blood of a specific-pathogen-free (SPF) 
cat by Ficoll density gradient centrifugation. The cells were washed twice and 
frozen at -135 DC in aliquots in CM supplemented with 10% FCS and 10% 
dimethyl sulfoxide. Before use, the cells were thawed and stimulated with ConA (5 
uglml) for 3 days and fhrther cultured with IL-2 (100 IU/ml). 
An F1V-susceptible clone of the Crandell feline kidney cell line (CrFK) was 
obtained from N. Pedersen (289). The cells were cultured in Dulbecco's modified 
Eagle's medium supplemented with penicillin (100 IO/ml), streptomycin (100 
uglml), L-glutamin (2 mM), Jl-mercaptoethanol (2 x 10-5 M), and 10% FCS. 
DNA isolation 
Genomic DNA was isolated from bone marrow cells. A total of 108 bone 
marrow cells of cat Amsterdam-19 were washed twice and lysed with 100 ug of 
proteinase K per ml and 0.5% sodium dodecyl sulfate (SDS) for 16 hours at 42 DC. 
Cesium chloride (1.25 glml of lysate) was added, and after centrifugation for 44 
hours at 60,000 rpm in a 70Ti rotor (Beckman), fractions containing the high-
molecular-weight DNA were collected, pooled, and dialysed against TE (10 mM 
Tris, pH 8.0, and 0.1 mM EDTA). 
Southern blot analysis of genomic DNA 
Genomic DNA was digested with BamHI or, Nhe!. After electrophoresis the 
DNA was transferred to nitrocellulose and hybridized with 12P-labeled gag probe P 2 
(see below) in hybridization buffer (3 x SSC [I x SSC is 0.15 M NaCI plus 0.Q15 
M sodium citrate], 50 mM Tris, 5 x Denhardt's solution, 0.5% SDS, 5 mM EDTA, 
50% formam ide, 10% dextran sulfate, and 10 ug of salmon sperm DNA per ml). 
The blots were washed twice with 0.2x SSC - 0.1% SDS for 30 minutes at 68 DC 
each'time and autoradiographed. 
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Molecular cloning of FIV proviral DNA 
Genomic DNA from bone marrow cells from cat Amsterdam-19 was partially 
digested with Sau3A. After size fractionation on a 5 to 25% NaCI gradient, 10- to 
20-kb fragments were ligated to EMBL-3 lambda arms (Stratagene) and packaged 
in vitro. The unamplified lambda phage library was screened with the probes P 2 
(1.8 kb Sstl - BamHI gag fragment) and P22 (2,1 kb BamHI - BamHI Pol fragment), 
which were obtained from R. Olmsted (188) and ENV-4 (a 2.6-kb fragment 
spanning the complete envelope gene obtained by polymerase chain reaction 
[216)). 
Positive plaques were purified, and the DNA was isolated. Sphl - Sall fragments 
of these clones were subcloned in pUCI9. The subclones were used for the 
dideoxynucleotide chain termination sequence reaction (229) of the env gene. The 
nucleotide and protein aligments as well as the percentage of similarity were 
determinated with Lasergene software (DNAstar Inc., London, United Kingdom). 
Purified lambda DNA was used for the constmction of a restriction enzym map. 
Lambda DNA from the clones was digested with the retsriction enzymes Ban!l·n, 
BglII, EcoR!, Kpnl, Nhel, Sphl, and Sstl and after electrophoresis on a 0.8% 
agarose gel, transferred to nitrocellulose. The filters were subsequently hybridized 
with P 2' P 22 or ENV -4 and autoradiographed. 
DNA transfection 
A sample of 5 ug lambda DNA was transfected into CrFK cells by using the 
cationic lipid DOTMA (lipofectin; Bethesda Research Laboratories, Inc.) according 
to the protocol of the manufacturer. Briefly, 5 ug of DNA in 50 ul of H,D was 
mixed with 50 ul lipofectin and incubated for 15 minutes at room temperature. 
CrFK cells were washed with semm-free Dulbecco's modified Eagle's medium, and 
the lipofectin reagent - DNA complex was added. Twenty-four hours after 
transfection CM containing 20% FCS, 100 IV of IL-2 per ml, and 5 x 106 ConA-
and IL-2 stimulated PBMC from an SPF cat were added. After 72 h, the PBMC 
and CrFK cells were washed and cultured separately. The culture supernatant was 
monitored for the presence of F1V antigen in an F1V antigen capture ELISA. 
Eighteen days after transfection, a virus stock was made and stored in aliquots at -
135°C. The RT activity was determined. The infected cells were used for electron 
microscopy essential as described by Gelderblom et al. (78). 
bifectioll of PBMC 
ConA and IL-2 stimulated PBMC of an SPF cat were infected with the 
molecular clones or with the biological isolate FIV Amsterdam-19 by resuspending 
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107 PBMC in I ml of virus dilution in CM containing 2 x 104 cpm of RT activity 
per m!. After I h at 37°C, the cells were washed twice with CM and cultured in 
CM supplemented with 10% FCS and 100 IU of IL-2 per m!. Twice a week, 1.5 ml 
of culture supernatant was centrifuged (10 min at 300 x g) and stored at -135°C 
until testing for presence of FIV antigen and RT activity. The cells were monitored 
for cytopathic effects like syncytium formation and cell viability and for the 
percentage of CD4+ and CD8+ cells by fluorescence-activated cell sOlter analysis 
with monoclonal antibodies provided by M.Cooper (1,129). 
RTassay 
RT activity was assayed in a microassay as previously described by Gregersen et 
al (87), with minor variations. Briefly, Iml culture supernatant was precipitated 
with 0.25 ml 32% polyethyleneglycol 6000-1.5 M NaC!. The pellets were 
resuspended in 10 ul of lysis buffer (50 mM Tris [PH 8.3], 20 mM dithiothreitol, 
0,25% Triton X-IOO) and mixed with 40 ul H,o and 50 ul of RT cocktail (100 mM 
Tris [pH 7.9], 150 mM KCL, 10 mM MgCl" 4 mM dithiothreitol, 0.6 U poly(rA) -
oligo(dT), 60 uCi of [lH]-TIP per ml). After incubation at 37°C for I h, the DNA 
was precipitated with 20 ul of 120 mM Na,p,07 . 10 H,O in 60% trichloroacetic 
acid for 15 minutes at 4°C. The DNA was spotted onto glass fiber filters with a 
Skatron cell harvester and washed with 12 mM PPNa in 5% trichloroacetic acid. 
The filters were dried, and eH] TIP incorporation was measured in a B-
scintallation counter. 
Nucleotide sequence accession number 
The sequences repOlted in this paper have been deposited in the GenBank 
database (accession no. for clone 19k1 is M73964 and for clone 19k32 is M73965). 
Results 
Molecular cloning alld characterization of FIV provirus 
Genomic DNA from bone marrow cells of a naturally FIV-infected free-roaming 
cat (Amsterdam-19) was digested with restriction enzymes and blotted onto 
nitrocellulose for hybridization with probe P2, FIV-specifie could be detected in 
this DNA preparation as well as in the DNA obtained from the spleen cells of cat 
Amsterdam- I 9 and the spleen and bone marrow cells of another naturally FIV-
infected cat (data not shown). Digestion with BamHI or Nhel yielded internal FIV 
fragments with sizes of 3.8 and 3.2 kb respectively. These fragments are also found 
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in the maps of lambda clones 19k1 and 19k32 (see below). 
Full length proviral FIV clones were obtained from a EMBL·3 lambda phage 
library made directly from the DNA of the bone marrow cells of cat Amsterdam· 19 
by using the P" P ", and ENV·4 probes for screening. The hybridizing clones were 
plaque purified and used for the isolation of lambda DNA. The replication 
competence of the cloned FIV provims was assayed by transfection into CrFK cells 
(see below). Three clones (l9kl, 19k32, and 19k36) gave rise to F1V antigen 
production upon transfection and were characterized fhrther. Restriction maps of 
these three clones showed a high degree of similarity (Fig. I). The maps of clones 
19k1 and 19k36 were identical, whereas an additional BgnI site is present in the 
envelope gene of 19k32. This additional BgnI site was later confirmed by sequence 
analysis. When the predicted maps of the two U.S. clones (204,259) were compared 
with that of clone 19k1, only 14 of 22 (34TFIO compared with 19k1, respectively) 
and 14 of 21 (PPR compared with 19k1, respectively) restriction sites appeared to 
be conserved. Between 34TFIO and PPR, 12 of 21 restriction sites are conserved 
(Fig. I). This indicates a high degree of heterogeneity among these different F1V 
strains. 
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Figure 1. Restriction map of infectious clones molecular clones of the FlY strains Petaluma (34TFlO), 
San Diego (PPR) and FIV Amslerdam-19 (19kl and 19k32). Reslriclion enzyme maps of 34TFlO and 
PPR are as predicted from their published nucleotide sequences (24,30). Maps of 19k1 and 19k32 were 
obtained by single and double restriction enzyme digestion of lambda DNA which contain the full lenght 
clones, followed by Southern blotting and hybridization with the 32p labeled FlY specific probes Pl' Pn 
or ENY·4. Restriction enzyme cleaving sites: B, BamHI; Bg, BglJI; RI, EcoRI; K, Kplll; N. Nhel; Sp. 
Sphl and S, Sst!. 
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We obtained the nucleotide sequence of the envelope gene of the three clones of 
FlV Amsterdam-19. The nucleotide sequences of the envelope genes and the 
preliminary restriction site analysis of the 5'- and 3'- flanking sequences of the 
clones 19k1 and 19k36 showed no differences, which suggests that these clones are 
fully identical. On the other hand, we found that clones 19k1 and 19k32 differed in 
the length of their flanking sequences (data not shown), and only the sequences of 
these clones were analyzed further. The 2,571 nucleotide of the envelope genes of 
these clones differ in only nine positions. Because of the lack of direct amino acid 
sequence data, it is as yet unclear where the exact initiation codon of the envelope 
gene is located. We have presumed the conserved ATG at position 6264 of clone 
34TF 10 of the Petaluma strain (259) to be the initiation codon for the ellv gene, 
which then encodes an 857-amino-acid glycoprotein with a potential cleavage site 
after 611 amino acids, resulting in a 61l-amino-acid surface glycoprotein and a 
246-amino-acid transmembrane glycoprotein. The predicted amino acid sequences 
of the envelope glycoproteins of these clones were compared with those of the 
34TF 10 clone of the Petaluma strain and the PPR clone of the San Diego strain 
(204,259) (Fig. 2). The amino acid identity of the envelope glycoproteins of clones 
19k1 and 19k32 is 99.3%. The sequence identities of these two highly related 
clones with the 34TFIO and PPR clone envelope sequences are 86 and 84%, 
respectively. We have aligned the four envelope gene sequences (Fig. 2). Although 
amino acid variation is found throughout the entire ellv gene, we observed the 
presence of five hypervariable (HV) regions, designated HV-I through l'IV-5, as 
indicated in Fig. 2. These HV regions concur in part with the variable regions 
described by Phillips et al. (204). All four sequences are remarkably colinear, with 
insertions andlor deletions only found in HV -5 (Fig. 2). Most of the potential N-
linked glycosylation sites are conserved between the envelope sequences of all four 
clones (21 of 22); some variation of the cystein residues is observed within the first 
150 amino acids. 
Biological characterization 
Lambda phage, containing apparently full-length proviral DNA of clones 19k1, 
19k32, and 19k36, was transfected into CrFK cells. These were then cocultivated 
with PBMC for 72 hours. Both cell populations were then cultured separately. In 
the PBMC cultures infected with clone 19k I and 19k32, FIV antigen could be 
detected within 8 days after transfection. FIV antigen was also detected in the 
PBMC culture of clone 19k36 12 days after transfection. Transmission electron 
microscopy pictures from all of these cultures showed mature and immature virus 
particles and particles budding from the cell membrane (data not shown). FIV 
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Figure 2. Comparison of the predicted amino acid sequence of the eve lope genes of molecular clones of 
the FIV strains Petaluma (34TFIO), San Diego (PPR) and FIV Amsterdam-19 (l9kl and 19k32). HV 
regions (HV·l through HV·S) are boxed. Solid lines, potential conserved glycosylation sites; dashed 
lines, non-conserved sites; closed circles, conserved cysteine residues; open circles, nonconserved 
residues. The presumed cleavage site between the surface glycoprotein (SU) and transmembrane (TM) is 
also shown. (see text for details) 
antigen could not be detected in the supernatant of the CrFK cell cultures. The 
PBMC cultures were expanded, and virus stocks were stored at _135°C. The RT 
activities of the stocks were 2.3 x 10', 2.9 X 10', and 0.5 x 10' cpmlml for 19k1, 
19k32, and 19k36, respectively. On the basis of apparent genetic identity of 19k1 
and 19k36 (see above), we have concentrated on clones 19k1 and 19k32 for further 
analysis. 
64 
A 
'" 
'" 
'" 
c 
RT activity 
o 1 , 1 ft U M 21 « 21 
daye poallnfeellon 
% viable cells 
.. vr.bl. ctll. 
'" 
o I 4 1 '1 14 ~ 21 24 n 
day, post Infection 
B FIV antigen 
00450 
'''' 
." 
." 
." 
'" 
D 
" 
" 
" 
" 
o 1 4 1 11 « " ~ ~ » 
days pOSllnfectlon 
% CD4+ cells 
1 4 7 11 14 la 
daya post Infection 
Chapter 2 
Figure 3. Virus production, cell viability, and percent of CD4+ cells in feline PBMC infected in vitro 
with FlY as described in the text. (A) RT activities in culture supernatant; (8) FIV antigen in culture 
supernatant; (C) percent of viable cells; (D) percentages of viable cells which were CD4+, Symbols: '* . 
non-infected; 0 I biological isolate FlY Amsterdam-19; III. molecular clone 19k1; +, molecular clone 
19k32. 
ConA and IL-2- stimulated PBMC (10') from an SPF cat were infected with 
equal amounts of RT activity (2xlO' cpm) of the viral progeny of clone 19k1 or 
19k32 or the biological isolate FlY Amsterdam-19 obtained from in vitro-
propagated PBMC. The cultures were monitored for syncytium formation, cell 
death, percentage CD4+ and CDS+ cells, FlY antigen production, and RT activity. 
The results are shown in Fig 3. Syncytium formation was seen 4 days post infection 
(p.L) in the culture infected with 19k1 and 6 days p.i in the culture infected with 
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Figure 4. Syncytium formation of feline PBMC which are infected with viral progeny of molecular 
clone 19k1 (magnification 400 x). 
19k32 or the biological isolate (Fig. 4). FlY antigen and RT activity could be 
detected after II (19kl) and 14 (l9k32 and FlY Amsterdam-19) days in the FIY-
infected cultures but not in the non-infected control culture for 28 days p.i. (Fig. 3A 
and B). 
The percent viable cells decreased from 95 to 55% during 28 days of culturing 
in the noninfected culture, whereas there was a more rapid decrease of viable cells 
in the FlY-infected cultures (only 15% viable cells after 28 days) (Fig. 3C), 
indicating cell death caused by FlY infection. 
The percentages of the viable cells which were CD4+ and CD8+ cells could be 
measured accurately only during 18 days of culture following infection because of 
the low percent viable cells after this period. The percentages of viable cells which 
were CD4+ and CD8+ cellso were 44 and 35%, respectively, at the time of infection. 
After 18 days of culture, these percentages in the non-infected culture were 36 and 
38%, respectively. The mean percent CD4+ cells in all of the infected cultures 
decreased to 6% in 18 days pj .. The mean percent CD8+ cells increased to 66% in 
this period (data not shown), indicating a selective depletion of CD4+ cells in 
infected cultures (Fig. 3D). 
Two SPF cats were infected with the viral progeny of molecular clone 19k I, and 
two cats were infected with the biological isolate FlY Amsterdam-19. FlY could be 
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isolated from these cats 2 weeks p.i., and seroconversion occured 2 weeks later 
(data not shown). This demonstrates that these vimses are infectious in vivo. 
Discussion 
We have generated molecular clones of FIV directly from the DNA of bone 
marrow cells of an FlV-infected cat and characterized these clones for genetic and 
biological properties. Cloning directly from ill vivo-infected cells obviates the need 
for ill vitro culturing of FlV in cell lines or in stimulated PBMC. III vitro culture 
systems may select some viral genotypes over others, as has been shown in 
numerous instances for HIV -I (44,66, 17l), or may even introduce modifications in 
the cultured vims as demonstrated for SIVm" (102,132). These drawbacks bring the 
inherent danger that a molecularly cloned vims obtained from ill vitro cultures is 
not representative of the virus population present ill vivo in the infected animal. The 
high load of FlV proviral DNA in the bone marrow cells of the naturally infected 
symptomatic cat Amsterdam-I 9 has allowed us to obtain complete molecular clones 
of FIV directly ex vivo. FIV specific DNA could be detected in genomic DNA of 
bone marrow cells of cat Amsterdam-19 and in the DNA of bone marrow cells of 
only one of six other naturally infected cats. It is as yet unclear whether the 
detection of FlV proviral DNA in the genomic DNA of bone marrow cells of FIV-
infected cats is a general feature. In this paper, we show that the viral progeny of 
these clones has biological properties very similar to the virus isolate obtained from 
the PBMC of cat Amsterdam-19. 
FlV has been shown to cause a depletion of CD4-bearing cells in infected 
animals, as HIV-l does in infected humans (2,16,269). For HIV-l, this depletion 
may be partly explained by its selective tropism for and cytopathic effect on CD4+ 
cells, which has been demonstrated ill vivo. Additionally, HIV -I can downregulate 
the CD4 receptor on infected cells (38,43). Although the CD4 analog in cats has 
been identified, the results as to its filllctioning as the receptor for FlV have so far 
been inconclusive. We demonstrate here that an FIV isolate as well as two 
infectious molecular clones of FIV selectively deplete CD4+ cells from a culture of 
feline PBMC (Fig. 3 D). The viruses also induce the formation of syncytia in these 
cultures, indicating that the observed CD4+ cell depletion could well be the result of 
direct cytopathic effects, although we cannot rule out that downregulation of CD4 
also plays a role. The fact that these molecularly cloned viruses induce syncytia 
formation and deplete CD4+ cells ill vitro may indicate that they do the same ill 
vivo upon experimental infection. Such effects would result in progression towards 
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immunodeficiency. In preliminary experiments, the viral progeny of at least one of 
the two described clones (namely, 19k1) proved to be infectious in vivo. The 
experimentally infected animals will monitored closely for hematologic and 
immunologic parameters as well as for signs of FIV disease. 
To facilitate transfection of the molecular clones, we have relied on an adherent 
cell line that is permissive for FlV replication, namely, the CrFK cell line. After 
transfection, the CrFK cells produced FIV particles whose viral progeny was 
thereupon rescued by co cultivation with feline PBMC. Interestingly, we could not 
show productive reinfection of CrFK cells by these viruses, indicating that one 
round of replication is not sufficient for adaptation of FlV to CrFK cells. At the 
same time, these data demonstrate that the lack of gro\\1h of many FlV strains on 
CrFK cells is the result of a block at viral entry rather than at virus replication. 
To date, two envelope sequences of FIV molecular clones have been obtained. 
The comparison of the sequences of these two u.s. isolates revealed an amino acid 
sequence similarity of approximately 85%. To assess the amount of variation 
between strains from widely different geographical locations, we have obtained the 
complete envelope sequence of the two molecular clones 19k1 and 19k32. These 
two sequences are remarkably similar (99.3% similarity), whereas they differ by 
approximately 15% from both U.S. isolates, which is the amount of variation found 
between the U.S. isolates. A high degree of sequence similarity between two 
different proviruses is unusual for lentiviruses, which in general show much more 
sequence variation, especially in the envelope gene. The observed conservation may 
indicate that the obtained FIV clones are the progeny of the original viral clone that 
colonized the bone marrow of cat Amsterdam-19. 
To predict the amino acid sequence of the envelope gene, we took the ATG at 
position 6264 of the 34TF 10 clone of the Petaluma strain to be the start codon for 
env. This results in an 857- amino-acid glycoprotein with a potential cleavage site 
at position 611 (259). The precursor of 857 amino acids can be cleaved into two 
smaller glycoproteins: an outer membrane protein of 611 amino acids and a 
transmembrane protein (TM) of 246 amino acids. The newly generated N terminus 
at the presumed transmembrane glycoprotein is highly hydrophobic and could serve 
as a fusion domain as demonstrated for the homologous regions in SIV m" and HIV-
I (27,74). Although there is no obvious sequence similarity between this domain in 
FlV and those of SlV and HlV-I, we observed a high incidence of amino acids 
with very short side chains like glycine and alanine in all three viruses. This GA 
repeat may well be impOliant for the function of the fusion domain. Most of the 
stmcturally impoliant features of the envelope glycoproteins, like cystein residues 
and N-linked glycosylation sites, are conserved between these clones. Some 
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nonconserved cysteine residues were found in the putative L gene region of the 
envelope glycoprotein, preceding the leader sequence identified by others (204,259). 
The molecular clones described in this report have shown to be infectious both 
in vitro and in vivo. Such clones may enable us to delineate the molecular basis of 
the pathogenesis of FlV. 
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Abstract 
Viral progeny of the molecular clone 19k I of feline immunodeficiency virus 
(FIV) can infect feline T-cells but not Crandell feline kidney (CrFK) cells. In 
contrast, the biological isolate FIV -AM6c, which was CrFK adapted by co-
cultivation of FIV-AM6 infected thymocytes with CrFK cells, can infect both 
thymocytes and CrFK cells. The envelope gene of FIV-AM6c was amplified by 
polymerase chain reaction using DNA from infected CrFK cells, and subsequently 
cloned and sequenced. To map viral determinants of CrFK cell tropism, chimeric 
viruses with a 19k1 background containing envelope gene fragments of FIV-AM6c 
were constructed. CrFK cells were transfected with DNA of these chimeric clones 
and co-cultivated with thymocytes. After 3 days the CrFK cells and the thymocytes 
were cultured separately. FIV antigen could be detected in most of the thymocyte 
cultmes within 14 days and in one of the CrFK cultures after 52 days. The resulting 
virus from this CrFK cultme can infect both CrFK cells and thymocytes. The 
results of this study indicate that the envelope region contains determinants of CrFK 
tropism. The delay in replication indicates that also determinants other than those 
identified here are involved in CrFK cell tropism. More chimeric clones are being 
studied at present to map these determinants. 
Introduction 
Feline immunodeficiency virus (FIV), like the other lentiviruses, displays a high 
degree of sequence variation in the envelope gene. Most of this variation maps to 
the so-called variable regions (197,204). In other lentivirus systems, this genetic 
variation often has biological consequences, e.g. with regard to cytopathic potential 
and cell tropism (37). The variable region number 3 (V3) of the human 
immunodeficiency virus type I (HIV -I) envelope, which contains the principal 
neutralizing determinant, also contains the primary determinants for both cell 
tropism and for syncytium inducing capacity (88), although variation in both these 
parameters has also been mapped to regions other than V3 (10,264). 
FIV can infect a variety of cell types, like CD4 and CD8 positive T -cells, 
macrophages and astrocytes (29,30,53). Furthermore some strains of FlV can infect 
Crandell feline kidney cells (CrFK cells) upon adaptation in vitro (204). Infection 
75 
Envelope protein determinants 
of CrFK cells with FIV is widely used in virus neutralization assays. Using this 
system a variety of FIV neutralizing antibodies have been described. Most sera that 
neutralize FIV infection of CrFK cells tend to be broadly reactive, i.e. they all 
neutralize the different CrFK -adapted FIV strains, independent of the viral isolate 
against which they were initially raised (272). Such FIV neutralizing antibodies 
have also been generated in rabbits and mice using a synthetic peptide 
corresponding to the V3 region of the FIV envelope (148). This peptide also 
corresponds to an immunodominant epitope in F1V infected cats (13), which 
suggests that antibodies to this region contribute to the F1V-neutralizing activity in 
the sera of these cats. 
Recently we have described a vims neutralization assay for F1V using activated 
T cells, one of the natural target cells for the virus (242). With this assay we have 
only been able to demonstrate genotypic-specific virus neutralization: single point 
mutations, either induced in vitro, or naturally occurring, completely abolished virus 
neutralization by a polyclonal senlln. No evidence for broad cross-neutralization of 
FIV was found. These differences in virus neutralization between the two systems, 
led us to investigate the molecular basis for the adaptation of F1V to CrFK cells. 
Presently nothing is known of the relationship between genetic variation of FIV and 
cell tropism. Information regarding this issue may help us to understand the 
requirements for the infection of different cell types by F1V and, at the same time, 
may reveal the important biological aspects involved in virus neutralization in both 
systems. 
In order to determine whether the adaptation of FIV to CrFK cells is dependent 
on virus entry we have exchanged parts of the surface glycoprotein of FIV 
molecular clone 19k1 (which cannot replicate in CrFK cells) with the homologous 
fragments of the CrFK-adapted virus strain FIV-AM6c. We examined these 
chimeric clones for the potential to replicate in feline thymocytes and/or CrFK cells. 
Materials and Methods 
Cells and virlls 
Peripheral blood mononuclear cells (PBMCs) were derived from heparinized 
blood of a 2-year-old specified pathogen-free (SPF) cat by Ficoll density gradient 
centrifugation. Thymocytes were derived by homogenizing the thymus of an 8-
week-old SPF cat. PBMCs and thymocytes were washed twice and frozen at -135 
°c in aliquots. Before use the cells were thawed and stimulated with Concanavalin 
A (Con A) (5 pglml) in CM [RPMI-1640 supplemented with penicillin (l00 
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IU/ml), streptomycin (100 ;lg/ml), L-glutamin (2 mM) and p-mercaptoethanol (2 x 
10" M) and 10% fetal calf serum). After 3 days the cells were washed and cultured 
in CM supplemented with lL-2 (100 IU/ml). 
An FlV susceptible clone of the CrFK cell line was obtained from N. Pedersen 
(289) and cultured as described previously (240). 
Replication competent molecular clone 19k1 was obtained directly from bone 
marrow cells of a naturally FlV infected cat as described previously (240). 
FlV was isolated from PBMCs from II naturally FlV infected cats. To this end 
the PBMCs of these cats were stimulated with Con A. After 3 days the cells were 
washed and co-cultured with Con A and lL-2 stimulated PBMCs from a SPF cat in 
CM supplemented with lL-2 (100 IU/ml). The culture supernatant was tested 
weekly for the presence of FlV antigen by ELISA (see below). When FlV antigen 
was detected subcontluent monolayers of CrFK cells were co-cultivated for one 
week with 106 infected PBMCs. The CrFK cells were washed, trypsinized and 
subcultured at a split ratio of 1:5 weekly. The culture supernatants were tested 
weekly in an FlV antigen ELISA. One of the FlV isolates which was adapted to 
replicate in CrFK cells was designated FlV-AM6c and was used in this study. 
FIV antigen ELISA 
Culture supernatants were tested in an ELISA for the presence of FlV antigen 
as described previously (239). 
Generation of chimeric c/ones 
The envelope gene of FlV -AM6c was amplified by polymerase chain reaction 
(PCR) as described previously (242). The env gene was cloned into pUC 19 and the 
sequence was determined by the dideoxynucleotide chain termination reaction. The 
nucleotide sequence was compared with the sequence of the envelope gene of 
molecular clone 19k!. To generate chimeric clones four conserved restriction sites 
were used to exchange parts of the envelope gene of 19k I with corresponding parts 
of FlV-AM6c (Fig. I). Three chimeric clones were generated: 19k1PBAM6 (l9kl 
which contain the 144 bp PflMI-Bsal fragment of FlV-AM6c), 19k1BNAM6 (l9kl 
which contain the 343 bp Bsal-Nsil fragment of FlV-AM6c) and 19k1NKAM6 
(l9kl which contain the 248 bp NsiI-Kpni fragment of FlV-AM6c). 
Transfecfion 
Five micrograms DNA of the molecular clone 19k1 and the chimeric clones 
19kIPBAM6, 19k1 BNAM6 and 19k1NKAM6 were transfected into CrFK cells 
using the cationic lipid DOTMA (lipofectin; Bethesda Research Laboratories Inc.,) 
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Figure 1. Schematic representation of the envelope genes of molecular clone 19k1 and the chimeric 
clones of 19k1 which contain the hypervariable regions 3, 4 or 5 of the CrFK adapted isolate FIV 
AM6c. The uppermost bars represent the major open reading frames gag, pol and env. The black boxes 
represent the hypervariable regions in the envelope protein. The patterns are corresponding to the 
parental clones. 
according to the protocol of the manufacturer. After 24 h the transfected cells were 
cocultivated with Con A- and IL-2 -stimulated feline thymocytes. After 3 days the 
CrFK cells and thymocytes were cultured separately. The culhlre supernatants were 
monitored for the presence of FlY antigen by ELISA weekly. When FlY antigen 
could be detected, the culture supernatant was collected, filtered through a 220 nm-
pore-size filter and stored in aliquots. 
Results 
Adaptation of FlV to replicate in CrFK cells 
Con A and IL-2 stimulated PBMCs were infected with II FlY isolates in 
separate cultures. Within 7 days FlY antigen could be detected in the supernatants 
of all cultures by ELISA (Table I). The PBMCs were then co-cultured with CrFK 
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Table 1. FlY antigen detection in culture supernatants of PBMC's and CrFK cells 
Isolate FIV antigen in supernatant of 
PBMC's 
FIV-AMI 
FIV-AM2 
FlV-AM3 
FlV-AM4 
FlV-AM5 
FIV-AM6 
FlV-AM7 
FlV-AM8 
FlV-AM9 
FlV-AMIO 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
FIV-AMI9 + 
NT: Not tested 
CrFK cells 
NT 
+ 
+ 
NT 
NT 
NT 
Chapter 3 
cells. In four cultures a cytopathic effect (cpe) typical for feline syncytium forming 
virus (FeSFV) was observed in the CrFK cell culture (not shown). These cultures 
were discarded. FIV antigen could only be demonstrated in the CrFK cell culture 
infected with FIV-AM4 and FIV-AM6 28 days post infection (Table I). Viral 
progeny of molecular clone 19k I could not be adapted to replicate in CrFK cells 
using this procedure (not shown). 
Transjeclion of chimeric clones 
Upon transfection with DNA of the molecular clone 19k1 and the chimeric 
clones 19kIPBAM6, 19kIBNAM6 and 19k1NKAM6 the CrFK cells were 
cocultivated with thymocytes. After 72 h the CrFK cells and thymocytes were 
cultured separately and monitored for the presence of FlV antigen in the culture 
supernatant. Within 3 weeks post trans feet ion FlV antigen was detected in the 
supernatant of all the thymocyte cultures (Fig. 2a). Only in the culture supernatant 
of the CrFK cells, which were transfected with 19k1PBAM6 FlV antigen could be 
detected 52 days post transfection whereas no antigen could be detected in the 
culture supernatant of the CrFK cells, which were transfected with 19k I, 
19kIBNAM6 or 19k1NKAM6 (Fig. 2b). 
The culture supernatant of the CrFK cells, which was found positive in the FIV 
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antigen ELISA was collected 52 days post transfection, filtered and designated FlV-
19k1PBAM6c. CrFK cells were infected with FIV-19klPBAM6c or FIV-AM6c and 
monitored at regular intervals for FIV antigen production in the culture supematant. 
Within II days FlV antigen could be detected in the supernatant of both cultures 
(Fig. 3). These results show that chimeric clone 19k1PBAM6c is adapted to infect 
and replicate in CrFK cells with the same kinetics as FlV-AM6c. 
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Figure 2. FIV antigen production in culture supernatant of PBMC's (A) and CrFK cells (B) after 
transfection with molecular clone 19k1 (e) and the chimeric clones 19k1PBAM6 (II), 19k1BNAM6 
(A) and 19k1NKAM6 (0). 
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Figure 3. FIV antigen production in culture supernatant of CrFK cells infected with FIV-AM6c (D) and 
FIV-19kIPBAM6c (II). 
Sequence analysis 
To minimize additional mutations by long term culture, 4 days after infection 
with 19kIPBAM6c, CrFK cells were lysed and the FlV envelope gene was 
amplified by PCR and cloned into pUCI9. The surface protein was sequenced and 
compared with the sequence of 19k!. The 19k1PBAM6c sequence differs at five 
positions from the 19k1 env sequence (Fig. 4). Foul' of these, three situated in HV-3 
and one between HV-3 and HV-4, are the result of the exchange of the 144 bp 
PjlMI-BsaI fragment of FIV-AM6c. An additional G to A mutation at nucleotide 
position 1225 was observed, which causes an amino acid substitution mutation of 
glutamic acid to lysine at position 409. 
<------HV-3-----> 
<--------------pfl~n Bsal fragment-----------> 
360 380 400 
19k! cmmNQKAYYNQCSWEQTDVKFQCQRTQSQPGSWlRAISSWRQRNRWEWRPDFESER 
19k1PBAM6c ...... Y .... S.R ...................... T .........•........ K. 
Figure 4. Amino acid sequence of 19k1 and 19k1PBAM6c from amino acid position 354 to 8410. The 
144 bp PflMI - Bsal fragment and the HV-3 region is indicated at the top. 
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Discussion 
A limited number of all FlV isolates known to date replicate in CrFK cells. 
These cells are widely used in FlV -neutralization assays which makes elucidation of 
the molecular basis for CrFK-adaptation of FIV an important research goal. This 
importance is underlined by the fact that using these cells predominantly broadly 
neutralizing antibodies are detected, which contrast with the results using T cells, 
one of the natural target cells for FIV. 
The viral progeny ofFIV molecular clone 19k1 cannot infect CrFK cells, and we 
have never been able to adapt FIV 19k1 to grow in these cells even after prolonged 
periods of cocultivation of CrFK cells with FIV 19k1 infected T cells (up to 3 
months). Transfer of an envelope fragment of the CrFK-adapted FlV-AM6c isolate 
to 19k1 has now allowed us to adapt 19k1 to CrFK cells after 52 days. This 
envelope fragment contains the variable V3 region; no other envelope fragments 
have yielded similar results. The resulting adapted virus is now able to infect CrFK 
cells and does not demonstrate the 52-day delay observed in the adaptation process. 
It is therefore likely that the fully adapted virus has accumulated other mutations, in 
the envelope gene or elsewhere, that have now convelied the phenotype of the vhus 
to the fully adapted form. One of such changes, just 3' of the originally exchanged 
V3 region is discussed below. Preliminary experiments indicate that this single 
mutation is not by itself sufficient for adaptation (in preparation). We cun'ently 
investigate the contribution of other envelope regions and of the other viral genes to 
CrFK adaptation. 
Other lentiviruses, like HIV -I, also display a high degree of genetic variation in 
the envelope gene. Mapping experiments have demonstrated that the highly variable 
V3 region of the HIV -I envelope contains an impOliant determinant for 
cytopathicity and cell tropism, as well as the principal neutralization domain (88). 
In our experiments we could only adapt FIV 19k1 to replicate in CrFK cells when 
we replaced the V3 region of 19k1 with the envelope V3 region of the CrFK-
adapted vhus FIV-AM6c, suggesting that here also the V3 region plays a role in 
determining cell tropism. This parallel between the fimctional roles of the V3 
regions of HIV -I and FlV can be extended when we take into account that a 
synthetic V3 peptide of both of these viruses can elicit virus neutralizing antibodies. 
Interestingly in the FIV system these antibodies will only neutralize FlV infection 
of CrFK cells, and not of primary T cells. Understanding the requirements for FlV 
to productively infect CrFK cells may elucidate the basis for virus neutralization in 
both systems. This information will prove useful in the rational design of virus 
vaccines that aim at inducing high titers of broadly reactive virus neutralizing 
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antibodies, both for F1V and for HIV-1. 
Since we have determined only the sequence of the gene encoding the surface 
glycoprotein in this study, we cannot exclude that other mechanisms playa role in 
the acquisition of CrFK cell tropism by FIV. Our present studies focus on the 
potential involvement of the gag, pol and regulatory genes of F1V in this 
phenomenom. 
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Abstract 
We infected a specific-pathogen-free cat (cat 14) with molecularly cloned feline 
immunodeficiency virus clone 19k1 (l9kl [K.H.J. Siebelink, I. Chu, G.F. 
Rimmelzwaan, K. Weijer, A.D.M.E. Osterhaus, and M.L. Bosch, J.Virol. 66:1091-
1097, 1992). Serum of this cat obtained 22 weeks post infection (serum 1422) 
neutralized FlV19kl but not FIV 19k32, which is 99.3% identical to FIV19kl in 
the envelope gene. Serum 1422 also neutralized virus isolated from cat 14 at weeks 
2 and 32 post infection. We then cultured FIVI9kl in the continuous presence of 
serum 1422, which resulted in a delay in virus replication of 6 weeks. The resulting 
virus population appeared to be resistant to virus neutralization by serum 1422. 
Nucleotide sequencing of the env open reading frame of this presumed escape 
mutant revealed the presence of one silent and two substitution mutations, both of 
the latter in hypervariable region 5. Through the construction of chimeric viruses 
and site-directed mutagenesis, we demonstrated that one of these mutations, the 
substitution of lysine to glutamine at amino acid position 560 in hypervariable 
region 5, was sufficient to allow the escape of FlV19kl from neutralization by 
serum 1422. 
Introduction 
Feline immunodeficiency virus (FIV) is a recently discovered T-Iymphotropic 
lentivirus (199) which appeared to be the cause of an AIDS-like disease in naturally 
infected cats (27,108,199,236,248,289). FlV resembles human immunodeficienc 
virus type 1 (HlV-l) in its biological and morphological properties. A decline in 
numbers of CD4+ lymphocytes observed in vivo and in vitro (2,16,104,240), a 
gradual loss of immune function (16,94,147,241,269,289) and the occurrence of 
opportunistic infections as in human AIDS make FIV infection in cats a useful 
small animal model for the study of HlV infections in humans. 
Infection with lentiviruses, including FIV and HIV -1, generally results in 
persistence of the virus in the host, leading to a continuous interaction between the 
virus and the immune system (67,73,170,176,182,183,289). Genetic variation allows 
the virus to escape from the continuous pressure exerted by antibodies 
(169,214,284, for a review, see reference 187) and cytotoxic T cells (202). Domains 
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on the envelope glycoprotein that induce vims neutralizing (VN) antibodies have 
been determined (76,85,103,131,264) and escape from VN antibodies has been 
described in various lentiviral systems. After infection with HIV-I, two types of 
VN semm antibodies are observed. Shortly after infection, type-specific neutralizing 
antibodies that are mainly targeted to the principal neutralizing determinant (PND) 
within the variable region 3 arise (85,196,227). Later in the course of infection, 
more broadly neutralizing antibodies, in which other antigenic sites on the envelope 
protein are also involved are induced (76,122,162,208,264; for a review, see 
reference 84). The envelope gene of FlV is highly variable but exhibits, like the 
envelope gene of HIV-I, constant and more variable regions (179,204,240). FIV 
neutralizing antibodies have been demonstrated in the sera of infected cats (69,271), 
but the sites involved in their induction have not been identified. The generation of 
VN escape mutants and studies concerning the mechanisms leading to escape may 
provide more information about the structural and functional properties of these 
antigenic sites. Two mechanisms by which a lentivirus can escape from VN 
antibody pressure have been described. The first involves changes in the binding 
site itself, whereas the other involves changes elsewhere on the envelope 
glycoproteins (169,284). The availability of molecular clones of HIV-I has allowed 
the identification of the molecular basis underlying the escape of the virus from 
neutralizing antibody and has provided evidence that both mechanisms are 
operational (169,214,284). 
In an attempt to elucidate the mechanism by which FIV would escape from VN 
pressure, we have used the same approach. Thus, we have identified a single amino 
acid change in the envelope glycoprotein of FIV that leads to the escape of the 
virus from neutralizing antibody. 
Materials and Methods 
Virus 
Viral progeny of replication-competent molecular clones 19k1 (FlVI9kl) and 
19k32 (FIVI9k32) and the uncloned isolate FlV A'daml9 were obtained as 
described previously (240). A lO-week-old specific-pathogen-free (SPF) cat (cat 14) 
was infected with FIVl9kl by intraperitoneal inoculation of 10' 50% tissue culture 
infectious doses. Vims was reisolated from this cat at 2 and 32 weeks postinfection 
(p.i.) and designated FlV19klR2 and FIVI9kIR32, respectively. 
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Sera 
Serum of a naturally FlV infected cat, A'daml9 was designated serum AI9 
(240). Serum of cat 14 was taken prior to infection (preserum) and at 22 weeks p.i. 
(designated serum 1422). Serum of a noninfected SPF cat was used as a control 
serum (SPF serum). All sera were heat inactivated for I h at 56°C prior to use. 
Gag- alld EIlV-specific ELISAs 
The presence of antibodies directed against the envelope protein of FIV was 
detected in a recombinant FIV envelope protein enzyme-linked immunosorbent 
assay (ELISA) as described elsewhere (218), and antibodies raised against Gag 
proteins were detected in a commercially available FlV p24!p 17 antibody ELISA as 
recommended by the manufacturer (European Veterinary Laboratory, Amsterdam, 
The Netherlands) 
RTassay 
Reverse transcriptase (RT) activity was determined as previously described (240). 
VN assay 
Since low virus passage levels were used to avoid additional mutations by in 
vitro culturing, and the virus titer of the stocks propagated in feline peripheral 
blood mononuclear cells (PBMC) (240) was low (approximately 102), we decided to 
standardize the viral input by RT activity. Virus stocks of FIVI9kl, FlV19k32, the 
uncloned isolate FIV A;damI9, and the reisolates FIVI9klR2 and FIVI9klR32 
were tested in an RT assay. For this assay, 450 III of diluted virus stocks containing 
RT activity of 5 x 10' cpmlml were incubated with 50 III of a serum sample for 60 
minutes at 37°C. concanavalin A (ConA) and interleukin-2 (IL-2)-stimulated 
PBMC (106) were added. After 60 minutes at 37°C the cells were washed and 
incubated for 14 days in CM (RPMI 1640 [GIBCO], penicillin [100 !U/ml], 
streptomycin [100 Ilglml], L-glutamine [2 mM], Il-mercaptoethanol [2 x 10 ., M], 
IL-2 [100 !u/ml]) supplemented with 2% of the respective serum sample. RT 
activity was determined as a measure for virus production. Virus neutralization was 
considered positive when the RT activity did not increase over two times the 
background level defined as the mean RT activity of uninfected cells. In previous 
experiments it was observed that the RT activity of FlV-infected cultures was at 
least five times the background level (not shown). 
Generation of escape /IIl/tants 
ConA and IL-2 stimulated PBMC of an SPF cat (l06) were infected with 
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FIV19k1. After 24 h, the cultures were divided between two identical flasks. To 
one of the cultures we added 2% of serum 1422, and to the other we added 2% 
SPF serum (control serum). The culture supernatants were harvested weekly, 
replaced with fresh CM supplemented with 2% concentration of the respective 
serum, and tested for the presence of RT activity. When RT activity over five times 
background values was present, the supernatant was filtered through a 220-nm-pore-
size filter and stored at -135°C. Viruses derived from these cultures were 
designated 19k1A and 19k1B when derived from cultures with serum 1422 or with 
SPF serum, respectively. Dilutions of the culture supernatant of 19k1A and 19k1B 
containing RT activity of 5 x 10' cpmlml were incubated with 10% of serum 1422 
or SPF serum for 60 minutes at 37°C. ConA and IL-2 stimulated PBMC of an SPF 
cat (106) were added to each culture. After 60 minutes of incubation at 37°C, the 
cells were washed and cultured in CM supplemented with a 2% concentration of the 
respective serum. The culture supernatant was tested for the presence of RT activity 
twice a week. When RT activity could be demonstrated, the culture supernatant was 
filtered through a 220-nm-pore-size filter and stored at -135°C. The viruses were 
designated 19k1A,A and 19k1A,B for 19k1A propagated in the presence of serum 
1422 or SPF serum, respectively, and 19k1B,A and 19k1B,B for 19k1B propagated 
in the presence of serum 1422 and SPF serum, respectively. 19k1A,A was further 
designated 19k1esc. 
Sequence analysis 
The sequence of the envelope gene of 19k1 has been described previously (240). 
The envelope gene of the escape mutant 19k I esc was amplified by polymerase 
chain reaction (PCR). PBMC (10') from the 19k1esc culture were pelleted and 
lysed with 100 III K-buffer (50 mM KCl, 10 mM Tris (PH 8.4], 1.5 mM MgCl" 
0.5% Tween-20, and 100 Ilg of proteinase K per ml) for 45 min at 56°C. The 
reaction was stopped by incubating the mixture for 5 minutes at 95 °C. Two 
oligonucleotide primers were designed (primer 1, 5' 
GGCGAATTCATGGCAGAAGGATTTGTAGCC-3' and primer 2, 5'-
TA TGCA TGCTCA TTCCTCCTCTTTTTCAGACA TGCC-3 ') which contained 
EcoRI and Spltl restriction enzyme cleavage sites (underlined), respectively, to 
facilitate subsequent cloning into pUC19. PCRs were carried out in a separate 
laboratory (to avoid contamination) in a volume of 100 III containing 10 III of the 
cell lysate, 50 mM KCI, 10 mM Tris [pH 8.4], 1.5 mM MgCI" 0.02% gelatin, 250 
11M deoxynucleotide triphosphates, I 11M each primer, and 2.5 U of Taq 
polymerase. Samples were overlayered with 100 III of mineral oil to avoid 
evaporation and the subjected to 35 amplification cycles consisting of a denaturing 
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step (94°C, 1 min.), a primer-annealing step (60 °C, 1 min.), and a primer-
extension step (72 °C, 2 min.). Negative controls (noninfected PBMC from an SPF 
cat) were amplified in parallel. Amplification products were analyzed by agarose 
gel electrophoresis (0.8%) for the presence of the appropriately sized DNA 
fragments. Excess primers in the PCR reaction were eliminated by using Centricon-
30 microconcentrator (Amicon). DNA was digested with EcoRI and Sphl and 
cloned into pUC19. The subclone was used for the dideoxy nucleotide chain 
termination reaction (229) of the envelope gene. The nucleotide and protein 
alignments were done with Lasergene software (DNAstar inc. London, United 
Kingdom). The observed nucleotide variation of 19k1esc was confirmed by using 
an independent PCR amplification to exclude Taq errors. 
Generation of chimeric clones 
The construction of chimeric clones is schematically represented in Fig. 1. 
Restriction mapping identified a common and unique internal Sphl site in both FlV 
genomes. To generate recombinant viruses, the lambda clones 19k1 and 19k32 were 
digested with Safl and Sphl. The Safl and Sphl fragments generated after digestion 
were cloned into plasmid vector pUC 19 from which the Kpnl site has been deleted. 
The plasmids containing the 5' long terminal repeat, gag, and 5' part of pol were 
designated 5' subclones. Plasmids containing the 3' part of pol, env, and 3' long 
terminal repeat were designated 3' subclones and were used to exchange internal 
1,662-bp Kpnl fragments between the clones 19k1 and 19k32. 
The 1,662-bp Kpnl fragment of clone 19k1 was also cloned into pUC19 and was 
designated the 3'KK sub clone of 19k1. A 144-bp Nsil - Mst2 fragment of the 
19k1esc envelope (see above) was exchanged, as was a 144-bp Nsl1 - Mst2 
fragment of clone 19k I in which one nucleotide was substituted by site-directed 
mutagenesis at either position 1667 or position 1678. Site-directed mutagenesis was 
performed by PCR on the 3' subclone of 19k!. To that end, three oligonucleotides 
were designed. Primer I (5'-CCTTATTATGCATTTCAATATGACAAAAGCTG-
3') contained an Nsil site (underlined); primer mutl (5'-
GCCI I I I ICCTCAGGACATTCCAI I I IIATTGTGTGAGfATTG-3') contained 
an MstII site (underlined) and a T-to-G substitution at position 1667 (italic); primer 
mut2 (5'-GCCTTTTTCCTCAGGACATTCCATTTGfATTG-3') contained an MstII 
site (underlined) and a T-to-G substitution at position 1678 (italic). Two PCRs 
were carried out, using in both reactions primer 1 to prime from the 5' end. In one 
reaction primer mut I was used while in the other reaction primer mut2 was used to 
prime from the 3' end. The conditions for the PCR are described above. PCR 
fragments were digested with Nstl and MstII and cloned into the 3' KK subclone of 
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Figure 1. Schematic representation of the construction of chimeric FlY clones (see text for details), The 
uppermost bars represent the major open reading frames gag, pol and env, Restriction enzyme cleaving 
sites are indicated as: K:KpnI; M:Alst2; N:Nsil; S:Sall; Sp:SphL Individual point mutations are indicated 
with "T", 
19k I. The mutagenesis was confirmed by sequence analysis. 
The 1,662-bp KpnI fragments from the 3' KK subclones in which 144 bp NsiI 
and MstII fragments were exchanged were cloned into the 3' subclone of 19k1; 2.5 
J.lg amounts of each of the 3' sub clones and the 5' sub clones were mixed, digested 
with SphI, and ligated. After digestion with Sal! the constructs were transfected into 
Crandell feline kidney (CrFK) cells as previously described (240). Virus production 
was rescued by cocultivation of transfected cells with ConA and IL-2 stimulated 
PBMC for 3 days. Cultures were monitored for syncytium formation of PBMC and 
RT activity in the culture supernatant. When RT activity could be measured, culture 
supernatant was filtered through an 220-nm-pore-size filter and stored in aliquots at 
-135°C. 
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Synthesis and reaction of peptides with sera 
Twelve-mer peptides with an overlapping sequence of II amino acids were 
synthesized and analyzed for reactivity with sera as previously described (81). The 
amino acid sequences of the peptides were based on the amino acid sequences of 
the envelope proteins of clones 19k1 and 19k1esc between amino acid position 549 
and 583. Three 12-mer control peptides with an overlapping sequence of eight 
amino acids were synthesized according to the epitope between position 596 and 
616 as described by Avrameas et al. (13). 
Results 
Infection of cats 
Upon experimental infection with viral progeny of clone 19k1, cat 14 
seroconverted within 4 weeks. The Gag- and Env-specific serum antibodies 
measured by ELISA reached plateau levels within 8 weeks after infection (Table I). 
Virus was reisolated 2 and 32 weeks p.i. (Table I). The serum collected 22 weeks 
p.i. (serum 1422) and the two vhus isolates (FIVI9klR2 and FIVI9kIR32, 
respectively) from this cat were used in the experiments described below. 
Table 1. Anti FlY serum antibody response of cat #J4 deotermined by gag- and 
env specific ELISA and virus isolation after infection with FIV19kl of cat #14. 
Wk antibody response 
p.i. 
Gag Env virus isolation 
OD'50 
, 
reciprocal titer 
0 <50 <40 NDb 
2 <50 40 + 
4 722 640 ND 
6 902 >5120 ND 
8 1,031 >5120 ND 
\I 1,186 >5120 ND 
22 1,079 >5120 ND 
32 1,036 >5120 + 
a OD4S0 optical density at 450 nm (x to'1); b ND: not determined. 
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VN activity 
Serum from cat 14 (serum 1422) was tested for VN activity against FIVI9kl, 
FIVI9k32 and the uncloned isolates FIV A'damI9, FIVI9klR2, and FIVI9kIR32. 
SPF serum was used as a control. The results are listed in Table 2. Virus replication 
as determined by RT activity was demonstrated in all cultures in the presence of 
SPF serum. Replication of virus was detected in the presence of serum 1422 in the 
cultures of FIVI9k32 and the uncloned isolate FIV A'damI9. However, no virus 
replication was detected in the culture infected with FIVI9kl and the reisolates 
FIVI9klR2 and FIVI9klR32 cultured in the presence of serum 1422, indicating 
complete neutralization. Serum 1422 which was absorbed with protein-A Sepharose 
beads to remove antibodies (particularly immunoglobulin G) failed to neutralize 
molecular clone 19k1, which indicates that serum immunoglobulin is responsible for 
the observed neutralizing activity (not shown). 
Table 2. Virus neutralization of FlV isolate, molecular 
clones and FIV re-isolates with serum 1422 and SPF serum 
RT activity after neutralization with: 
Virus 
serum 1422 SPF serum 
FIV A'daml9 24,219 61,480 
FIVI9kl 157 12,333 
FIVI9k32 26,864 59,187 
FIVI9klR2 82 58,442 
FIVI9klR32 103 18,145 
Generatioll of escape lIIutants 
FIVl9kl-infected PBMC from an SPF cat were cultured in the presence of 
serum 1422 (culture A) or SPF serum (culture B). Within 17 days, RT activity 
could be measured in the supernatant of culture B. After 44 days of culture, RT 
activity was detected in culture A (Fig. 2A). RT activity increased during time of 
culture. No RT activity could be demonstrated in the noninfected cultures which 
were cultured in the presence of serum 1422 or SPF serum for 52 days of culture 
(data not shown). 
The supernatants of cultures A and B were collected, filtered 52 days p.i., and 
designated 19k1A and 19kIB, respectively. These culture supernatants were 
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incubated with serum 1422 or SPF serum. ConA- and IL-2 stimulated PBMC from 
an SPF cat were added to the virus - serum mixture and cultured further in the 
presence of the respective serum, serum 1422 or SPF serum. The cultures were 
designated 19k1A,A and 19k1A,B for the cultures of 19k1A cultured in the 
presence of serum 1422 or SPF serum, respectively (Fig. 2B) and 19k1B,A and 
19kIB,B for the cultures of 19k1B cultured in the presence of serum 1422 or SPF 
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Figure 2. Kinetics of virus replication expressed in RT activity of FIVI9kl (A), FIVI9klA (8), and 
FIVI9kl8 (C) in the presence of serum 1422 (dashed line) or SPF serum (solid line). 
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serum, respectively (Fig 2C). RT activity was demonstrated after 17 days of 
infection in both cultures of 19k1A. The kinetics of virus replication of 19k1A,A 
were similar to those of the control 19k1A,B (Fig. 2B) and 19k1B,B (Fig 2C). As 
expected no virus replication was observed in the culture 19k1B,A (Fig. 2C). These 
results show that 19k1A,A is resistant to virus neutralization by serum 1422. 
Sequence analysis 
Cells of the culture 19k1A,A further designated 19k1esc were lysed and the 
envelope gene of the FlV genome, integrated in the cellular DNA, was amplified by 
PCR. The PCR product was digested with EcoRi and Spill and cloned into pUCI9. 
The envelope gene of 19k1esc was sequenced and compared with the envelope 
sequence of the parental clone 19k1 and clone 19k32 (Fig. 3). At position 468 in 
hypervariable region 2 (HV-2), we observed a silent transition of T to C (not 
shown). Two A-to-C transversions were observed in HV-5. One at position 1667 
causes an amino acid substitution of asparagine to threonine (amino acid position 
556), whereas the other at position 1678 causes an amino acid substitution of lysine 
to glutamine (amino acid position 560). Comparison of the nucleotide sequence of 
the envelope gene of clone 19k1 with 19k32, which exhibited the same phenotype 
as 19k1esc in a VN assay using serum 1422, showed the presence of a T-to-G 
transversion at position 1665 and a transition of C to T at position 1669, resulting 
in a substitution of asparagine with lysine (amino acid position 555) and histidine 
with tyrosine (amino acid position 557), respectively (Fig. 3). 
position 540 550 560 
19k1 N S D L P TNI'I GYM KeN C T N D T S N N H T I K M E C PEE K 
19k1esc • T • Q 
19k32 K . Y 
Figure 3. Comparison of the amino acid sequences of HV-5 of the envelope genes of the molecular 
clones 19k1, 19k32 and 19k1e,c. 
Virus neutralization of chimeric clones 
Viral progeny of the parental clone 19k1 and of those in which the envelope 
gene had been exchanged partially or an amino acid had been substituted by site 
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directed mutagenesis and the escape mutant 19k1esc were incubated with serum 
1422 01' SPF serum prior to infection of ConA and IL, stimulated thymocytes. The 
results of this experiment are similar to those of a number of previous experiments 
in which the chimeric clones were tested separately for neutralization by serum 
1422. RT activity was measured 9 and 12 days p.i. RT activity could be measured 
in all the control cultures 9 days p.i. and continued to increase through 12 days p.i. 
(Fig.4). As expected, FIV19kl was neutralized by serum 1422 and not by the SPF 
serum (Fig. 4A). As before, FIVl9k32 was not neutralized by serum 1422 (Fig. 
4B). To investigate whether the differences in virus neutralization between the two 
molecular clones was caused by the differences in the surface protein, we 
exchanged the 1,662-bp KpnI fragment. The chimeric clones were designated 
19k1KK32 (19kl containing the KpnI fragment of 19k32) and 19k32KKl (l9k32 
containing the KpnI fragment 19k1). Chimeric clone 19k1KK32 was not 
neutralized, whereas chimeric clone 19k32KKl was neutralized with selum 1422 
(not shown), indicating that an epitope within the 1,662-bp KpnI fragment of the 
envelope gene is involved in neutralization. 
The escape mutant of FIV19kl, grown in the presence of sel1lm 1422 was not 
neutralized by this serum (Fig. 4C). Comparison of the amino acid sequence of the 
envelope protein of 19k1 and the sequence of the escape mutant showed two amino 
acid substitutions within HV-5. To study whether these substitutions underlie the 
escape of FIV19kl from serum 1422, we exchanged the l44-bp NsiI - MstII 
fragment, containing the whole HV-S, of clone 19k1 with that of the escape mutant. 
This chimaera, designated 19k1NMesc was not neutralized by serum 1422 (Fig. 
4D), indicating that one or both amino acid substitutions are involved in the escape 
mechanism. By site-directed mutagenesis, the two amino acids were substituted 
separately. These point-mutated clones were designated 19k1mutl (position 556, 
Asn to Thr) and 19k1mut2 '(position 560, Lys to Gin). FIV19klmutl was 
neutralized by serum 1422 (Fig. 4E), whereas FIV19klmut2 could not be 
neutralized by serum 1422 (Fig. 4F), indicating that the point mutation at amino 
acid position 560 resulting in an amino acid substitution from lysine to glutamine is 
responsible for escape ofFIV19kl from serum 1422. 
To investigate whether the differences in HV-S between clones 19k1 and 19k32 
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Figure 4. Neutralization of viral progeny of parental and chimeric FlY clones and 19k1esc with serum 
1422 (dashed line) or SPF serum (solid line) as determined by measuring RT activity. (A) FIVI9kl; (8) 
FIVI9k32; (e) FIVl9klesc; (D) FIVI9kINMesc; (E) FIVI9klmut!; (F) FIVl9klmut2. 
also underlie differences in neutralization with serum 1422, we reciprocally 
exchanged the 144 bp NsiI - Mst2 fragment between the two clones. This exchange, 
however, did not result in a change in virus neutralization (not shown), indicating 
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. that yet another epitope is involved. 
Pepscan analysis 
Twelve-mer peptides representing the amino acid sequence of the clones 19k1 
and the escape mutant 19k1 esc between amino acid positions 549 and 583 were 
analyzed for reactivity with serum 1422, serum from a naturally FlV infected cat, 
A'daml9 (serum AI9), and SPF serum. As a control for the peptide scanning 
(pepscan) procedure, three 12-mer peptides spanning, with an overlap of eight 
amino acids, a previously described linear epitope on the envelope protein of FlV 
(from amino acid position 596 to 616) were scanned with serum 1422, serum A19, 
and SPF serum. No reactivity in these sera was detected with the HV-5 peptides, 
whereas serum 1422 and serum A19 did react in the control pepscan (not shown) 
suggesting that no linear B-cell epitope in the C-terminal half of HV-5 is 
recognized by serum 1422 and serum A19. 
Discussion 
In this report we have demonstrated that a single amino acid substitution in the 
HV-5 region of the surface glycoprotein of F1V (amino acid position 560) allows a 
molecular clone of F1V to escape neutralization by the serum of a cat, infected with 
this clone. Pepscan analysis of the region around amino acid 560 with and without 
the substitution showed no reactivity of the peptides with sera from cats infected 
with the molecular clone or with an uncloned isolate of FlV from the same origin. 
This finding suggests that the B cell epitope involved in the escape is either 
dependent on its three dimensional configuration or is located outside the region 
where the substitution took place. In the latter case, the amino acid substitution 
should have altered an epitope at a distant site. Similar studies with escape mutants 
of molecularly cloned HlV -I have shown that an amino acid substitution in the 
PND may directly result in the escape from neutralization by a PND - specific 
monoclonal antibody (169). Others have shown that an amino acid substitution in 
the transmembrane glycoprotein of HlV -1 induced resistance to neutralization by 
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sera from seropositive individuals (214). The basis for this resistance was shown to 
be most likely a conformational change altering a neutralization inducing 
determinant at a distant site (284). To elucidate the mechanism involved in the 
escape from neutralization observed in the FIV system, further studies identifYing 
antigenic sites that induce virus neutralization will be necessary. 
Our data, which showed that an FlV escape mutant could readily be generated in 
the presence of VN serum antibody, suggest the predominance of type specific VN 
antibodies in serum 1422. The finding that one amino acid substitution allowed 
FlVI9kl to escape from neutralization by the cat serum collected 22 weeks p.i. 
indicates that this substitution affects a dominant VN antibody-inducing determinant 
against which the majority of VN antibodies in this serum are directed during the 
first months of infection. Another explanation would be that this substitution 
influences more than one VN antibody-inducing epitope. The observation by 
Tozzini et at. (271) and Fevereiro et at. (69) that within 4 weeks after FlV 
infection, serum antibodies with broad VN activity can be detected suggests that as 
in HIV -I infection of humans, broadly reactive VN antibodies are formed. It 
should, however, be stressed that the VN assays that they used were carried out 
with FlV strains adapted to replication in a continuous fibroblastoid feline kidney 
cell (CrFK) line, whereas our VN assays were carried out in primary cat 
lymphocytes or thymocytes. Lymphoid cells, which are the natural target cells for 
FIV replication in vivo, can readily be infected with all strains of FIV, whereas 
only few FlV strains could be adapted to replication in CrFK cells. The genetic 
basis for this adaptation is currently unknown, but since upon transfection with 
proviral DNA, CrFK cells produce FlV that cannot reinfect CrFK cells, virus entry 
is probably the limiting step. Therefore it may be speculated that the broad 
neutralization observed in the assays based on CrFK cell adapted FlV strains 
specifically interferes with the process underlying this limiting step. 
Our future studies to elucidate the st11lctural basis of FlV neutralization will also 
be based on the observations made with FIV19k32. This virus, like FlVI9klesc was 
not neutralized by se11lm 1422. Exchange of the Nsil - MslII fragment of 19k1, for 
the homologous fragment of 19k32, which contains the HV-5 region, could not 
confer resistance to 19k1. Since exchanging the 1,662-bp KpnI fragment between 
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19k1 and 19k32 resulted in the transfer of the neutralization resistant phenotype and 
the envelope proteins of 19k1 and 19k32 differ in only six amino acids, two of 
which are located within the HY-5 region (Fig. 3), genetic exchange experiments 
will reveal the exact location of additional regions involved in escape from virus 
neutralization. 
As in other lentivirus infections, VN antibodies and cytotoxic T cells may be 
expected to play a crucial role in the pathogenesis of and the protective immunity 
against FlY infections. Therefore the detailed analysis of antigenic sites of FlY 
involved in the induction of VN antibodies and the mechanism leading to VN-
resistant FlY variants will lead to a better understanding of lentivirus pathogenesis 
and help in the design of effective lentivirus vaccines. 
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and Albert D.M.E. Osterhaus 
J. Virol. 69:5124-5127 (1995) 

Abstl'act 
Sites involved in antibody mediated neutralization of feline immunodeficiency 
virus were mapped by reciprocal exchange of envelope fragments or amino acids 
between molecular clones of feline immunodeficiency virus with different 
susceptibilities to neutralization by a polyclonal cat serum. Combinations of 
mutations within HV-4 or within HV-4 and HV-5 changed the susceptibility of the 
viruses to neutralizing antibody. 
Feline immunodeficiency virus (FIV) is a lentivirus that causes a severe 
impairment of immune function in experimentally and naturally infected cats, which 
eventually results in the development of a syndrome quite similar to AIDS in 
humans (2,16,53,104,115,143,199,236,241,248,289). For both human 
immunodeficiency virus type I and FIV it has been shown that single amino acid 
substitution mutations in the envelope glycoprotein, within or outside the presently 
identified VN epitopes, may confer resistance to virus neutralizing (VN) 
monoclonal or polyclonal antibody (126,169,242,243,284). It has also been 
postulated that glycosylation may play an important role in the proper expression or 
masking of VN epitopes (6,26,48,89,93). 
We have recently described two molecular clones of FlV (FIVI9kl and 
FIVI9k32), simultaneously derived from a naturally infected cat (240). These 
clones differed in their susceptibilities to virus neutralization in feline thymocytes 
by serum SI422, obtained from a specified-pathogen-free cat, 22 weeks after 
infection with FlVI9kl (242).The surface glycoproteins (SU) of the two molecular 
clones were shown to differ in only five amino acids (240). We have demonstrated 
that a single substitution mutation at amino acid position 560 (HV-5) or at position 
483 of FIVI9kl conferred resistance to virus neutralization by SI422 (242,243). In 
the present study we have further evaluated the involvement of different sites of the 
SU protein in antibody mediated neutralization by reciprocal exchange of FlVI9kl 
and FIVI9k32 envelope gene fragments and by site directed mutagenesis. This 
included a highly conserved potential N-linked glycosylation site at amino acid 
position 481 (245). 
Combinations of point mutations were made in the SU protein of FIV19k32, on 
basis of the FIV 19k I sequence, in order to obtain a virus neutralization sensitive 
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mutant of FlV19k32. To this end site directed mutagenesis and gene fragment 
exchange were carried out as previously described (242,243). Replication 
competence of the molecular and chimeric clones was confirmed by showing that 
the production of FlV antigen in independent duplicate thymocyte cultures was in 
the same order of magnitude as FlV antigen production of cultures infected with 
FlVI9kl or FIVI9k32 (less than 10°5 times difference), under previously described 
conditions (242,243). Two virus neutralization sensitive chimeric viruses, 
FIVI9k32motA (Asp- 454 to Asn and Ser-483 to Leu) and FlVI9k32motB (Ser-483 to 
Leu and HV-5 region of 19k1) were thus constructed. The VN indices of SI422 for 
the respective viruses were measured as previously described (242,243) and were 14 
and 25 on day 8 and 5 and 9 on day 12 (Fig. IA). FlVI9kl and FIVI9k32 and the 
chimeric viruses FIVl9kl m,tA, FlVl9kl m'tB, FIVI9k32motC, FIVI9k32motO and 
FlVI 9k32motE, which had been generated previously and contained only one or two 
point mutations compared with their parent viruses, were also tested in the same 
experiment. Essentially the same results were obtained as in previous studies 
(242,243) (Fig. IA). These data show that a point mutation reciprocal to the Leu to 
Ser mutation at amino acid position 483, which has been shown to render FlVI9kl 
insensitive to neutralization by S1422 (243), renders FIVI9k32 sensitive to this 
neutralization only if at least an additional mutation at amino acid position 454 is 
created or additional exchange of HV-5 is achieved (Fig. IA). 
The Leu to Ser substitution at amino acid position 483 of FlV 19k I introduces a 
potential N-linked glycosylation site at position 481. To investigate the role of this 
potential N-linked glycosylation in the mechanism of neutralization and escape, 12 
chimeric clones were constructed by site directed mutagenesis (Fig. IB). To test 
whether the Ser at amino acid position 483 itself was important, we substituted in 
the SU protein of FlVI9kl, FlV19k32, FIVI9k32m,IA and FlVI9k32motB the Leu by 
a Thr at this position. This resulted in chimeric clones FlVl9kl m,tD, FlV19k32mot', 
FlVI9k32m,tAi and FlV19k32motBl , respectively with a potential N-linked 
glycosylation site in the absence of a Ser at this position. Replication of 
FlVI9kl motO in presence of SI422 proved to be inhibited (Fig. IB). Thus 
independent from the potential N-linked glycosylation site, the actual amino acid 
present at amino acid position 483 does influence the SI422 vims neutralization 
phenotype of the virus. The VN phenotypes of chimeric clones FlV19k32m'tF, 
FlVI9k32motAI and FIVI9k32motBI were similar to that of the parent vims FIV19k32: 
None of these chimeric vimses were neutralized by SI422 (Fig. 1B). 
To disrupt the potential N-linked glycosylation site at position 481 in the SU 
protein of FlVl9kl motB, FlV19k32, FIV19k32motC and FIVI9k32m'tE the Asn at 
amino acid position 481 was substituted by a Gin, another uncharged polar amino 
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Figure 1. Schematic representation of parts of the HV·4 and HV-5 regions of FIVl9kl and FIV19k32 
and chimeric viruses constructed by exchange of single or multiple amino acids in the HV-4 and HV-5 
regions of FIVl9kl and FIVl9k32 (A) and by altering the potential N-linked glycosylation site at amino 
acid position 481 (B). SI422 VN indices measured on days 8 and 12 against the respective viruses are 
also shown (*, data from reference 20). The envelope glycoprotein is diagrammed at the top. The 
hypervariable regions are numbered 1 through 5 in the top box. Restriction enzyme cleaving sites: K. 
KpIII; M, Mstll; N, NsiI. Open and shaded bars, sequence of FIVI9kl and FIV19k32, respectively. The 
amino acid sequence of clone FIV19kl is shown. The individual mutated (and relevant nonmutated) 
amino acids are indicated, with shading and lack of shading indicating the virus of origin (see above). 
Amino acids which alter the potential N-Iinked glycosylation site and which are not present in FIV19kl 
or FIVl9k32 are highlighted in black. 
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acid. This resulted in chimeric viruses FIVI9kl m,t81, FIVI9k32m,'G, FIV19k32m'ICI 
and F1VI9k32motE1 , respectively. None of these viruses were neutralized by S1422 
(Fig. lB). 
Finally, to control for a potential virus neutralization site disruption by the 
presence of a Gin at amino acid position 481, the Asn at amino acid position 481 of 
clones FIVI9kl, FIVl9k32motD, F1V19k32molA and FIV19k32motB was also substituted 
by a Gin, resulting in chimeric clones FIVl9kl motE, FIVI9k32motDl , F1V19k32mo1A2 
and F1VI9k32mot82, respectively. With the exception of FIV19k32motA2, the 
introduction of Gin at this position did not change the S 1422 virus neutralization 
phenotype of these viruses significantly. The replication of F1VI9k32motA2 proved to 
be slightly inhibited. The neutralization of the parent virus of F1V 19k32m,t82 was 
not significantly different from neutralization of the mutated virus (Fig. IB). 
In the experiments presented in this article we have used a thymocyte virus 
neutralization assay, since viral progeny of molecular clones 19k1 and 19k32 
replicates only in feline T cells, a primary target for F1V infection. It has been 
shown that sera from F1V infected cats that neutralize F1V infection of CrFK cells 
with CrFK adapted F1V strains fail to neutralize FIV infection of thymocytes, 
peripheral blood mononuclear cells, or a T-Iymphoid cell line (14,242,272). The 
FIV neutralizing activity demonstrated in the CrFK virus neutralization assay 
proved to be mediated predominantly by antibodies directed to an immunodominant 
epitope in HV-3 (50,148). This suggests that HV-3 specific antibodies largely fail to 
neutralize F1V in the thymocyte virus neutralization assay, and that the HV-3 
domain, if at all, is only indirectly involved in the mechanisms of virus 
neutralization in feline thymocytes. 
Be it as it may, in the present article we have shown that both the HV -4 and 
HV -5 domains of two closely related FIV clones are directly involved in F1V 
neutralization in feline thymocytes. Using bacterial expressed envelope fragments of 
F1V it was shown that the HV-4 region contains a highly type specific antigenic site 
(50,198). However, in pepscan analysis of both regions using 12-mers we could not 
obtain evidence for true linear epitopes in these regions (242,243) (unpublished 
data), indicating that the epitopes involved are to a certain extent conformation 
dependent. It is interesting to note that the location of the regions involved in FIV 
neutralization identified here is reminiscent of the CD4 binding site of human 
immunodeficiency virus type 1, which is a discontnuous site with contributions 
mostly from the carboxy terminal half of the SU protein. Antibodies to the CD4 
binding site have VN activity, just like the antibodies present in serum S1422. On 
the basis of these similarities it may be hypothesized that the HV-4 and HV-5 
regions of the SU protein contribute to the definition of the binding site for the 
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cellular receptor of FlV. 
Together with previously repo11ed results (242,243) the data presented show that 
mutations in the HV -4 and HV -5 regions influence the susceptibility of FlV to 
antibody mediated neutralization. 
This work was supported by a grant from the Dutch Advisory Council on Health 
Research (RGO grant no. 88-90/89028). 
We thank Conny Kmyssen for assistance in preparing the manuscript. 
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Chapter 4.1 
Removal of the Cleavage Site of Recombinant Feline 
Immunodeficiency Virus Envelope Protein 
Facilitates Incorporation of the Surface 
Glycoprotein in Immune-Stimulating Complexes 
Guus F. Rimmelzwaan, Kees RJ. Siebelink, Robin C. Huisman, 
Bernard Moss, Michael J. Francis, 
and Albeit D.M.E. Osterhaus 
J. Gen. Virol. 75:2097-2102 (1994) 

Abstract 
Recombinant vaccinia viruses were constructed that expressed the complete ellv 
gene of feline immunodeficiency virus with or without the nucleotide sequence 
encoding the cleavage site between the surface (SU) protein and the transmembrane 
(TM) protein. Removal of the cleavage site resulted in the expression of a 150 K 
protein that is processed to a 130 K protein and was not cleaved into the SU and 
the TM proteins. Removal of the cleavage site facilitated incorporation of the SU 
protein in immune stimulating complexes (iscoms). Antibody responses to both an 
SU and a TM peptide representing two immunodominant B cell epitopes were 
measured. These were higher in cats immunized with iscoms prepared from the 
cleavage site deleted envelope protein than in cats immunized with iscoms prepared 
from the native envelope protein or immunized with the envelope protein and the 
adjuvant Quil A. 
Feline immunodeficiency virus (FIV) is a lentivirus that was first isolated from 
domestic cats which displayed clinical signs similar to those found in humans with 
AIDS (199). Like human and simian lentiviruses, F1V is T Iymphotropic, causes a 
loss of CD4+ T cells, can infect macrophages and astrocytes, persists in infected cats 
and causes immunodeficiency in its natural host (10,30,53,104,241,269). Because of 
the similarities found between FIV infection in cats and human immunodeficiency 
virus (HIV) infection in humans, feline AIDS has been considered to be a useful 
small-animal model for the evaluation of strategies for the development of antiviral 
compounds and experimental vaccines to combat human AIDS. 
The e/lv gene encoded surface (SU) and transmembrane (TM) glycoproteins of 
lentiviruses playa crucial role in the process of virus-cell attachment and fusion and 
serve as targets for neutralizing antibodies and cytotoxic T cells which are major 
components of antiviral immunity. Consequently, for the development of vaccines 
against F1V infections in cats, the incorporation of FIV glycoproteins presented in a 
form that stimulates both cell- and antibody-mediated immunity should be 
considered. It has been shown that immune-stimulating complexes (iscoms) induce 
both virus-neutralizing antibodies (51,177,194) and MHC class I-restricted CDS+ 
cytotoxic T lymphocytes (CTL) against retrovirus glycoproteins (256). FUl1hermore, 
we and others have recently documented that the iscom presentation form allows 
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the endogenous processing which is necessary for both MHC class 1- and class 11-
restricted recognition by CD8+ and CD4+ T cells, respectively (98,180,274). 
Therefore, we have chosen the iscom structure as a basis for our strategy for the 
development of an FIV vaccine. 
The incorporation of proteins into iscom is largely facilitated by the presence of 
regions which allow hydrophobic interaction with the iscom matrix (39). Since only 
the TM protein of FIV env is highly hydrophobic and the non-covalently bound TM 
and SU proteins readily dissociate, our strategy was to incorporate an F1V env 
protein from which the cleavage site between the SU and TM proteins had been 
deleted. We generated a recombinant vaccinia virus (rVV) that expresses an FIV 
env protein from which this cleavage site has been deleted in order to facilitate 
incorporation of the SU protein in the iscom matrix. 
The FIV env gene (2.6 Kb) encoding the env precursor protein was amplified by 
PCR. Bonc marrow-dcrived DNA, obtained fi'om an FIV-infected cat was used as a 
source of F1V proviral DNA (240). The oligonucleotides for PCR amplification 
were synthesized on an Applied Biosystems DNA synthesizer. They were based on 
the nucleotide sequence of the Petaluma strain of FIV (259): 
5'GGCAGTTGCAATCTACATTATC3' and 5'GCAACAATAAGAATGGCAG3' 
(prime from the 5' end), 5 'CTCAGCACAGTATCTCCC3' and 
5'GACATACCTTCCTCAAAGGG3' (prime from the 3' end). The amplified 
fragment was cloned into the HincH site of the cloning vector pBluescript II SK(+) 
(Stratagene). The FIV env gene was excised fi'om the pBluescript construct 
(pBslenv), with the restriction enzymes Xho1 and Smal, and cloned into the Safl 
and Smal-digested plasmid pSC65 (S. Chakrabarti and B. Moss, unpublished 
results). This plasmid contained vaccinia virus thymidine kinase (TK) sequences 
flanking the cloning site, a synthetic earlyllate vaccinia virus promotor and the lacZ 
gene under control of the vaccinia 7.5 K promotor. The resulting plasmid was 
dcsignated pGR657. Plasmids were screened by restriction endonuclease analysis 
and DNA hybridization using gel-purified env gene as labeled probe (ECL; 
Amersham) and were grown by standard procedures. For the construction of an 
rVV that expresses the env precursor protein without the cleavage site between the 
SU and TM proteins, the nucleotide sequence at position 1822 to 1833, coding for 
the potential cleavage site RRKR, was deleted. To this cnd, 3 Ilg of the pBSlenv 
was used as template DNA for amplification by PCR using primers 5' -del 
(5'GGAAGTCATGGAATATAAACCTGCAGCTATTCATGTTATGTTGGC3'; nt 
1800 to 1856 from which nt 1822 to 1833 were deleted) and 3' BgflI 
(5'GGGGGTAGATCTTTTGTTTGGTTATACC3'; nt 2204 to 2227), to obtain 
fragment 5'-deIl3'-BgflI. Using primer pair 3'-del (reverse complementary to 5'-
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del) and 5'-Nsil (5'GACCTTATTATGCATITCAATATGACAAAAGCTG3'; nt 
1534 to 1567), fragment 5'-NsiIl3'-del was obtained. To obtain the 5'-NsiIl3'-BglII 
fragment with the deletion, a PCR was performed with the 5'-Nsil and 3'-BglII 
primers and 500 ng of the fragments 5' -NsiI/3' -del and 5' -deI/3' -BglII as template. 
The PCR-derived 5'-Ns11/3'-BglII fragment was purified by preparative gel 
electrophoresis, digested with Nsil and BglII and cloned into NsiIlBglII-digested 
pGR657. The resulting plasmid was designated pGR657X15. The presence of the 
deletion was confirmed by determination of the nucleotide sequence in this region 
using the dideoxynucleotide chain termination sequencing. Subsequently rVVs were 
generated as previously described (155) by homologous recombination with vaccinia 
virus (WR strain), which was obtained originally from the ATCC. Recombinant 
virus plaques were visualised by their blue color as a result of the co-expression of 
the lacZ gene and overlay with X-gal (36). The viruses were plaque-purified three 
times and stocks of vGR657 and vGR657XI5 were grown in Hela cells. 
The FIV proteins expressed by vGR657 and vGR657XI5 were analyzed by 
pulse-labeling in a radioimmunoprecipitation assay (RIPA) and Western blot 
analysis. For RIPA Hela cells were infected with vGR657, vGR657XI5 or vSC65 
(control rVV made with pSC65) at an m.o.i. of 30 p.f.u. per cell. At 4 h post 
infection the cells were incubated in methionine- and cysteine-free medium for 30 
min, after which they were pulse-labeled for 30 minutes with [35S)methionine and 
[35S)cysteine (200 IlCi/ml), followed by different chase periods (0, 2 and 24 h). 
FIV-specific proteins were immuneprecipitated from both culture supernatants and 
cell Iysates with polyclonal anti-FIV antibody (senun from the naturally infected cat 
Adam 19; (240) and a monoclonal antibody (MAb) 6-13-12, specific for F1V TM 
protein (see below). 
For the generation of this MAb, BALB/c mice were immunized with iscoms in 
which the FIV envelope proteins expressed by rVV vGR657 were incorporated. For 
incorporation in iscoms, Iysates of vGR657-infected cells were solubilized in PBS 
containing 2% MEGA-1O (Boehringer Mannheim). Subsequently, glycoproteins 
were purified by affinity chromatography using lentil lectin-Sepharose (Phannacia). 
The purified protein was mixed with the lipids cholesterol and 
phosphatidylethanolamine (Sigma) and Quil A (Spikoside; ISCOTEC) at a ratio of 
I: 1:5 (w/w) and after ultrasonication for 30 s incubated for I h at room temperature 
in the presence of 0.2% MEGA-IO. The mixture was then dialyzed against PBS for 
16 h at room temperature followed by dialysis against PBS for 24 h at 4'C. The 
resultant iscom were analyzed by electron microscopy, revealing the typical cage-
like structure, and also by SOS-PAGE followed by Western blot analysis. This 
provided evidence for the predominant incorporation of TM protein (not shown). 
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Figure 1. Pulse-chase analysis of the generation of FIV proteins after rVV infection of Hela cells. After 
infection with rVV vSC65, vGR657 or vGR657X15, cells were labeled with [35S]methionine and 
[JSS]cysteine. At 0, 2 and 24 hours after labeling (lanesl, 2 and 3 respectively) FlY ellv proteins in cell 
Iysates and culhlre medium were visualized by immune precipitation and PAGE using (a) MAb 6-13-12 
and (b) serum from FlY-seropositive cat Adam 19. 
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Figure 2. Western blot analysis ceillysates of vSC65· (lanes I), vGR657· (lanes 2) and vGR657X15· 
(lanes 3) infected BHK cells, using (a) MAb 6·13·12 and (b) serum from FIY·seropositive cat Adam 
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Figure 3. \Veslern blot analysis of iscoms prepared with lentil lectin chromatography·purified Iysates of 
vGR657- (lanes I) and vGR657X15- (lanes 2) infected BHK cells, using (a) MAb 6-13-12 and (b) 
serum from FIY·seroposive cat Adam 19. 
BALBIc mice were immunized with these iscoms and hybridomas were generated 
according to standard procedures (195). For the identification of hybridomas 
producing antibodies reactive with FlV env proteins an FlV env-specific ELISA 
was used (218). MAb 6-13-12, selected for these studies, proved to be specific for 
the TM protein of FlV as demonstrated by its reactivity with FlV env proteins in 
RIPA (Fig. la) and immunostaining of Western blots (Figs. 2a and 3a). 
Directly after pulse labelling of cells infected with vGR657 two FlV proteins 
with M,s of 150K and 130K were observed in the cell Iysates by 
immulloprecipitation with the serum of cat Adam 19. After a chase period of 2 h 
119 
Vaccine development 
the 150K protein had disappeared and only the 130K protein remained. Twenty four 
h after labelling a smear of protein with a mean M, of 32K and a 95K protein were 
visualized in addition to the 130K protein. In the supernatant of the culture infected 
with vGR657 only a 95K protein was only observed (Fig. I b). 
These results show that in cells infected with rVV vGR657 a 150K FIV 
precursor envelope protein is synthesized which is then processed into a 130K 
protein. This protein is subsequently cleaved into a 95K protein that is released into 
the culture supernatant and most likely represents the SU protein and a 32K protein 
which most likely represents the TM protein. Thus the processing of FlV 
glycoproteins expressed by rVV appears to be similar to the processing of FIV 
glycoproteins in persistently infected Crandell feline kidney (CrFK) cells as 
described by Stephens et al. (254). 
In the cell lysate fraction of cells infected with rVV vGR657XI5 FIV proteins 
with M, of 150K and 130K were also present directly after pulse labelling. After a 
chase period of 2 h the 130K protein proved to be predominantly precipitated and 
after a chase period of 24 h this was the only FlV protein observed. No FlV protein 
was precipitated from the supernatants of the cultures infected with rVV 
vGR657XI5 (Fig. Ib). These data suggest that in cells infected with vGR657X15, 
an FIV precursor envelope protein with an M, of 150K was synthesized and that 
this protein was processed into a 130K protein that is not cleaved like the native 
protein. Immunoprecipitation studies with MAb 6-13-12 using the same samples 
confirmed this suggestion. With this MAb, the 150K, 130K and 32K proteins, but 
not the 95K protein, were immunoprecipitated from lysates of cells infected with 
rVV vGR657 (Fig. la). Proteins with M,s of 150K and 130K were precipitated 
fi'om cells infected with rVV vGR657XIS. No 32K protein was precipitated from 
these Iysates, indicating that the 130K protein expressed by vGR657XI5 is not 
cleaved. 
When Iysates of rVV infected BHK cells were tested for the presence of FIV 
proteins by Western blot analysis, the 130K protein could be detected in 
vGR657Xl5-infected cells but not in vSC65- or vGR657-infected cells. In vGR657-
infected cells the TM protein could be detected but it was not detected in vSC65- or 
vGR657XIS-infected cells (Fig. 2), which confirms the findings of the pulse 
labelling experiment. 
Incorporation studies with lentil lectin purified extracts from BHK cells infected 
with the respective rVVs showed that iscom prepared from purified extracts of rVV 
vGR6S7Xl5-infected cells (as described above) predominantly incorporated the 
whole unclcaved 130K protein, in addition to minor amounts of TM protein (32K 
protein), as shown in Western blot analysis using MAb 6-13-12 (Fig. 3a) or sel1lm 
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from seropositive cat Adam 19 (Fig. 3b). We speculated that the presence of the 
32K protein was the result of a putative secundary cleavage site and that this 
protein was found now as a result of the concentration of the hydrophobic proteins 
during the process of iscom formation. In contrast, iscoms prepared from similarly 
purified extracts of vGR657-infected cells incorporated no 130K protein, but did 
incorporate the 1M protein and a 64K protein that was speculated to represent a 
dimer of the TM protein (Fig. 3). The 130K protein incorporated in the iscom 
matrix is of particular interest as an immunogen since it may be expected to contain 
the majority of the T and B cell epitopes of the native envelope proteins, although 
it cannot be ruled out that the conformation of this protein has changed by deletion 
of the cleavage site. However, it was recently shown that an rVV expressed gp 160 
of HIV -1 from which the cleavage site had been deleted still bound soluble CD4 
(54) or membrane bound CD4 (123), indicating that at least the conformation 
dependent CD4-binding site had retained its conformation in this protein. 
The inuuunogenicity of these candidate FlY vaccines was tested in cats. Three 
groups of six cats were immunized subcutanously twice with 4 week interval. Each 
vaccine dose contained either 10 ~lg vGR657 iscoms, 10 jlg vGR657x15 iscoms or 
10 jlg vGR657xl5 as soluble protein mixed with 20 jlg Quil A. A fomih group was 
immunized twice in the same way with 10 jlg of control iscoms prepared with 
cleavage site deleted simian immunodeficiency virus (SIYmac) envelope protein, 
essentially in the same way as described for vGR657xl5 iscoms. Plasma samples 
collected at day 0, 28 and 56 post-immunization were tested in serial twofold 
dilutions for the presence of antibodies against two synthetic peptides in an ELISA. 
The peptides were a kindly gift from R. van Herwijnen, European Veterinary 
Laboratory, Woerden, The Netherlands. The first peptide contained the linear virus 
neutralization site within variable region 3 comprises amino acid residues 396 to 
412 of the surface protein of the FlY Petaluma strain (SU peptide) (148), and the 
second peptide comprised a B cell epitope between amino acid positions 824 and 
848 of the transmembrane protein of the same FlY strain (TM peptide) (13). 
Antibody titers in plasma samples were calculated by determining the highest 
dilution at which the OD450 was still higher than three times the OD"o of the 
plasma sample from the same cat taken prior to immunization. 
All six cats immunized with vGR657x15 iscoms showed plasma antibody titers 
ranging from 50 to 200 to both the SU and TM peptides 56 days post-immunization 
(Fig. 4). Five of six cats immunized with vGR657 iscoms showed plasma antibody 
titers ranging from 50 to 200 to the SU peptide, whereas no plasma antibodies to 
the TM peptide could be demonstrated. This is surprising since these iscoms 
contained TM protein and no detectable SU protein. One explanation for this 
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Figure 4. Plasma antibody titers of individual cats immunized with vGR657 iscoms, vGR657xl5 
iscoms, vGR657x15 soluble protein mixed with Qui! A or SlY env iscoms, against surface (SU) and 
transmembrane (TM) peptides, measured by ELISA at day 56 after the first immunization. 
observation may be that the conformation of the epitope presented by the TM 
peptide was not properly exposed in vGR657 iscoms. Apparently the vGR657 
iscoms still contained enough residual SU protein to induce an SU-specific 
antibody response. Only three of the six cats immunized with vGR657xl5 soluble 
protein mixed with Qui! A developed plasma antibodies to the SU peptide with 
titers ranging from 100 to 200, whereas no antibodies to the TM peptide could be 
detected. None of the cats immunized with the control SlY envelope iscoms 
developed detectable plasma antibodies to either of the peptides. Thus the cleavage 
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site-deleted envelope protein incorporated into the iscom matrix proved to be most 
efficient in inducing antibodies to both the SU and TM proteins. 
The antibody responses wiII be analyzed further to evaluate whether antibodies 
to other epitopes or vims neutralizing antibodies have been induced. The evaluation 
of vGR657xl5 iscoms as a potential candidate FlV vaccine is the subject of our 
present studies. 
The authors wish to thank Mr. N. Cooper for technical assistance, Ms. E. 
Hulskotte for preparing the SIV iscom, Mr. R. van Herwijnen, European Veterinary 
Laboratory, Woerden, The Netherlands for production and purification of the 
synthetic peptides and Ms. M. Eskens and. Ms. C. Kl1Iyssen for preparation of the 
manuscript. 
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Enhancement of Feline Immunodeficiency Virus 
Infection after Immunization with Envelope 
Glycoprotein Subunit Vaccines 
Kees H.J. Siebelink, Edwin Tijhaar, Robin C. Huisman, Willem Huisman, 
Anthony de Ronde, Ian H. Darby, Michael J. Francis, 
Guus F. Rimmelzwaan, and Albert D.M.E. Osterhaus 
J. Viro!. 69:3704-3711 (1995) 

Abstract 
Cats were immunized three times with different recombinant feline 
immunodeficiency virus (FlV) candidate vaccines. Recombinant vaccinia virus 
(rVV)-expressed envelope glycoprotein with (vGR657) or without (vGR657xI5) the 
cleavage site and an FIV envelope bacterial fusion protein (p-Galactosidase-Env) 
were incorporated into immune-stimulating complexes or adjuvanted with Quil A. 
Although all immunized cats developed antibodies against the envelope protein, 
only the cats vaccinated with the rVV-expressed envelope glycoproteins developed 
antibodies which neutralized FlV infection of Crandell feline kidney cells. These 
antibodies failed to neutralize infection of thymocytes with a molecularly cloned 
homologous FlV. After the third immunization the cats were challenged with 
homologous FlV. Two weeks after challenge the cell-associated viral load proved to 
be significantly higher in the cats immunized with vGR657 and vGR657x15 than in 
the other cats. The cats immunized with vGR657 and vGR657x15 also developed 
antibodies against the Gag proteins more rapidly than the cats immunized with P-
Galactosidase-Env or the control cats. This suggested that immunization with rVV-
expressed glycoprotein of FlV results in enhanced infectivity of FlV. It Was shown 
that the observed enhancement could be transferred to naive cats with plasma 
collected at the day of challenge. 
Introduction 
Feline immunodeficiency virus (FIV) is a T-lymphotropic lentivirus that causes 
feline AIDS, which is similar to AIDS in humans (10,16,53,104,115,199,236,241, 
248,289). The similarities between FIV and human immunodeficiency virus (HIV) 
on the one hand and between the pathogeneses of the syndromes they cause on the 
other hand have led. to the use of FIV infection of cats as an animal model to 
evaluate the potential of preventive and therapeutic measures for HIV infection in 
humans. Since FIV infection is widespread among cats all over the world, the 
development of preventive and therapeutic measures for feline AIDS is also of 
major veterinary importance. 
Different vaccination strategies for lentivirus infections have been evaluated with 
varying degrees of success. Most attempts to develop candidate vaccines against 
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lentivirus infections were without success (for a review, see reference 135). 
Neve11heless, in some experiments chimpanzees were successfully vaccinated 
against HIV type I (HIV-I) (20), and macaques were successfully vaccinated 
against HIV-2 or simian immunodeficiency virus (SIV) infections with candidate 
whole inactivated virus, live attenuated virus, recombinant virus, subunit virus 
vaccines, or combinations of these candidate vaccines (34,47,113,120,192,209,211, 
235). The mechanisms by which protective immunity was established in these 
systems are not well understood at present, although there are indications for a 
major role of both virus neutralizing (VN) antibodies and cell-mediated immunity 
(64,144,210). However, contradictory data have also been obtained in some of these 
studies (12,21,110,231). In the macaque SIV model it was shown that at least part 
of the protective immunity induced could be attributed not to virus-specific, but 
rather to cell-specific antibodies (141,255). In the SIV system it was recently shown 
that vaccine-induced protection against infection with SlY-infected cells correlated 
with the presence of a certain major histocompatibility complex class I genotype of 
the monkeys, indicating the involvement of major histocompatibility complex class 
I-restricted cytotoxic T-Iymphocyte responses (99). 
Several approaches to develop a preventive vaccine against FlV infection have 
also proven to be unsuccessfhl (110,278). However, Yamamoto et a1. reported the 
induction of protective immunity in cats against homologous and to a lesser extent 
also to heterologous FlV challenge, by vaccination with inactivated whole virus or 
FlV-infected cells (286,287). This protective effect could be transferred to naive 
cats with plasma from vaccinated animals, indicating that antibodies may be at the 
basis of this protective immunity (l05). It was shown that serum antibodies against 
FlV envelope glycoproteins, with different VN domains, correlated more with 
protective immunity than antibodies to other viral proteins. 
FlV vaccines based on recombinant envelope proteins would have clear 
advantages over inactivated or attenuated virus vaccines. However, so far 
vaccination strategies using FlV purified envelope glycoproteins or fractions of 
these proteins as immunogens have failed (II 0, 149). Here we report the results of a 
series of vaccination experiments in cats with different envelope proteins of FlV, 
expressed by recombinant vaccinia viruses (rVY) or as a bacterial fusion protein 
and presented in the context of different adjuvant systems. The most striking 
finding of these studies is that vaccines containing intact envelope glycoprotein 
induced enhancement of infectivity rather than protective immunity against 
homologous FlV infection. The observed enhancement could be transferred to naive 
cats with the plasma of the vaccinated cats. 
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Materials and Methods 
Cells and challenge virus 
Peripheral blood mononuclear cells (PBMC) and thymocytes were derived from 
an 8-weeks-old specific-pathogen-free (SPF) cat (240). These cells were stimulated 
with concanavalin A (5 ~g1ml) in culture medium (RPMI 1640 [GIBCO, 
Gaithersburg, MD.], penicillin [100 IU/ml], streptomycin [100 ~g1ml], L-glutamine 
[2 mM], 2-mercaptoethanol [2 x 10" M], interleukin-2 [100 IU/ml]) and 10% fetal 
calf serum. After 3 days the cells were washed and cultured further in culture 
medium. An FlV-susceptible clone of Crandell feline kidney (CrFK) cells, named 
CrFK !DIO, was kindly provided by N. Pedersen (289). The FIV AMl9 strain was 
isolated from PBMC of a cat naturally infected with FlV (240). Concanavalin A-
and interleukin-2 stimulated cells were infected with FIV AMI9. When FlV antigen 
was detected in culture supernatant by enzyme-linked immunosorbent assay 
(ELISA) (239), it was filtered through a 220 nm-pore-size filter, aliquoted, and 
stored at -135°C. This FIV stock was titrated in vivo. Groups of four SPF cats were 
inoculated intramuscularly (i.m.) with 0.5 ml of 1:100, 1:400, 1:1,600, 1:6,400, or 
1:25,600 dilutions of the FIV stock. All cats receiving 1:100 and 1:400 dilutions 
became infected by 4-8 weeks postinfection as shown by seroconversion and virus 
isolation. Three out of the four cats inoculated with I: 1,600-diluted FlV stock and 
one out of four cats inoculated with I :6,400-diluted stock became virus isolation 
positive and seropositive. One cat 50% cat infectious dose (CID,o) was therefore 
estimated to be 0.5 ml of a I :3,200 dilution of the FIV stock. 
FlV AM6c was isolated from PBMC of a cat naturally infected with FlV and 
adapted to replicate in CrFK IDIO cells as previously described (244). env gene 
sequence homology of FIV AM6c and FlV 19k1 is 94.8%. CrFK !DIO cells were 
infected with FIV AM6c, and after 6 days the culture medium was refreshed. After 
another 4 days of culture, when FIV antigen was detected in the culture supernatant, 
it was filtered through a 220-nm-pore-size filter and stored in aliquots at -135°C. 
This FIV stock was titrated in CrFK !D I 0 cells and the highest dilution (20 . 
TCID,os) which consistently resulted in detectable antigen production within 8 days 
was used in the VN assay (see below). 
Preparation of candidate FIV vaccines 
The envelope glycoproteins of FIV AM19, were expressed by an rVV in BHK 
cells either in their native form (vGR657) or after deletion of the cleavage site 
between the surface (SU) and the transmembrane (TM) proteins (vGR657xI5) to 
facilitate incorporation into immune-stimulating complex (iscoms) (219). After 
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lectin purification these proteins were incorporated into iscoms, which resulted in 
two iscom preparations - vGR657 and vGR657xl5 iscoms - as previously described 
(219). An 1,870-bp fragment of the envelope gene was excised from pBluescript, 
containing the whole envelope gene, by using the restriction enzymes BamHI and 
Bgn! (nucleotide position 350 and 2220, respectively) and subcloned into BamHI-
digested pEX vector (Stratagene, La Jolla, Calif.). This vector allows inducible 
expression of proteins as p-galactosidase (p-Gal) fusion protein. This protein was 
pal1ially purified as inclusion bodies, solubilized and mixed with Quil A as an 
adjuvant. 
SIV envelope glycoprotein iscoms were prepared by E. Hulskotte using a method 
similar to that used for the cleavage site-deleted F1V envelope glycoprotein iscoms 
(114). 
Vaccination and challenge infection of cals 
Six groups of six SPF cats each were vaccinated three times subcutaneously 
according to the following schedule: group 1, vGR657 iscoms; group 2, vGR657xl5 
iscoms; group 3, vGR657xl5 plus Quil A; group 4, p-Gal-FIV Env plus Quil A; 
group 5, SIV Env iscoms; and group 6, phosphate buffered saline. The cats were 
vaccinated with 10 Ilg of protein at week 0, 4 and 10. Two weeks later the cats 
were challenged by the intramuscular route with 20 CID"s of FIV AMI9. PBMC 
and plasma samples were collected every 2 weeks postchallenge (p.c.) during an 8-
week period. 
Serological assays 
Antibodies against the Gag proteins p24 and p 17 were detected with a 
commercially available test kit, using recombinant p24 and p 17 proteins (catalog 
number FI002-ABOI; European Veterinary Laboratory B.V., Woerden, The 
Netherlands). Antibody titers were expressed as the optical density at 450 nm 
(aD,,,) value of the serum mUltiplied by the dilution divided by three times the 
OD"o value of the negative control serum. 
Antibodies against the envelope protein were detected by ELISA using synthetic 
peptides and bacterial fusion proteins, representing different regions of the envelope 
protein as shown in Fig. 1. The synthetic peptides were purchased from European 
Veterinary Laboratory B.V. (catalog numbers: SU peptide, EVS-000-PE-003; TM 
peptide, EVS-000-PE-004). The first synthetic peptide contains the 
immunodominant VN epitope within variable region 3 spanning amino acid residues 
396 to 412 of the surface protein of the Petaluma strain (SU peptide) (148). The 
second peptide contains a B-cell epitope between amino acid positions 695 and 706 
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of the transmembrane protein of the same FlV strain (TM peptide). Antibody titers 
were calculated as described for the Gag ELISA. 
An ELISA based on the detection of antibodies to a series of bacterial fusion 
proteins as shown in Fig. I was performed as described elsewhere (50). 
SUl 
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SU3 
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SU5 
SU6 
TMl 
TM2 
TM3 
su- peptide 
TM· peptIde 
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SU TM 
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Figure 1. Surface (SU I to 8U6) and transmembrane (TM I to TM3) bacterial fusion products and SU 
and TM peptides used in the ELISA to detcct antibodies against the envelope protein. The top bar 
represents the envelope protein of FIV, including the leader (L), surface (SU). and transmembrane (TM) 
proteins. The black boxes represent hypervariable regions in the envelope protein. The different bacterial 
fusion products and the peptides are indicated as bars. 
VN assays 
VN serum antibodies were determined in two different VN assays. The feline 
lymphocyte VN assay was based on inhibition of infection of thymocytes with 
molecularly cloned FlV 19k1 as previously described (242). The CrFK VN assay 
was based on the inhibition of infection of CrFK IDIO cells with FIV-AM6c, 
which is adapted to replicate in these cells. For this assay CrFK IDIO cells (3.5 x 
103) were seeded into a 96-well plate in 100 !-II of Dulbecco modified Eagle 
medium supplemented with 5% fetal calf serum. The next day the cells were 
washed and incubated for I h at 37°C with Polybrene (8 flg/ml) in Dulbecco 
modified Eagle medium supplemented with 5% fetal calf serum. A mixture of equal 
volumes of the diluted (see above) virus stock of FlV-AM6c, and twofold serial 
dilutions of heat-inactivated serum were incubated for one hour at 37°C. Then the 
CrFK cells were washed and incubated with the virus-serum mixture at 37°C. After 
24 hours the CrFK cells were washed twice and propagated in Dulbecco modified 
Eagle medium supplemented with 2% fetal calf serum. After 8 days the culture 
supernatant was tested for the presence of FlV antigen by ELISA (239). The 
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neutralizing antibody titer was expressed as the highest dilution of the serum still 
preventing FlV antigen production in the culture supernatant. 
Cell associated virus load: infectious center test 
Serially diluted PBMC samples (l x [OJ, 3 X 10J, and I x [04 cells) were 
prepared from cats before and after challenge as previously described (240). These 
cells were cocultivated with [0' Concanavalin A- and interleukin-2-stimulated 
PBMC from an SPF cat in eight duplicate wells. After 3 weeks the culture 
supernatants were tested for the presence of FIV antigen by ELISA. The number of 
infected cells in the PBMC in vivo was calculated from the in vitro culture 
assuming that one infected cell gave rise to antigen production after cocultivation 
with Concanavalin A- and interleukin-2-stimulated PBMC from an SPF cat, when 
one or more cultures tested in eight duplicate wells were negative for FIV antigen 
production. 
Plasma transfer 
A plasma pool was prepared by mixing equal volumes of the plasma samples 
derived from all the vaccinated cats from groups I and 2 at the day of challenge 
(plasma pool A). A second pool (plasma pool B) was prepared similarly by mixing 
plasma samples from all the cats of group 6 at the day of challenge. Two groups of 
four SPF cats, 10 weeks old, weighing between 800 and 1,250 g were used in the 
transfer experiment. Cats of group A and group B were injected intravenously with 
7 ml of plasma pool A and plasma pool B, respectively. Six hours later the cats 
were challenged by the intramuscular route with 20 CID"s of FIV AM 19 as 
described above. PBMC and plasma samples of the cats were collected at weekly 
intervals and tested for viraemia by virus isolation and for the development of 
plasma antibodies against the Gag protein. 
Results 
Development of FIV-specific plasma antibodies IIpon vaccination 
All plasma samples collected at the day of challenge were tested in the SU and 
TM peptide ELISA (Table I, week p.c. 0). All the cats vaccinated with the vGR657 
and vGR657xl5 iscoms (groups I and 2) had developed plasma antibody titers to 
these peptides, ranging from 200 to 25,000, whereas all the cats vaccinated with 
Quil A-adjuvanted vGR657xl5 (group 3) had developed antibody titers to at least 
one of the two peptides ranging from 50 to 3,000. Five of six cats vaccinated with 
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Table 1. Antibody response against SU and TM peptides in vaccinated cats at 
different times p.c.a 
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a SU peptide ELISA results: no symbol, titer <200; ., titer between 200 and 1,000; 
-. titer between 1,000 and 5,000; -. titer between 5,000 and 25,000; -, 
titer >25,000. TM peptide ELISA results: no symbol, titer <50; -, titer between 50 
and 300; -, titer between 300 and 3,000; -. titer between 3,000 and 1O,000j 
-, titer >10,000. 
the Qui! A-adjuvanted bacterial FIV envelope fusion protein (group 4) had also 
developed serum antibody titers to the TM peptide, ranging from 50 to 3,000, 
whereas only one animal had developed a titer of 300 to the SU peptide. One cat of 
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the two control groups, groups 5 and 6, showed an apparently nonspecific plasma 
antibody titer to the SU and TM peptides, which already existed before the start of 
the immunization procedure (not shown). Subsequently the same plasma samples 
were tested in ELISA for antibody titers against the respective bacterial F1V 
envelope SU and TM fusion proteins (Table 2). Vaccination with the vGR657- and 
vGR657xl5 iscoms (groups 1 and 2) resulted in high plasma antibody responses to 
all the SU and TM regions tested with the exception of the SU5 and TMI regions, 
Table 2. Levels of antibody against envelope fragments in vaccinated cats 
at the day of challengea 
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against which lower or no antibody levels were detected. Antibody levels induced 
with the native glycoprotein iscoms (group I) and the cleavage site-deleted 
envelope iscoms (group 2) are comparable. The overall OD45o values induced with 
the cleavage site deleted FlV envelope glycoprotein adjuvanted with Qui! A (group 
3) were lower than those found in the cats of groups I and 2. Vaccination with the 
p-Gal-FIV envelope fusion protein adjuvanted with Quil A failed to induce 
antibodies against the SUI, SU2, SU4, and SU5 regions. No significant levels of 
antibody to these fusion proteins were found in the cats of the two control groups 
(groups 5 and 6) 
All the plasma samples collected at the day of challenge were also tested in the 
two VN antibody assays. None of the samples exhibited VN activity in the feline 
lymphocyte VN assay (not shown). However, VN antibodies could be demonstrated 
in cats of groups I, 2, and 3 in the CrFK VN assay (Fig. 2). The VN titers in cats 
vaccinated with vGR657 iscoms (group I) ranged from 160 to 640, with a mean 
titer of 506. Those of vGR657xl5 iscom-vaccinated cats (group 2) ranged from 40 
to 640 with a mean titer of 206, which is not significantly different from the values 
found for group I. VN plasma antibody titers of cats vaccinated with the Quil A-
adjuvanted vGR657xl5 protein varied from 10 to 40, with a mean titer of 28, a 
value which is significantly lower than that found for groups 1 and 2 (Student I 
test; P<0.05). In cats vaccinated with the p-Gal-FlV envelope filsion protein (group 
4) and the cats of the control groups 5 and 6, no VN antibody response could be 
demonstrated at the day of challenge. 
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Figure 2. Plasma VN antibody titers of the individual cats of the six different vaccination groups as 
measllred in the CrFK VN assay at the day of challenge. The titers in the individual cats are indicated 
with different symbols. The mean titer per group is indicated by a bar. 
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As expected, none of the cats had developed plasma antibodies to the F1V Gag 
protein at the day of challenge (Fig. 3). 
Kinetics of FIV-specific plasma antibodies aj/er FIV challenge 
Plasma antibody titers, against the SU and TM peptides of most of the cats 
immunized with the recombinant F1V envelope proteins (groups I to 4) increased 3-
to 10-fold within 4 weeks after challenge infection. Within 8 weeks all the cats, 
including the control animals in groups 5 and 6, had developed anti-SU and anti-
TM peptide plasma antibodies (Table I). At 8 weeks p.c. the SU peptide-specific 
antibody titers in the cats vaccinated with rVV -expressed F1V envelope glycoprotein 
were significantly higher than those of the nonvaccinated cats (Table I; P<O.05). 
Plasma antibodies to the FIV Gag protein could be detected 4 weeks after 
challenge in all the cats vaccinated with rVV -expressed F1V envelope glycoproteins 
(groups I, 2, and 3) (Fig. 3). In the cats vaccinated with the p-Gal-F1V envelope 
fusion protein (group 4) and in the cats of the two control groups, groups 5 and 6, 
it took about 2 weeks longer before FIV Gag-specific antibodies were detected. Not 
only was the induction of F1V Gag-specific antibodies in cats of groups I to 3 
faster, but also the 8 week p.c. plasma titers tended to be higher in these animals 
(Fig. 3). 
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Figure 3. Kinetics of the plasma antibody titer development against the Gag protein, in cats from the 
different vaccination groups. Mean anti-Gag titers at different times after challenge are presented. 
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Cell associated virus load 
Two weeks after infection FIV-infected PBMC were demonstrated in all the cats 
of groups I and 2 and in four of six cats of group 3 (Fig. 4). The numbers of the 
FIV-infected PBMC varied from 50 to 210, 30 to 1,000, and 0 to 106 per 106 
PBMC, respectively. In the other three groups no infected PBMC were 
demonstrated at this time. Two weeks later, FIV-infected PBMC could be 
demonstrated in all the cats of all groups. Although a lower average FIV load was 
observed in cats of group 4 compared with that in the other groups, the differences 
observed between the groups proved not to be significant. 
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Figure 4. Numbers of FIV-infected cells per 106 PBMe in the individual cats (indicated by different 
symbols) of the different vaccination groups at 2 and 4 weeks p.c. The mean numbers of infected PBMC 
per group are indicated by a bar. 
Plasma transfer experiment 
Pools of plasma collected at the day of challenge from the cats of groups I and 
2 (pool A) and from group 6 (pool B) were prepared, and VN titers were 
determined. The titers, measured in the CrFK VN assay, were 320 and <10, 
respectively. Two groups of four SPF kittens were inoculated intravenously with 7 
ml of plasma pool A or plasma pool B. No plasma VN antibodies could be detected 
6 h after the transfer. F1V could be demonstrated in PBMC of one of four cats of 
group A (20 infected cells per 106 PBMC) but not in PBMC of cats of group B 2 
weeks after challenge with 20 CIDsos of F1V AMI9 (Fig. 5). Three weeks after 
challenge three of four cats of group A and two of four cats of group B exhibited 
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Figure 5. Kinetics of numbers of FlY infected cells per 106 PBMC in individual cats (indicated by 
different bars) transferred with plasma pool A (groups 1 and 2) or plasma pool B (group 6), measured 
over 6 weeks p.c. 
cell-associated viremia, with significantly higher numbers of FIV-infected cells in 
the cats of group A (P<0.05). The mean numbers of infected PBMC in the cats 
from groups A and B at three weeks p.c. were 115 and 6 per 10' PBMC, 
respectively (Fig. 5). At four weeks p.c. the mean numbers of F1V-infected cells 
were III and 16 per 10' PBMC, respectively. Five and six weeks after challenge 
F1V could be reisolated from PBMC from all cats of both groups with no clear 
differences in cell-associated virus load. 
Four weeks after challenge, plasma antibodies to the Gag protein could be 
detected in three of four cats of group A (with ELISA titers ranging from 170 to 
800) and in none of the cats of group B (Fig. 6). At 5 weeks p.c. anti-FIV Gag 
plasma antibodies were demonstrated in all cats of group A (titers from 180 to 
2,600) and in only two of four cats from group B (titers from 70 to 100). In the 
plasma samples collected from all the cats of both groups at 6 and 8 weeks p.c., 
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antibodies against the Gag protein were demonstrated. The titers were significantly 
higher (P<O.05) in the cats of group A than those in the cats of group B from 4 
weeks p.c. onward. 
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Figure 6. Kinetics of plasma antibody titer development against the Gag protein in individual cats, 
transferred with plasma of pool A (groups 1 and 2) or plasma of pool B (group 6). 
Discussion 
The present paper describes the evaluation of the potential of different candidate 
FlY vaccines in a vaccination challenge experiment in SPF cats. The most striking 
finding was that immunization with rVV -expressed FLY glycoproteins, resnlting in 
VN plasma antibodies, led to enhanced FlY infection upon challenge in these cats 
(groups I, 2, and 3). This was demonstrated by the more rapid development of 
PBMC-associated viremia and Gag-specific plasma antibodies. The enhancement 
effect could be transferred to naive cats with plasma collected from cats immunized 
with these candidate vaccines. In contrast, cats immunized with an FlY envelope 
bacterial fusion protein (group 4) did not develop VN plasma antibodies and 
developed PBMC-associated viremia and Gag-specific plasma antibodies with the 
same kinetics as the two control groups. 
Comparison of the antibody levels induced in the first three groups of cats at the 
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day of challenge indicated that the immunogenicity of vGR657 and vGR657xl5 
incorporated into iscoms was higher than that of vGR657x IS presented with Quil 
A. Both VN plasma antibodies and plasma antibodies to the different SU regions 
proved to be higher in the first two groups (Fig. 2; Table 2). Plasma antibody levels 
against most of the SU regions were lower or absent in group 4 at the day of 
challenge (Table 2). It is not clear why the presence of VN plasma antibodies at the 
day of challenge correlated not with protective immunity but rather with enhanced 
susceptibility to FIV infection. It should be noted, however, that the VN activity 
was demonstrable only in the CrFK VN assay and not in the feline lymphocyte 
assay. The latter assay should probably be considered more relevant in terms of 
protective immunity against in vivo FlV infection since, in contrast to feline kidney 
cells, feline lymphocytes are natural targets for FIV infection. In the transfer 
experiment it was shown that the enhancement phenomenon could be transferred to 
naive cats with the plasma of cats of groups I and 2. Although not formally proven, 
this indicated that the enhancement was mediated by FIV-envelope specific 
antibodies. The mechanism of enhancement proved to be operational at relatively 
high dilutions: after plasma transfer, no VN antibody activity could be demonstrated 
in the plasma of the kittens which subsequently showed enhanced FlY infectivity. It 
has also been shown for HIV-I that antibody-dependent enhancement (ADE) could 
still be demonstrated at high dilutions (up to I :65,000), whereas VN antibody 
activity can rarely be demonstrated at dilutions higher than 1:1,000 (223). As no 
reliable systems are available at present to quantify or even detect FIV -enhancing 
antibodies in vi/ro, it should be realized that all FIV -neutralizing antibodies found, 
pel' definition, should be considered to be the net result of neutralization and 
enhancement of FIV infectivity measured in vi/ro. 
To date different mechanisms of ADE have been described for lentivirus 
infections. Complement- and Fc receptor-mediated ADEs have been shown to play 
a role in HIY-I, HIV-2, and SIV infections {I 06, 107, 175,22 1,257). Recently, 
another mechanism of ADE was described, in which antibodies neutralized or 
enhanced HIY-I, dependent on the phenotype of the virus involved (232). From our 
data it cannot be concluded which mechanism was involved in the observed 
enhancement of FlV infectivity. Indications for enhanced infectivity after FIV 
vaccination have been observed before {I 10). In the experiments of Yamamoto e/ 
al. (287) the presence of VN antibodies, demonstrated in an FeTi cell (feline 
lymphoid cell line) VN assay, correlated with protective immunity rather than with 
enhancement of infectivity. This immunity could be transferred to naive animals 
with plasma of immunized animals (105). The main difference between their 
vaccination appraoch and ours is that in our experiments recombinant envelope 
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proteins were used whereas Yamamoto ef al. used inactivated whole virus or virus 
infected cells as immunogens. Since transfer experiments showed that probably 
plasma antibodies are involved in the observed mechanisms of enhancement and 
protection in both series of experiments, it may be speculated that the differences in 
configuration in which the FIV envelope glycoproteins were presented in both 
vaccines has led to VN antibodies with different affinities. This may have had 
direct consequences for their in vivo effects. 
Furthermore, the cell substrates used for the production of challenge viruses, may 
have contributed to the observed differences in outcome of the vaccination 
experiments. The challenge virus used in our experiments was propagated in 
primary feline lymphocytes, whereas the challenge viruses in the experiments of 
Yamamoto e/ al. were propagated in a feline T cell line (287). Like in the HIV - I 
system, T-cell line-adapted FIV may be neutralized more efficiently than virus 
isolates from primary lymphocyte cultures, which may result in neutralization of the 
virus in the presence of enhancing antibodies. Furthermore, it may be speculated 
that, as was recently demonstrated for HIV-l isolates from one individual (232), T-
cell line-adapted FlV is less susceptible to ADE. 
Taken together, it should be stressed that the mechanisms leading to the observed 
phenomenon of FIV enhancement upon vaccination and passive transfer are not 
fully understood at present. For the development of an effective FlV vaccine, the 
elucidation of the underlying mechanisms may be crucial. This may also lead to a 
more rational strategy for the development of HIV - I vaccines. 
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Chapter 5 
Summarizing discussion 

In this thesis a series of experiments is described in which newly established 
molecular clones of FIV derived from a domestic cat with feline AIDS, are used to 
study the molecular basis of FIV cell tropism, escape from VN antibody, and the 
potential of candidate FIV vaccines. In chapter I, it is shown that FlV is a 
widespread pathogen of cats, which induces a immunodeficiency syndrome similar 
to AIDS in humans. It has characteristic propelties of a lentivims, including its 
morphology (199), genome organization (189,204), chapter I, 2.3), Mg'+ dependent 
reverse transcriptase (199), chapter 2.3) and it is antigenically related to ungulate 
lentiviruses like Visna virus, CAEV and EIAV (57). Based on molecular 
phylogenetic comparison of the FIV pol and gag genes with those of other 
lentiviruses, FlV constitutes a separate cluster in the subfamily Lentivirinae which 
seems to be more related to the cluster of the ungulate lentivil1lses (Visna virus, 
CAEV, EIA V and BIV) than to that of the primate lentiviruses. It is interesting to 
note however, that the pathogenesis of FlV infection, eventually resulting in feline 
AIDS, shows more resemblance to that of the primate lentiviruses (Chapter I). This 
may be reminiscent of differences in cell tropism of the respective viruses: The 
ungulate lentiviruses predominantly infect cells of the macrophage lineage 
throughout the course of infection, whereas FIV, like the primate lentiviruses, 
predominantly replicates in cells of both the macrophage and the T cell lineages. 
Since FIV is a major pathogen of domestic cats , it should be considered of 
major veterinary importance. Large numbers of FIV infected domestic cats develop 
feline AIDS and related disorders, which require veterinary attention. The impact of 
infections with FIV related vil1lses on the health of large feral and captive felids is 
not fully understood at present (190). Although speculations have been made about 
a predisposing role of infection, with related viruses in outbreaks of infectious 
diseases in wild felids, like recent outbreaks of canine distemper infections in 
African lions and large felids in zoos, these speculations have so far not fully been 
substantiated (95,96). 
Besides the apparent veterinary importance of FlV infection of cats, the infection 
is also of invaluable importance as an animal model for human AIDS. This was 
extensively demonstrated in studies described in chapter 2.1 and in similar studies 
carried out by several other groups. We showed that cats, which were 
experimentally infected with the Petaluma strain of FIV, developed clear 
immunological abnormalities long before clinical signs could be detected. These 
included impaired mitogen and antigen induced proliferative T cell responses, and 
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inverted CD4/CD8 ratios (chapter 2.1, unpublished observations). Bishop et al. also 
showed that FlV infection in cats not only affected primaty, but also secondary T 
cell responses in the acute stage of the infection (23,24). These observations of 
impaired primary and secondary T cell responses, which parallel the findings in 
HIV seronegative individuals, may underlie the increased susceptibility to 
opportunistic infections generally observed in cats infected with FIV. Besides the 
apparent similarities in pathogeneses between the feline and primate lentivirus 
infections, another advantage of the FIV-cat model is the restricted host range 
which makes this small animal model relatively cheap and easily accessible for 
experimentation. It should however be realized that the use of another cellular 
receptor than the CD4 molecule and the relative genetic distance of FlV from the 
primate lentiviruses may constitute inherent limitations of this model. 
The specificity and kinetics of FIV specific serum antibody responses to 
struchlral proteins of the virus, were studied upon natural and experimental 
infection of domestic cats in chapter 2.3. Like in HIV-I infection of humans an Env 
protein specific response was detectable before Gag protein specific antibodies 
could be demonstrated in cats experimentally infected with FIV. Also in naturally 
infected cats, it was shown that Env protein specific antibodies were demonstrable 
in the absence of Gag protein specific antibodies. These data clearly indicated, that 
diagnostic tests should not solely be based on the demonstration of Gag protein 
specific serum antibodies. 
The generation of a series of molecular clones of FIV directly from the bone 
marrow of a cat with AIDS, thus obviating an in vitro culturing step, facilitated the 
study of a number of questions which are difficult to address in HIV infections of 
humans (Chapter 2.3). Two molecular clones of FlV out of a total of 36 - FlV 
19k1 and FIV 19k32 - were selected for these studies. These clones differed in six 
amino acids of the Env proteins and exhibited similar in vitro growth 
characteristics. Molecular clones FIV 19k1 and FlV 19k32 were first used to study 
the molecular basis of differences in cell tropism between different viruses, by 
making chimeric vimses in which Env protein domains had been exchanged 
between viruses with different phenotypes: FIV 19k1 could be adapted to replicate 
in CrFK cells , by exchanging the HV -3 region with that of a biological isolate 
(FIV AM6c) that had been adapted to replicate in CrFK cells. It was however also 
shown, that additional substitntions within and outside the Env protein were needed 
to complete this process of adaptation. One of these additional mutations proved to 
be a Glu to Lys substitution at amino acid position 409 of the Env protein. It may 
be speculated that for CrFK cell tropism, a critical basic amino acid sequence of 
HV-3 is required. The HV-3 region harbours an immunodominant antigenic site, 
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against which virtually all FlV infected cats develop antibodies (50,56,148). This 
may explain why serum samples from most FIV infected cats show a broad VN 
pattern towards a wide variety of CrFK adapted viruses when analyzed in CrFK 
cells. The broad VN activity is therefore merely a reflection of a dominant anti HV-
3 reactivity, leading to steric hindrance of viral entry into CrFK cells, than of in 
vivo significant VN activity. This was further substantiated by showing that indeed 
serum samples with a broad VN capacity as demonstrated in the CrFK VN assay, 
exhibited at the best a narrow homologous virus specific VN activity, when 
measured in a thymocyte VN assay (Chapter 3.2, 3.3). 
The molecular clones FIVI9kl and FlV 19k32 were also used in studies 
concerning the mechanisms of virus neutralization by feline antibodies in 
lymphocyte cultures. It was shown that two independent mutations in the Env 
protein of FlV 19k I conferred resistance to VN serum antibody of a cat infected 
with FlV 19k1 (SI422). It was demonstrated that FIV 19k32, which differs in only 
five amino acids in the SU protein from FlV 19k1, could be made sensitive to VN 
by SI422 through simultaneous amino acid substitutions in the HV-4 and HV-5 
regions between FIV 19k1 and FIV 19k32. The mutations, in HV-4 and HV-5 
respectively, were approximately 80 amino acids apart and may well be involved in 
the formation of a single conformation dependent epitope. In this light it is 
interesting to note that the two regions in which the relevant mutations have been 
observed are both located in the C-terminal part of the SU protein of FlV. For 
HIV -I it has been demonstrated that especially regions of the C-terminal part of the 
SU protein contributes to the conformation dependent region that interacts with the 
CD4 molecule, which is the cellular receptor for HlV (264, for a review, see 
reference 143). Therefore it may be speculated that the differences in HV-4 and 
HV-5 involved in the transfer of VN sensitivity between FIV 19k1 and FIV 19k32 
directly influence a conformational epitope that interacts with the cellular receptor 
ofFIV 
These studies showed that the availability of a series of closely related molecular 
clones of FlV, generated from the same cat at the same time point, offers the 
unique opportunity to study the molecular basis of several phenotypic differences 
between individual vil1lses by exchanging genes or gene fragments between viruses 
with different immunological or cell tropism phenotypes. The immune response and 
overall pathogenesis can be studied in laboratory cats infected with these viruses 
and the in vivo phenotypic differences may then be related to molecular differences 
between these viruses. This will lead to a better understanding of the molecular 
mechanisms underlying the complex features of lentivirus pathogenesis. So far 
differences in VN activity toward different molecularly cloned viruses, were only 
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studied with one polyelonal antibody, SI422 from one cat (Chapter 3.2, 3.3). 
Similar studies with monoclonal antibodies, or with serum samples collected at 
different times. after infection of cats with different chimeric viruses, may shed light 
on kinetics, specificities and biological significance of antibody responses against 
different sites of the virus. In essentially the same way, kinetics, specificities and 
biological significance of T cell responses could be studied with chimeric viruses 
exhibiting different interactions with feline T cells. The in vitro CrFK cell tropism 
studies. with different chimeric viruses could be extended with ill vivo cell tropism 
studies. To this end cats might be infected with a molecularly eloned virus like FlV 
19k1 or FIV 19k32 or selected chimeric viruses, and subsequently different cell 
types could be. monitored with time, for the presence of viruses with a different 
genetic make up. Similar studies with another molecular clone of FlV have recently 
been initiated by Beebe et al. (18). In contrast to studies on the pathogenesis of 
HIVe I infection in humans, individual animals used in these studies can be infected 
with well defined molecularly cloned or chimeric viruses, which creates the 
opportunity to. deliberately test for correlation of certain genetic changes with 
certain pathogenetic features. 
The molecularly cloned FlV and a corresponding biological isolate of the virus 
from the same cat were also used as a basis for a vaccination study in laboratory 
cats. To this end a virus challenge system was established. Different approaches 
were considered for the generation of the candidate vaccines to be used. From 
these, the iscom system for presentation of viral proteins to the immune system, 
was chos.en since it had recently been shown that iscoms not only induce long 
lasting, b.i'gh tHered biologically active antibody responses, but also potent and long 
lasting Ib and CTL responses (217). A envelope gene obtained by direct PCR 
amplification c.arried out on DNA of the bone marrow of cat AMI9 was used as the 
basis fox tbe production of envelope glycoprotein. The envelope glycoproteins were 
chosen since they have been shown to induce VN antibodies and T cell responses in 
the cat. Furthermore it has been shown that envelope glycoproteins incorporated 
into iscoms were capable of inducing protective immunity in the SIV and HIV-2 
macaque models (192,193). For the production of the FlV envelope glycoproteins, a 
rVV expression system was used since this system had been used snccessfully to 
produce high levels of native and properly glycosylated proteins of other 
lentiviruses (217). Only limited amounts of thus produced SU protein were 
incorporate.d into iscoms. Therefore it was decided to generate an iscom preparation 
with a glycoprotein from which the cleavage site between the TM and SU part of 
the precursor glycoprotein had been deleted. This indeed facilitated the 
incorporation of the FIV SU protein in the iscom structure. The two thus 
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constructed iscom preparations with FlV envelope glycoproteins with and without 
the cleavage site, and the relevant control preparations -cleavage site deleted FIV 
glycoproteins with QuilA, and a SIV iscom preparation- were used to immunize 
cats. In addition a non glycosylated bacterial expression product of the same 
envelope protein, was constructed to serve as an additional candidate vaccine in 
these studies. The most striking result of these vaccination - challenge experiments 
was that all the preparations that induced VN antibody detectable in the CrFK VN 
assay not only failed to induce protection, but even induced enhanced FlV 
infectivity. The observed enhancement was directly proportional to the levels of 
thus measured VN antibodies. It is interesting to note that none of the vaccinated 
cats had developed VN antibodies detectable in the lymphoc'yte VN assay with FlV 
19k!. The cats immunized with the non-glycosylated bacterial expression product, 
did not develop any VN antibody detectable in either of the VN assays. There may 
have been a hint of a decreased virus load after challenge in the cats immunized 
with the bacterial expression product, although possibly due to the low numbers of 
cats used, the differences were not significant. The enhancement phenomenon 
observed in the cats vaccinated with the glycosylated proteins of FIV, proved to be 
mediated by a component present in the plasma of vaccinated cats, since it could be 
transferred with plasma of vaccinated cats. Studies arc ongoing at present to prove 
that indeed antiviral antibodies induced by vaccination with the respective vaccines, 
have mediated the observed enhancement. Although indications for enhanced 
infectivity after vaccination with candidate FlV and ElA V vaccines have been 
obtained before (ll 0,280), little or no attention has been paid to the possible 
interference of these antibodies with protective immunity in lentivirus systems. 
Several mechanisms of ADE have been identified in lentivirus systems ill vitro. 
Whether they all playa role ill vivo in FlV and other lentivirus systems is not clear 
at present. The importance and the mechanisms underlying the observed 
enhancement phenomenon in vaccination studies, can well be addressed in the FlV 
cat model, using all the tools that were generated in the coUl'se of the studies 
presented in this thesis. 
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Het feline immunodeficiency virus (FIV) is een virus dat nog geen tien jaar 
gel eden werd ontdekt als de oorzaak van een AIDS-achtig ziektebeeld bij de kat. 
Net als HIV-infecties bij de mens hebben FlV-infecties bij de kat een persisterend 
verloop, resulterend in verschillende ziektestadia, die geleidelijk in elkaar overgaan 
en uiteindelijk leiden tot een dier met een emstig gestoorde immuunfunctie. FIV 
komt wereldwijd voor en de studies beschreven in dit proefschrift zijn grotendeels 
uitgegaan van FIV isolaten en moleculaire klonen verkregen uit Nederlandse katten 
met feline AIDS. Het virus heeft de karakteristieke eigenschappen van een 
lentivirus, zoals de morfologie, de genoomorganisatie, en een Mg'+ afhankelijk 
reverse transcriptase, en bovendien vertoont het een anti gene verwantschap met 
lentivirussen die bij hoefdieren voorkomen. In de familie van de lentivirussen neemt 
FlV een aparte plaats in, omdat het qua genoomorganisatie en de anti gene 
venvantschappen meer overeenkomt met hoefdier-lentivirussen, tenvijl het 
ziektebeeld meer gelijkenis vertoont met dat van primate-lentivirussen. Omdat FIV 
bij katten vrij algemeen voorkomt en een ziektebeeld veroorzaakt dat lijkt op AIDS 
bij de mens, is dit virus niet aIleen van groot veterinair belang, maar heeft infectie 
met dit virus ook waarde als model voor AIDS bij de mens. Een goed diermodel is 
vooral van belang om inzicht te verkrijgen in de pathogenese van lentivirusinfecties 
en in de mogelijkheden voor antivirale therapie en vaccinontwikkeling. 
Voor het ontwikkelen van FIV-infectie in de kat als diermodel voor AIDS bij de 
mens, was het allereerst belangrijk dat technieken, die routinematig worden gebruikt 
voor de bestudering van HIV-infecties, ook voor het FIV-model werden opgezet. 
Nadat de standaard virologische en serologische testen voor het FIV -model 
operationeel waren gemaakt, werd aangevangen met de bestudering van 
immuunfuncties in geYnfecteerde katten met en zonder klinische symptomen van 
feline AIDS. Allereerst werd aangetoond dat, net als bij HIV infectie, antistoffen 
tegen de envelopeiwitten van het virus eerder aantoonbaar zijn dan antistoffen tegen 
andere virale eiwitten. In sommige katten bleken tijdens de hele infectie zelfs 
uitsluitend antistoffen tegen envelopeiwitten aantoonbaar te zijn. Dit heeft als 
praktische consequentie dat bepaalde diagnostische testen, die uitsluitend op het 
aantonen van serumantistoffen tegen Gag-eiwitten van FIV zijn gebaseerd, een 
aanzienlijk percentage vals-negatieve resultaten oplevert. Tevens bleek dat reeds in 
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een vroeg stadium van de FlY -infectie, lang voordat klinische symptomen 
waameembaar waren, gestoorde immuunfuncties bij gei'nfecteerde katten m.b.v. in 
vitro technieken aantoonbaar waren. Ook bij de mens kan al spoedig na HIY 
infectie met soortgelijke technieken een gestoorde immuunfunctie worden 
aangetoond. 
Moleculaire klonen van FlY werden direct, zonder een in vitro kweekstap, 
gei'soleerd uit beenmergcellen van een huiskat met AIDS. Deze moleculaire klonen 
maakten studies mogelijk die bij met HIY gei'nfecteerde mensen niet kunnen 
worden uitgevoerd. Oit een totaal van 36 moleculaire klonen werden twee 
replicatie-competente klonen - FlY 19k1 en FlY 19k32 - geselecteerd. Deze 
klonen hadden vergelijkbare groeikarakteristieken en hun envelopeiwitten bleken 
maar in zes aminoZllren van elkaar te verschillen. Deze moleculaire klonen bleken 
net als prima ire FlY isola ten, aileen in kattelymfocyten te repliceren. Een aantal 
primaire vimsisolaten, o.a. FlY AM6c, bleek zich na adaptatie ook te kunnen 
vermeerderen in Crandell feline kidney (CrFK) cellen. Dit is een fibroblast-achtige 
ceIlijn, die oorspronkelijk gei'soleerd werd uit een nier van een kat. Na uitwisseling 
van het hypervariabele envelop gebied, HY-3, van FlY 19k1 met dat van FlY 
AM6c, bleek ook dit aldus gemodificeerde FlY 19k1 in staat om te repliceren in 
CrFK cellen. Het duurde echter 52 dagen voordat deze chimere kloon, FlY 
19k1PBAM6c, inderdaad dit vermogen om te kunnen repliceren in CrFK cellen 
vertoonde. Aangetoond werd dat additionele mutaties in en buiten envelopeiwitten 
nodig waren om FlY te adapteren aan CrFK cellen. 
De moleculaire klonen FlY 19k1 en FlY 19k32 zijn ook gebruikt om 
mechanismen van virusneutralisatie en het ontsnappen aan virusneutraliserende 
antilichamen te bestuderen. Daartoe werd een SPF kat gel'nfecteerd met FlY 19k!. 
Het serum van deze kat, S 1422, afgenomen 22 weken na infectie, bleek de 
infectiviteit van FlY 19k1 in primaire Iymfocyten te neutraliseren. Door FlY 19k1 
in aanwezigheid van dit serum in T cell en te laten repliceren, ontstond een zgn. in 
vitro "escape mutant" van FlY 19k!. Bij bestudering van deze mutant bleek dat een 
enkele substitutiemutatie in regio HY -5 van het oppervlakte-envelopeiwit voldoende 
was om FlY 19k1 te laten ontsnappen aan de virusneutraliserende antistoffen die in 
serum S1422 aanwezig waren. FlY 19k32 kon niet worden geneutraliseerd. door 
serum SI422. FlY 19k32, dat zoals gezegd in het envelopeiwit in zes aminozuren 
verschilt van F1YI9kl, kon aileen maar gevoelig gemaakt worden voor 
virusneutraliserende antistoffen in serum S 1422, door simultaan substitutiemutaties 
in HY-4 en HY-5 van het oppervlakte-envelopeiwit aan te brengen. Er kan 
gespeculeerd worden dat deze aminozuren in HY-4 en HV-5, die ver uit elkaar 
liggen, betrokken zijn bij een conformationeel epitoop, dat gelegen is in een domein 
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betrokken bij binding van het virus aan de cellula ire receptor. 
Het laatste deel van het proefschrift beschrijft de ontwikkeling en evaluatie van 
kandidaat F1V vaccins onder andere gebaseerd op F1V envelopeiwitten als 
immunogeen. Voor de presentatie van deze antigenen aan het immuunsysteem werd 
gekozen voor verschillende adjuveringssystemen, waaronder de iscom 
presentatievorm. In eerdere studies was gebleken dat iscoms niet aileen een 
langdurige antistofrespons kunnen opwekken maar tevens goede T-helper eel en 
cytotoxische T eel responsen kunnen induceren. Gekozen werd voor de produktie 
van envelopeiwitten van F1V met behulp van recombinant vacciniavirussen, die 
deze eiwitten in de geglycosyleerde vorm tot expressie brengen. Eiwitten met een 
hydrofoob gedeelte kunnen relatief eenvoudig ingebouwd worden in iscoms .. FIV 
heeft twee envelopeiwitten: het hydrofiele oppervlakte-eiwit en het hydrofobe 
transmembraan-eiwit. Deze twee eiwitten worden gevormd uit een "precursor eiwit" 
dat door enzymen op een specifieke "cleavage site" gesplitst wordt. Door deze 
"cleavage site" te deleteren werd middels een vacciniavirus-recombinant een 
envelopeiwit geproduceerd met een hydrofoob gedeelte dat niet snel gekliefd wordt. 
Het aldus gemaakte envelopeiwit bleek na zuivering inderdaad efficient 
geYncorporeerd te kunnen worden in iscoms. De FIV envelopeiwitten werden ook in 
een bacterieel systeem tot expressie gebracht, waardoor ook een niet-geglycosyleerd 
elwIt ter beschikking kwam. Gebruikmakend van verschillende 
adjuveringstechnieken werden katten vervolgens gevaccineerd met vaccins 
gebaseerd op de aldus geproduceerde expressieproducten. Na vaccinatie konden in 
aile katten die gevaccineerd waren met F1V envelopeiwitten, antistoffen tegen deze 
eiwitten worden aangetoond. Aileen in de katten die gevaccineerd waren met 
geglycosyleerde envelopeiwitten, werden virusneutraliserende antistoffen aangetoond 
in een test die gebaseerd is op het neutraliseren van FIV-infectie van CrFK cellen. 
Deze antistoffen waren echter niet in staat F1V -infectie van primaire lymfocyten te 
neutraliseren. Na challenge-infectie bleek bij de katten die genoemde 
virusneutraliserende antistoffen hadden ontwikkeld, eerder virus in het bloed 
aantoonbaar te zijn dan bij katten zonder deze neutraliserende antistoffen. De 
versnelde infectie kon met plasma van de gevaccineerde dieren worden overgebracht 
naar naYeve katten. Versnelde infectie na vaccinatie is ook bij andere lentivirussen 
waargenomen en deze studies benadrukken nogmaals dat bij de ontwikkeling van 
vaccins tegen lentivirussen met dit fenomeen rekening dient te worden gehouden. 
De mechanismen die aan het fenomeen van versnelde infectie ten grondslag liggen 
kunnen in het FIV -model waarschijnlijk goed worden bestudeerd. Dit vergroot de 
waarde van het FIV-model voor pathogenese- en vaccinstudies aan animale en 
humane lentivirussen. 
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Nicole, bedankt voor je inzet tijdens je stage. Je was altijd wei te vinden voor 
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Rob, je peptiden zijn van een uitzonderlijke kwaliteit en bedankt voor het testen 
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mogelijk was. 
VerdeI' bedank ik aile mensen van het RIVM bij wie ik regelmatig heb 
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aangeklopt. Zeker ook Jan Poolman, hoofd van het laboratorium L VM, die het 
mogelijk heeft gemaakt om dit promotieonderzoek op het RIVM af te ronden 
Op deze plaats wiI ik ook mijn familie en vrienden bedanken voor hun interesse 
en geduld. Met name wiI ik Peter en Nel bedanken voor hun steun. Ik hoop nu toch 
eindelijk eens die excursie door de wijngebieden te kunnen maken, Peter!! 
Suzanne en Maarten, nu heb ik eindelijk weer eens tijd om leuke dingen met 
jullie te gaan doen. Bedankt voor al die mooie tekeningen die dit boekje sieren. 
Gerda, jou wiI ik bedanken voor al die jaren, tijdens mijn stu die en 
promotieonderzoek, dat je achter me hebt gestaan en gestimuleerd hebt om toch 
door te gaan. Dit proefschrift draag ik dan ook aan jou op. 
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